BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Vallet-pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin-venier V, Fontaine H, Pol S. FIB-4: An inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology 2007;46:32-6. [DOI: 10.1002/hep.21669] [Cited by in Crossref: 1026] [Cited by in F6Publishing: 982] [Article Influence: 73.3] [Reference Citation Analysis]
Number Citing Articles
1 Petroni ML, Brodosi L, Bugianesi E, Marchesini G. Management of non-alcoholic fatty liver disease.BMJ. 2021;372:m4747. [PMID: 33461969 DOI: 10.1136/bmj.m4747] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
2 Zhang ZQ, Huang LW, Chen YP, Wang P. Routine indexes for cirrhosis and significant fibrosis detection in patients with compensated chronic hepatitis B. Dig Liver Dis 2019;51:127-34. [PMID: 30076017 DOI: 10.1016/j.dld.2018.07.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
3 Coppola N, Pisaturo M, Zampino R, Macera M, Sagnelli C, Sagnelli E. Hepatitis C virus markers in infection by hepatitis C virus: In the era of directly acting antivirals. World J Gastroenterol 2015; 21(38): 10749-10759 [PMID: 26478667 DOI: 10.3748/wjg.v21.i38.10749] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
4 Xu H, Kong W, Liu L, Chi X, Wang X, Wu R, Gao X, Wang H, Qu L, Qi Y, Pan Y, Niu J. Accuracy of M2BPGi, compared with Fibro Scan®, in analysis of liver fibrosis in patients with hepatitis C. BMC Gastroenterol 2017;17:62. [PMID: 28486931 DOI: 10.1186/s12876-017-0618-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
5 Ballestri S, Mantovani A, Baldelli E, Lugari S, Maurantonio M, Nascimbeni F, Marrazzo A, Romagnoli D, Targher G, Lonardo A. Liver Fibrosis Biomarkers Accurately Exclude Advanced Fibrosis and Are Associated with Higher Cardiovascular Risk Scores in Patients with NAFLD or Viral Chronic Liver Disease. Diagnostics (Basel) 2021;11:98. [PMID: 33435415 DOI: 10.3390/diagnostics11010098] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 13.0] [Reference Citation Analysis]
6 Paul J. Recent advances in non-invasive diagnosis and medical management of non-alcoholic fatty liver disease in adult. Egypt Liver Journal 2020;10. [DOI: 10.1186/s43066-020-00043-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
7 Carey KJ, Huang W, Linas BP, Tsui JI. Hepatitis C Virus Testing and Treatment Among Persons Receiving Buprenorphine in an Office-Based Program for Opioid Use Disorders. J Subst Abuse Treat 2016;66:54-9. [PMID: 26988423 DOI: 10.1016/j.jsat.2016.01.009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
8 Lesko CR, Lau B, Chander G, Moore RD. Death after diagnosis of noncommunicable disease comorbid conditions, stratified by injection drug use. AIDS 2019;33:285-93. [PMID: 30325772 DOI: 10.1097/QAD.0000000000002054] [Reference Citation Analysis]
9 Leroy V. Other non-invasive markers of liver fibrosis. Gastroenterol Clin Biol. 2008;32:52-57. [PMID: 18973846 DOI: 10.1016/s0399-8320(08)73993-9] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
10 Alboraie M, Khairy M, Elsharkawy M, Asem N, Elsharkawy A, Esmat G. Value of Egy-Score in diagnosis of significant, advanced hepatic fibrosis and cirrhosis compared to aspartate aminotransferase-to-platelet ratio index, FIB-4 and Forns' index in chronic hepatitis C virus. Hepatol Res. 2014; Jul 3. [Epub ahead of print]. [PMID: 24995544 DOI: 10.1111/hepr.12385] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
11 Izumi G, Takeda A, Yamazawa H, Sasaki O, Kato N, Asai H, Tachibana T, Matsui Y. Forns Index is a predictor of cardiopulmonary bypass time and outcomes in Fontan conversion. Heart Vessels 2020;35:586-92. [PMID: 31562553 DOI: 10.1007/s00380-019-01515-w] [Reference Citation Analysis]
12 Lv DD, Wang ML, Chen EQ, Wu DB, Tao YC, Zhang DM, Tang H. A retrospective study of the efficacy of sofosbuvir plus NS5A inhibitors for patients with hepatitis C virus genotype-2 chronic infection. Eur J Gastroenterol Hepatol 2019;31:382-8. [PMID: 30383554 DOI: 10.1097/MEG.0000000000001299] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
13 Deng YQ, Zhao H, Ma AL, Zhou JY, Xie SB, Zhang XQ, Zhang DZ, Xie Q, Zhang G, Shang J, Cheng J, Zhao WF, Zou ZQ, Zhang MX, Wang GQ; China HepB Related Fibrosis Assessment Research Group. Selected Cytokines Serve as Potential Biomarkers for Predicting Liver Inflammation and Fibrosis in Chronic Hepatitis B Patients With Normal to Mildly Elevated Aminotransferases. Medicine (Baltimore). 2015;94:e2003. [PMID: 26559292 DOI: 10.1097/md.0000000000002003] [Cited by in Crossref: 23] [Cited by in F6Publishing: 12] [Article Influence: 4.6] [Reference Citation Analysis]
14 Yasui Y, Abe T, Kurosaki M, Matsunaga K, Higuchi M, Tamaki N, Watakabe K, Okada M, Wang W, Shimizu T, Takaura K, Masugi Y, Nakanishi H, Tsuchiya K, Takahashi Y, Itakura J, Sakurai U, Hashiguchi A, Sakamoto M, Izumi N. Non‐invasive liver fibrosis assessment correlates with collagen and elastic fiber quantity in patients with hepatitis C virus infection. Hepatol Res 2019;49:33-41. [DOI: 10.1111/hepr.13286] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
15 Tani J, Senoh T, Moriya A, Ogawa C, Deguchi A, Sakamoto T, Takuma K, Nakahara M, Oura K, Tadokoro T, Mimura S, Fujita K, Yoneyama H, Kobara H, Morishita A, Himoto T, Tsutsui A, Nagano T, Takaguchi K, Masaki T. Long-Term Outcomes and Evaluation of Hepatocellular Carcinoma Recurrence after Hepatitis C Virus Eradication by Direct-Acting Antiviral Treatment: All Kagawa Liver Disease Group (AKLDG) Study. Cancers (Basel) 2021;13:2257. [PMID: 34066708 DOI: 10.3390/cancers13092257] [Reference Citation Analysis]
16 Xu B, Zhou NM, Cao WT, Li XJ. Evaluation of elastography combined with serological indexes for hepatic fibrosis in patients with chronic hepatitis B. World J Gastroenterol 2018; 24(37): 4272-4280 [PMID: 30310260 DOI: 10.3748/wjg.v24.i37.4272] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
17 Scalioni LP, Santos BRD, Spritzer PM, Villela-Nogueira CA, Laura Lewis-Ximenez L, Pollo-Flores P, Bordalo Cathalá Esberard E, Brandão-Mello CE, Lampe E, Villar LM. Impact of vitamin D receptor and binding protein gene polymorphisms in clinical and laboratory data of HCV patients: Cross sectional study. Medicine (Baltimore) 2018;97:e9881. [PMID: 29465575 DOI: 10.1097/MD.0000000000009881] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 3.3] [Reference Citation Analysis]
18 Huh JH, Lee KJ, Lim JS, Lee MY, Park HJ, Kim MY, Kim JW, Chung CH, Shin JY, Kim HS, Kwon SO, Baik SK. High Dietary Sodium Intake Assessed by Estimated 24-h Urinary Sodium Excretion Is Associated with NAFLD and Hepatic Fibrosis. PLoS One 2015;10:e0143222. [PMID: 26571018 DOI: 10.1371/journal.pone.0143222] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
19 Langohr K, Sanvisens A, Fuster D, Tor J, Serra I, Rey-Joly C, Rivas I, Muga R. Liver enzyme alterations in HCV-monoinfected and HCV/HIV-coinfected patients. Open AIDS J 2008;2:82-8. [PMID: 19274066 DOI: 10.2174/1874613600802010082] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
20 Hashimoto S, Yatsuhashi H, Abiru S, Yamasaki K, Komori A, Nagaoka S, Saeki A, Uchida S, Bekki S, Kugiyama Y, Nagata K, Nakamura M, Migita K, Nakao K. Rapid Increase in Serum Low-Density Lipoprotein Cholesterol Concentration during Hepatitis C Interferon-Free Treatment. PLoS One. 2016;11:e0163644. [PMID: 27680885 DOI: 10.1371/journal.pone.0163644] [Cited by in Crossref: 52] [Cited by in F6Publishing: 52] [Article Influence: 10.4] [Reference Citation Analysis]
21 Ho SY, Liu PH, Hsu CY, Hsia CY, Su CW, He YJ, Lee YH, Huang YH, Hou MC, Huo TI. Current noninvasive liver reserve models do not predict histological fibrosis severity in hepatocellular carcinoma. Sci Rep 2018;8:15074. [PMID: 30305679 DOI: 10.1038/s41598-018-33536-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
22 Liu F, Ning Z, Liu Y, Liu D, Tian J, Luo H, An W, Huang Y, Zou J, Liu C, Liu C, Wang L, Liu Z, Qi R, Zuo C, Zhang Q, Wang J, Zhao D, Duan Y, Peng B, Qi X, Zhang Y, Yang Y, Hou J, Dong J, Li Z, Ding H, Zhang Y, Qi X. Development and validation of a radiomics signature for clinically significant portal hypertension in cirrhosis (CHESS1701): a prospective multicenter study. EBioMedicine 2018;36:151-8. [PMID: 30268833 DOI: 10.1016/j.ebiom.2018.09.023] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 9.3] [Reference Citation Analysis]
23 Gounder PP, Haering C, Bruden DJT, Townshend-Bulson L, Simons BC, Spradling PR, McMahon BJ. Does Incorporating Change in APRI or FIB-4 Indices Over Time Improve the Accuracy of a Single Index for Identifying Liver Fibrosis in Persons With Chronic Hepatitis C Virus Infection? J Clin Gastroenterol 2018;52:60-6. [PMID: 27875352 DOI: 10.1097/MCG.0000000000000753] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
24 Kawaguchi T, Torimura T, Takata A, Satomi S, Sata M. Valine, a branched-chain amino Acid, reduced HCV viral load and led to eradication of HCV by interferon therapy in a decompensated cirrhotic patient. Case Rep Gastroenterol. 2012;6:660-667. [PMID: 23185147 DOI: 10.1159/000343094] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
25 Jung CH, Rhee EJ, Kwon H, Chang Y, Ryu S, Lee WY. Visceral-to-Subcutaneous Abdominal Fat Ratio Is Associated with Nonalcoholic Fatty Liver Disease and Liver Fibrosis. Endocrinol Metab (Seoul) 2020;35:165-76. [PMID: 32207277 DOI: 10.3803/EnM.2020.35.1.165] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 9.0] [Reference Citation Analysis]
26 Kawaguchi T, Ide T, Koga H, Kondo R, Miyajima I, Arinaga-Hino T, Kuwahara R, Amano K, Niizeki T, Nakano M, Kuromatsu R, Torimura T. Rapidly growing hepatocellular carcinoma after direct-acting antiviral treatment of chronic hepatitis C. Clin J Gastroenterol 2018;11:69-74. [PMID: 29082453 DOI: 10.1007/s12328-017-0789-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
27 Zhou J, Deng Y, Yan L, Zhao H, Wang G; China HepB-Related Fibrosis Assessment Research Group. Serum platelet-derived growth factor BB levels: a potential biomarker for the assessment of liver fibrosis in patients with chronic hepatitis B. Int J Infect Dis 2016;49:94-9. [PMID: 27292607 DOI: 10.1016/j.ijid.2016.06.004] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
28 Frossard JL, Giostra E, Rubbia-Brandt L, Hadengue A, Spahr L. The role of transient elastography in the detection of liver disease in patients with chronic pancreatitis. Liver Int. 2013;33:1121-1127. [PMID: 23560827 DOI: 10.1111/liv.12163] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
29 Kawamura Y, Saitoh S, Arase Y, Ikeda K, Fukushima T, Hara T, Seko Y, Hosaka T, Kobayashi M, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Fukuzawa K, Hamada Y, Takahashi J, Kobayashi M, Kumada H. Three-dimensional magnetic resonance imaging for stringent diagnosis of advanced fibrosis associated with nonalcoholic steatohepatitis. Hepatol Int 2013;7:850-8. [DOI: 10.1007/s12072-012-9419-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
30 Sun J, Althoff KN, Jing Y, Horberg MA, Buchacz K, Gill MJ, Justice AC, Rabkin CS, Goedert JJ, Sigel K, Cachay E, Park L, Lim JK, Kim HN, Lo Re V 3rd, Moore R, Sterling T, Peters MG, Achenbach CJ, Silverberg M, Thorne JE, Mayor AM, Crane HM, Kitahata MM, Klein M, Kirk GD; North American AIDS Cohort Collaboration on Research and Design of IeDEA. Trends in Hepatocellular Carcinoma Incidence and Risk Among Persons With HIV in the US and Canada, 1996-2015. JAMA Netw Open 2021;4:e2037512. [PMID: 33595662 DOI: 10.1001/jamanetworkopen.2020.37512] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
31 Ahmed Hassan E, Sharaf El-Din Abd El-Rehim A, Ahmed Sayed ZE, Farah Mohamed Kholef E, Sabry A, Abd El-Rehim Abo Elhagag N. VAP score as a novel non-invasive liver fibrosis model in patients with chronic hepatitis C. Hepatol Res 2017;47:1408-16. [PMID: 28247581 DOI: 10.1111/hepr.12884] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
32 Muir AJ. Understanding the Complexities of Cirrhosis. Clinical Therapeutics 2015;37:1822-36. [DOI: 10.1016/j.clinthera.2015.05.507] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 3.7] [Reference Citation Analysis]
33 Mazzotti A, Caletti MT, Brodosi L, Di Domizio S, Forchielli ML, Petta S, Bugianesi E, Bianchi G, Marchesini G. An internet-based approach for lifestyle changes in patients with NAFLD: Two-year effects on weight loss and surrogate markers. J Hepatol. 2018;69:1155-1163. [PMID: 30290973 DOI: 10.1016/j.jhep.2018.07.013] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
34 Sugiura A, Joshita S, Umemura T, Yamazaki T, Fujimori N, Kimura T, Matsumoto A, Igarashi K, Usami Y, Wada S, Mori H, Shibata S, Yoshizawa K, Morita S, Furuta K, Kamijo A, Iijima A, Kako S, Maruyama A, Kobayashi M, Komatsu M, Matsumura M, Miyabayashi C, Ichijo T, Takeuchi A, Koike Y, Gibo Y, Tsukadaira T, Inada H, Kiyosawa K, Tanaka E. Past history of hepatocellular carcinoma is an independent risk factor of treatment failure in patients with chronic hepatitis C virus infection receiving direct-acting antivirals. J Viral Hepat 2018;25:1462-71. [DOI: 10.1111/jvh.12973] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
35 Torti C, Scaglione V, Cesana BM, Costa C, Marascio N, Schiaroli E, Busti C, Bastianelli S, Mazzitelli M, Trecarichi EM, Francisci D. Effect of directly acting antivirals for hepatitis C virus infection on proprotein convertase subtilisin/kexin type 9 level. Health Sci Rep 2021;4:e273. [PMID: 33969232 DOI: 10.1002/hsr2.273] [Reference Citation Analysis]
36 Bertot LC, Jeffrey GP, de Boer B, MacQuillan G, Garas G, Chin J, Huang Y, Adams LA. Diabetes impacts prediction of cirrhosis and prognosis by non-invasive fibrosis models in non-alcoholic fatty liver disease. Liver Int. 2018;38:1793-1802. [PMID: 29575516 DOI: 10.1111/liv.13739] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 12.3] [Reference Citation Analysis]
37 Enomoto M, Morikawa H, Tamori A, Kawada N. Noninvasive assessment of liver fibrosis in patients with chronic hepatitis B. World J Gastroenterol 2014; 20(34): 12031-12038 [PMID: 25232240 DOI: 10.3748/wjg.v20.i34.12031] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
38 Paternostro R, Pfeiffenberger J, Ferenci P, Stättermayer AF, Stauber RE, Wrba F, Longerich T, Lackner K, Trauner M, Ferlitsch A, Reiberger T, Weiss KH. Non-invasive diagnosis of cirrhosis and long-term disease monitoring by transient elastography in patients with Wilson disease. Liver Int 2020;40:894-904. [PMID: 31898387 DOI: 10.1111/liv.14368] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
39 Debnath P, Nair S, Rathi P, Junare P, Jain S, Chandnani S, Singh A, Contractor Q. Serum biomarkers as an alternative to vibration controlled transient elastography in liver fibrosis staging in chronic hepatitis C. Acta Gastroenterol Belg 2021;84:43-50. [PMID: 33639692 DOI: 10.51821/84.1.776] [Reference Citation Analysis]
40 Hubert C, Sempoux C, Humblet Y, van den Eynde M, Zech F, Leclercq I, Gigot JF. Sinusoidal obstruction syndrome (SOS) related to chemotherapy for colorectal liver metastases: factors predictive of severe SOS lesions and protective effect of bevacizumab. HPB (Oxford) 2013;15:858-64. [PMID: 23458554 DOI: 10.1111/hpb.12047] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
41 Purnak T, Olmez S, Torun S, Efe C, Sayilir A, Ozaslan E, Tenlik I, Kalkan IH, Beyazit Y, Yuksel O. Mean platelet volume is increased in chronic hepatitis C patients with advanced fibrosis. Clin Res Hepatol Gastroenterol. 2013;37:41-46. [PMID: 22572524 DOI: 10.1016/j.clinre.2012.03.035] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 4.0] [Reference Citation Analysis]
42 Greulich T, Altraja A, Barrecheguren M, Bals R, Chlumsky J, Chorostowska-Wynimko J, Clarenbach C, Corda L, Corsico AG, Ferrarotti I, Esquinas C, Gouder C, Hećimović A, Ilic A, Ivanov Y, Janciauskiene S, Janssens W, Kohler M, Krams A, Lara B, Mahadeva R, McElvaney G, Mornex JF, O'Hara K, Parr D, Piitulainen E, Schmid-Scherzer K, Seersholm N, Stockley RA, Stolk J, Sucena M, Tanash H, Turner A, Ulmeanu R, Wilkens M, Yorgancioğlu A, Zaharie A, Miravitlles M. Protocol for the EARCO Registry: a pan-European observational study in patients with α1-antitrypsin deficiency. ERJ Open Res 2020;6:00181-2019. [PMID: 32154291 DOI: 10.1183/23120541.00181-2019] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
43 Karanjia RN, Crossey MME, Cox IJ, Fye HKS, Njie R, Goldin RD, Taylor-Robinson SD. Hepatic steatosis and fibrosis: Non-invasive assessment. World J Gastroenterol 2016; 22(45): 9880-9897 [PMID: 28018096 DOI: 10.3748/wjg.v22.i45.9880] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 25] [Article Influence: 5.4] [Reference Citation Analysis]
44 Nasrullah M, Sergeenko D, Gvinjilia L, Gamkrelidze A, Tsertsvadze T, Butsashvili M, Metreveli D, Sharvadze L, Alkhazashvili M, Shadaker S, Ward JW, Morgan J, Averhoff F. The Role of Screening and Treatment in National Progress Toward Hepatitis C Elimination - Georgia, 2015-2016. MMWR Morb Mortal Wkly Rep. 2017;66:773-776. [PMID: 28749925 DOI: 10.15585/mmwr.mm6629a2] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 8.3] [Reference Citation Analysis]
45 Mazzitelli M, Torti C, Sabatino J, D'Ascoli GL, Costa C, Pisani V, Raffetti E, De Rosa S, Strazzulla A, Focà A, Liberto MC, Indolfi C; CARDIAC study group. Evaluation of cardiac function by global longitudinal strain before and after treatment with sofosbuvir-based regimens in HCV infected patients. BMC Infect Dis 2018;18:518. [PMID: 30326844 DOI: 10.1186/s12879-018-3426-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
46 Arai T, Atsukawa M, Tsubota A, Kondo C, Shimada N, Abe H, Itokawa N, Nakagawa A, Okubo T, Aizawa Y, Iwakiri K. Vitamin D-related gene polymorphisms do not influence the outcome and serum vitamin D level in pegylated interferon/ribavirin therapy combined with protease inhibitor for patients with genotype 1b chronic hepatitis C: Vitamin D-Related Gene Polymorphisms for Hepatitis C. J Med Virol 2015;87:1904-12. [DOI: 10.1002/jmv.24244] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
47 Scaglione V, Mazzitelli M, Costa C, Pisani V, Greco G, Serapide F, Lionello R, La Gamba V, Marascio N, Trecarichi EM, Torti C. Virological and Clinical Outcome of DAA Containing Regimens in a Cohort of Patients in Calabria Region (Southern Italy). Medicina (Kaunas) 2020;56:E101. [PMID: 32121135 DOI: 10.3390/medicina56030101] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
48 Chávez-tapia NC, Ridruejo E, de Mattos AA, Bessone F, Daruich J, Sánchez-ávila JF, Cheinquer H, Zapata R, Uribe M, Bosques-padilla F, Gadano A, Soza A, Dávalos-moscol M, Marroni C, Muñoz-espinoza L, Castro-narro G, Paraná R, Méndez-sánchez N. An update on the management of hepatitis C: guidelines for protease inhibitor-based triple therapy from the Latin American Association for the Study of the Liver. Annals of Hepatology 2013;12:S3-S35. [DOI: 10.1016/s1665-2681(19)31404-8] [Cited by in Crossref: 6] [Article Influence: 0.8] [Reference Citation Analysis]
49 Zhao W, Xue N, Cui P, Liu L, Wang Y, Zhang X, Tang Y, Du H, Nan Y. Plasma YAP1 predicts esophageal varices and the risk of variceal bleeding in liver cirrhosis. Biomark Med 2021;15:1411-22. [PMID: 34533050 DOI: 10.2217/bmm-2020-0573] [Reference Citation Analysis]
50 Kahler CW, Liu T, Cioe PA, Bryant V, Pinkston MM, Kojic EM, Onen N, Baker JV, Hammer J, Brooks JT, Patel P. Direct and Indirect Effects of Heavy Alcohol Use on Clinical Outcomes in a Longitudinal Study of HIV Patients on ART. AIDS Behav 2017;21:1825-35. [PMID: 27392417 DOI: 10.1007/s10461-016-1474-y] [Cited by in Crossref: 26] [Cited by in F6Publishing: 31] [Article Influence: 8.7] [Reference Citation Analysis]
51 Mocroft A, Neuhaus J, Peters L, Ryom L, Bickel M, Grint D, Koirala J, Szymczak A, Lundgren J, Ross MJ, Wyatt CM; INSIGHT SMART Study Group., ESPRIT Study Group. Hepatitis B and C co-infection are independent predictors of progressive kidney disease in HIV-positive, antiretroviral-treated adults. PLoS One 2012;7:e40245. [PMID: 22911697 DOI: 10.1371/journal.pone.0040245] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 5.3] [Reference Citation Analysis]
52 Marasco G, Colecchia A, Silva G, Rossini B, Eusebi LH, Ravaioli F, Dajti E, Alemanni LV, Colecchia L, Renzulli M, Golfieri R, Festi D. Non-invasive tests for the prediction of primary hepatocellular carcinoma. World J Gastroenterol 2020; 26(24): 3326-3343 [PMID: 32655261 DOI: 10.3748/wjg.v26.i24.3326] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 5] [Article Influence: 9.0] [Reference Citation Analysis]
53 Kumada T, Toyoda H, Yasuda S, Tada T, Tanaka J, Chayama K, Johnson PJ, Irving WL. Comparison of the Prognosis of Decompensated Cirrhosis in Patients with and Without Eradication of Hepatitis C Virus. Infect Dis Ther 2021;10:1001-13. [PMID: 33881712 DOI: 10.1007/s40121-021-00441-7] [Reference Citation Analysis]
54 Li N, Xu JH, Yu M, Wang S, Si CW, Yu YY. Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy. World J Gastroenterol 2015; 21(43): 12421-12429 [PMID: 26604649 DOI: 10.3748/wjg.v21.i43.12421] [Cited by in CrossRef: 1] [Article Influence: 0.2] [Reference Citation Analysis]
55 Leone S, Lorenzini P, Cozzi-Lepri A, Orofino G, Bernacchia D, Castagna A, Menozzi M, Guaraldi G, Madeddu G, Di Biagio A, Puoti M, Gori A, d'Arminio Monforte A; ICONA Foundation Study Group. Impact of diabetes on the risk of serious liver events and liver-related deaths in people living with HIV and hepatitis C co-infection: data from the ICONA Foundation Cohort Study. Eur J Clin Microbiol Infect Dis 2019;38:1857-65. [PMID: 31230205 DOI: 10.1007/s10096-019-03618-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
56 Khandelwal R, Dassanayake AS, Conjeevaram HS, Singh SP. Non-alcoholic fatty liver disease in diabetes: When to refer to the hepatologist? World J Diabetes 2021; 12(9): 1479-1493 [PMID: 34630901 DOI: 10.4239/wjd.v12.i9.1479] [Reference Citation Analysis]
57 Hwang J, Yoon HM, Kim KM, Oh SH, Namgoong JM, Kim DY, Cho YA. Assessment of native liver fibrosis using ultrasound elastography and serological fibrosis indices in children with biliary atresia after the Kasai procedure. Acta Radiol 2021;62:1088-96. [PMID: 32811156 DOI: 10.1177/0284185120948489] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
58 Shousha HI, Saad Y, Saleh DA, Dabes H, Alserafy M, ElShazly Y, Said M. Simple predictors of nonresponse to direct-acting antivirals in chronic hepatitis C patients. Eur J Gastroenterol Hepatol 2020;32:1017-22. [PMID: 31789947 DOI: 10.1097/MEG.0000000000001612] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
59 Fujita K, Oura K, Yoneyama H, Shi T, Takuma K, Nakahara M, Tadokoro T, Nomura T, Morishita A, Tsutsui K, Himoto T, Masaki T. Albumin-bilirubin score indicates liver fibrosis staging and prognosis in patients with chronic hepatitis C. Hepatol Res 2019;49:731-42. [PMID: 30892804 DOI: 10.1111/hepr.13333] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 8.5] [Reference Citation Analysis]
60 Nagano T, Seki N, Tomita Y, Sugita T, Aida Y, Itagaki M, Sutoh S, Abe H, Tsubota A, Aizawa Y. Impact of Chronic Hepatitis C Virus Genotype 1b Infection on Triglyceride Concentration in Serum Lipoprotein Fractions. Int J Mol Sci 2015;16:20576-94. [PMID: 26334270 DOI: 10.3390/ijms160920576] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
61 Tada T, Toyoda H, Kumada T, Kurisu A, Sugiyama A, Akita T, Ohisa M, Aikata H, Miki D, Chayama K, Tanaka J. Comparison of liver disease state progression in patients with eradication of versus persistent infection with hepatitis C virus: Markov chain analysis. J Viral Hepat 2021;28:538-47. [PMID: 33215790 DOI: 10.1111/jvh.13444] [Reference Citation Analysis]
62 Boyle M, Masson S, Anstee QM. The bidirectional impacts of alcohol consumption and the metabolic syndrome: Cofactors for progressive fatty liver disease. Journal of Hepatology 2018;68:251-67. [DOI: 10.1016/j.jhep.2017.11.006] [Cited by in Crossref: 52] [Cited by in F6Publishing: 52] [Article Influence: 17.3] [Reference Citation Analysis]
63 Di Maria MV, Silverman L, Younoszai AK, Meyers ML, Capocelli KE, Narkewicz MR. Acoustic radiation force impulse of the liver after Fontan operation: Correlation with cardiopulmonary exercise test. Congenit Heart Dis 2018;13:444-9. [PMID: 29473337 DOI: 10.1111/chd.12594] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
64 Valva P, Ríos DA, De Matteo E, Preciado MV. Chronic hepatitis C virus infection: Serum biomarkers in predicting liver damage. World J Gastroenterol 2016; 22(4): 1367-1381 [PMID: 26819506 DOI: 10.3748/wjg.v22.i4.1367] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
65 Awori V, Nakigozi G, Kisakye A, Batte J, Anok A, Mayanja R, Nakasujja N, Robertson KR, Gray RH, Wawer MJ, Sacktor N, Saylor D. The Veterans Aging Cohort Study Index is not associated with HIV-associated neurocognitive disorders in Uganda. J Neurovirol 2020;26:252-6. [PMID: 31721082 DOI: 10.1007/s13365-019-00806-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
66 Inoue J, Akahane T, Nakayama H, Kimura O, Kobayashi T, Kisara N, Sato T, Morosawa T, Izuma M, Kakazu E, Ninomiya M, Iwata T, Takai S, Nakamura T, Sano A, Niitsuma H, Masamune A; THERME Study Group. Comparison of hepatitis B virus genotypes B and C among chronically hepatitis B virus-infected patients who received nucleos(t)ide analogs: A multicenter retrospective study. Hepatol Res 2019;49:1263-74. [PMID: 31254482 DOI: 10.1111/hepr.13398] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
67 Morales-Arraez D, Nieto Bujalance Y, Diaz-Flores F, de Vera A, Jiménez A, Garcia Dopico JA, Quintero E, Hernández-Guerra M. Risk of liver fibrosis progression in patients with suboptimal diagnosis of hepatitis C virus infection. Eur J Gastroenterol Hepatol 2020;32:528-34. [PMID: 31490420 DOI: 10.1097/MEG.0000000000001534] [Reference Citation Analysis]
68 Procopet B, Cristea VM, Robic MA, Grigorescu M, Agachi PS, Metivier S, Peron JM, Selves J, Stefanescu H, Berzigotti A, Vinel JP, Bureau C. Serum tests, liver stiffness and artificial neural networks for diagnosing cirrhosis and portal hypertension. Dig Liver Dis. 2015;47:411-416. [PMID: 25732434 DOI: 10.1016/j.dld.2015.02.001] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
69 Nakajima K, Oshida H, Muneyuki T, Saito M, Hori Y, Fuchigami H, Kakei M, Munakata H. Independent association between low serum amylase and non-alcoholic fatty liver disease in asymptomatic adults: a cross-sectional observational study. BMJ Open 2013;3:e002235. [PMID: 23293250 DOI: 10.1136/bmjopen-2012-002235] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
70 Hiraoka A, Kumada T, Ogawa C, Kariyama K, Morita M, Nouso K, Toyoda H, Tada T, Ochi M, Murakami T, Izumoto H, Ueki H, Kitahata S, Aibiki T, Okudaira T, Yamago H, Iwasaki R, Tomida H, Miyamoto Y, Mori K, Miyata H, Tsubouchi E, Kishida M, Ninomiya T, Michitaka K. Proposed a simple score for recommendation of scheduled ultrasonography surveillance for hepatocellular carcinoma after Direct Acting Antivirals: multicenter analysis. J Gastroenterol Hepatol 2019;34:436-41. [PMID: 29996177 DOI: 10.1111/jgh.14378] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
71 Fitzpatrick E, Dhawan A. Noninvasive biomarkers in non-alcoholic fatty liver disease: Current status and a glimpse of the future. World J Gastroenterol 2014; 20(31): 10851-10863 [PMID: 25152587 DOI: 10.3748/wjg.v20.i31.10851] [Cited by in CrossRef: 68] [Cited by in F6Publishing: 59] [Article Influence: 9.7] [Reference Citation Analysis]
72 Mada PK, Malus ME, Saldaña Koppel DA, Adley S, Moore M, Alam MJ, Feldman M. Predicting Liver Fibrosis in the Hepatitis C Population: Concordance Analysis Between Noninvasive Scoring Systems and Percutaneous Liver Biopsy. Cureus 2020;12:e10376. [PMID: 33062499 DOI: 10.7759/cureus.10376] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
73 Mera J, Vellozzi C, Hariri S, Carabin H, Drevets DA, Miller A, Reilley B, Essex W, Gahn D, Lyons L, Leston J, Ward JW. Identification and Clinical Management of Persons with Chronic Hepatitis C Virus Infection — Cherokee Nation, 2012–2015. MMWR Morb Mortal Wkly Rep 2016;65:461-6. [DOI: 10.15585/mmwr.mm6518a2] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 7.2] [Reference Citation Analysis]
74 Jung JY, Park SK, Ryoo J, Oh C, Kang JG, Lee J, Choi J. Effect of non-alcoholic fatty liver disease on left ventricular diastolic function and geometry in the Korean general population: NAFLD, left ventricular diastolic dysfunction. Hepatol Res 2017;47:522-32. [DOI: 10.1111/hepr.12770] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
75 Rogal SS, Yan P, Rimland D, Re VL, Al-rowais H, Fried L, Butt AA; The ERCHIVES (Electronically Retrieved Cohort of HCV Infected Veterans) Study Group. Incidence and Progression of Chronic Kidney Disease After Hepatitis C Seroconversion: Results from ERCHIVES. Dig Dis Sci 2016;61:930-6. [DOI: 10.1007/s10620-015-3918-z] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 5.7] [Reference Citation Analysis]
76 Bhogal H, Sterling RK. Staging of liver disease: which option is right for my patient? Infect Dis Clin North Am. 2012;26:849-861. [PMID: 23083819 DOI: 10.1016/j.idc.2012.08.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
77 Naganuma A, Chayama K, Notsumata K, Gane E, Foster GR, Wyles D, Kwo P, Crown E, Bhagat A, Mensa FJ, Otani T, Larsen L, Burroughs M, Kumada H. Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection. J Gastroenterol 2019;54:752-61. [PMID: 30868245 DOI: 10.1007/s00535-019-01569-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
78 Nassar ES, Elkalbashawy YA, Kamal A, Zakaria NHE. Galectin-3 is not useful for hepatocellular carcinoma surveillance in cirrhotic patients but it may be a marker of cirrhosis development. Clin Exp Hepatol 2021;7:74-8. [PMID: 34027118 DOI: 10.5114/ceh.2021.104385] [Reference Citation Analysis]
79 Cheng CH, Chu CY, Chen HL, Lin IT, Wu CH, Lee YK, Hu PJ, Bair MJ. Direct-acting antiviral therapy of chronic hepatitis C improves liver fibrosis, assessed by histological examination and laboratory markers. J Formos Med Assoc 2021;120:1259-68. [PMID: 33339709 DOI: 10.1016/j.jfma.2020.11.018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
80 Bichoupan K, Schwartz JM, Martel-Laferriere V, Giannattasio ER, Marfo K, Odin JA, Liu LU, Schiano TD, Perumalswami P, Bansal M, Gaglio PJ, Kalia H, Dieterich DT, Branch AD, Reinus JF. Effect of fibrosis on adverse events in patients with hepatitis C treated with telaprevir. Aliment Pharmacol Ther 2014;39:209-16. [PMID: 24266536 DOI: 10.1111/apt.12560] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
81 Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ;  Nash Clinical Research Network. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009;7:1104-1112. [PMID: 19523535 DOI: 10.1016/j.cgh.2009.05.033] [Cited by in Crossref: 620] [Cited by in F6Publishing: 561] [Article Influence: 51.7] [Reference Citation Analysis]
82 Nakajima T, Karino Y, Hige S, Suii H, Tatsumi R, Yamaguchi M, Arakawa T, Kuwata Y, Hasegawa T, Toyota J. Factors affecting the recovery of hepatic reserve after sustained virologic response by direct-acting antiviral agents in chronic hepatitis C virus-infected patients. J Gastroenterol Hepatol 2021;36:367-75. [PMID: 32991760 DOI: 10.1111/jgh.15280] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
83 Buzzetti E, Lombardi R, De Luca L, Tsochatzis EA. Noninvasive Assessment of Fibrosis in Patients with Nonalcoholic Fatty Liver Disease. Int J Endocrinol 2015;2015:343828. [PMID: 26064107 DOI: 10.1155/2015/343828] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 4.7] [Reference Citation Analysis]
84 Forrester JE, Rhee MS, McGovern BH, Sterling RK, Knox TA, Terrin N. The association of HIV viral load with indirect markers of liver injury. J Viral Hepat. 2012;19:e202-e211. [PMID: 22239520 DOI: 10.1111/j.1365-2893.2011.01529.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
85 Zhang JZ, Cai JJ, Yu Y, She ZG, Li H. Nonalcoholic Fatty Liver Disease: An Update on the Diagnosis. Gene Expr 2019;19:187-98. [PMID: 31010457 DOI: 10.3727/105221619X15553433838609] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
86 Wei R, Wang J, Wang X, Xie G, Wang Y, Zhang H, Peng CY, Rajani C, Kwee S, Liu P, Jia W. Clinical prediction of HBV and HCV related hepatic fibrosis using machine learning. EBioMedicine 2018;35:124-32. [PMID: 30100397 DOI: 10.1016/j.ebiom.2018.07.041] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 9.7] [Reference Citation Analysis]
87 Ikeda H, Watanabe T, Shimizu H, Hiraishi T, Kaneko R, Baba T, Takahashi H, Matsunaga K, Matsumoto N, Yasuda H. Efficacy of ledipasvir/sofosbuvir with or without ribavirin for 12 weeks in genotype 1b HCV patients previously treated with a nonstructural protein 5A inhibitor-containing regimen. Hepatol Res. 2018;48:802-809. [PMID: 29504692 DOI: 10.1111/hepr.13074] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
88 Matas M, Picornell A, Cifuentes C, Payeras A, Bassa A, Homar F, González-Candelas F, López-Labrador FX, Moya A, Ramon MM, Castro JA. Generalized Linear Model (GLM) framework for the association of host variables and viral strains with liver fibrosis in HCV/HIV coinfected patients. Infect Genet Evol 2013;13:284-91. [PMID: 23174528 DOI: 10.1016/j.meegid.2012.10.020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
89 Orito E, Hasebe C, Kurosaki M, Osaki Y, Joko K, Watanabe H, Kimura H, Nishijima N, Kusakabe A, Izumi N; Japanese Red Cross Liver Network. Risk of hepatocellular carcinoma in cirrhotic hepatitis B virus patients during nucleoside/nucleotide analog therapy. Hepatol Res 2015;45:872-9. [PMID: 25244601 DOI: 10.1111/hepr.12427] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
90 Kinoshita A, Koike K, Mizuno Y, Ogata I, Kobayashi Y, Hasegawa K, Shiraishi K, Yoshida H, Nakata R, Yamada N, Yasuda K. Efficacy and safety of glecaprevir/pibrentasvir in patients with hepatitis C virus infection aged ≥75 years. Geriatr Gerontol Int 2020;20:578-83. [PMID: 32267087 DOI: 10.1111/ggi.13919] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
91 Forlano R, Mullish BH, Mukherjee SK, Nathwani R, Harlow C, Crook P, Judge R, Soubieres A, Middleton P, Daunt A, Perez-Guzman P, Selvapatt N, Lemoine M, Dhar A, Thursz MR, Nayagam S, Manousou P. In-hospital mortality is associated with inflammatory response in NAFLD patients admitted for COVID-19. PLoS One. 2020;15:e0240400. [PMID: 33031439 DOI: 10.1371/journal.pone.0240400] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 13.0] [Reference Citation Analysis]
92 Kushner LE, Wendelboe AM, Lazzeroni LC, Chary A, Winters MA, Osinusi A, Kottilil S, Polis MA, Holodniy M. Immune biomarker differences and changes comparing HCV mono-infected, HIV/HCV co-infected, and HCV spontaneously cleared patients. PLoS One 2013;8:e60387. [PMID: 23593207 DOI: 10.1371/journal.pone.0060387] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
93 Cho Y, Choi YI, Oh S, Han J, Joo SK, Lee DH, Jung YJ, Kim BG, Lee KL, Kim W. Point shear wave elastography predicts fibrosis severity and steatohepatitis in alcohol-related liver disease. Hepatol Int 2020;14:270-80. [PMID: 31858403 DOI: 10.1007/s12072-019-10009-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
94 Toyoda H, Kumada T, Tada T, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Kitabatake S, Ito T. Risk factors of hepatocellular carcinoma development in non-cirrhotic patients with sustained virologic response for chronic hepatitis C virus infection. J Gastroenterol Hepatol. 2015;30:1183-1189. [PMID: 25678094 DOI: 10.1111/jgh.12915] [Cited by in Crossref: 58] [Cited by in F6Publishing: 60] [Article Influence: 11.6] [Reference Citation Analysis]
95 Gvinjilia L, Nasrullah M, Sergeenko D, Tsertsvadze T, Kamkamidze G, Butsashvili M, Gamkrelidze A, Imnadze P, Kvaratskhelia V, Chkhartishvili N, Sharvadze L, Drobeniuc J, Hagan L, Ward JW, Morgan J, Averhoff F. National Progress Toward Hepatitis C Elimination - Georgia, 2015-2016. MMWR Morb Mortal Wkly Rep. 2016;65:1132-1135. [PMID: 27764081 DOI: 10.15585/mmwr.mm6541a2] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 8.2] [Reference Citation Analysis]
96 Sato S, Genda T, Ichida T, Amano N, Sato S, Murata A, Tsuzura H, Narita Y, Kanemitsu Y, Hirano K, Shimada Y, Iijima K, Wada R, Nagahara A, Watanabe S. Prediction of Hepatocellular Carcinoma Development after Hepatitis C Virus Eradication Using Serum Wisteria floribunda Agglutinin-Positive Mac-2-Binding Protein. Int J Mol Sci. 2016;17. [PMID: 27999409 DOI: 10.3390/ijms17122143] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
97 Lee Y, Kim SU, Song K, Park JY, Kim DY, Ahn SH, Lee B, Kang ES, Cha B, Han K. Sarcopenia is associated with significant liver fibrosis independently of obesity and insulin resistance in nonalcoholic fatty liver disease: Nationwide surveys (KNHANES 2008-2011): Steatohepatitis/Metabolic Liver Disease. Hepatology 2016;63:776-86. [DOI: 10.1002/hep.28376] [Cited by in Crossref: 152] [Cited by in F6Publishing: 148] [Article Influence: 30.4] [Reference Citation Analysis]
98 Civan JM, Lindenmeyer CC, Whitsett M, Herrine SK. A Clinical Decision Rule Based on the AST-to-Platelet Ratio Index Improves Adherence to Published Guidelines on the Management of Acute Variceal Bleeding. J Clin Gastroenterol 2015;49:599-606. [PMID: 26167719 DOI: 10.1097/MCG.0000000000000173] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
99 Takakusagi S, Sato K, Suzuki Y, Yamazaki Y, Kosone T, Kakizaki S, Kusano M, Takagi H. Improvement of Proteinuria due to Combination Therapy with Daclatasvir and Asunaprevir in Hepatitis C Virus-associated Renal Disease without Cryoglobulinemia. Intern Med 2018;57:2189-95. [PMID: 29526955 DOI: 10.2169/internalmedicine.9624-17] [Reference Citation Analysis]
100 Li W, Alazawi W. Non-alcoholic fatty liver disease. Clin Med (Lond) 2020;20:509-12. [PMID: 32934047 DOI: 10.7861/clinmed.2020-0696] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
101 Voican CS, Louvet A, Trabut J, Njiké-nakseu M, Dharancy S, Sanchez A, Corouge M, Lamouri K, Lebrun A, Balian A, Prévot S, Lachgar M, Maitre S, Agostini H, Mathurin P, Perlemuter G, Naveau S. Transient elastography alone and in combination with FibroTest ® for the diagnosis of hepatic fibrosis in alcoholic liver disease. Liver Int 2017;37:1697-705. [DOI: 10.1111/liv.13440] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
102 Honma Y, Shibata M, Hayashi T, Kusanaga M, Ogino N, Minami S, Kumei S, Oe S, Miyagawa K, Senju M, Matsuoka H, Watanabe T, Hiura M, Abe S, Harada M. Effect of direct-acting antivirals on platelet-associated immunoglobulin G and thrombocytopenia in hepatitis C virus-related chronic liver disease. Liver Int 2019;39:1641-51. [PMID: 31009141 DOI: 10.1111/liv.14120] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
103 Li J, Gordon SC, Rupp LB, Zhang T, Boscarino JA, Vijayadeva V, Schmidt MA, Lu M. The validity of serum markers for fibrosis staging in chronic hepatitis B and C. J Viral Hepat. 2014;21:930-937. [PMID: 24472062 DOI: 10.1111/jvh.12224] [Cited by in Crossref: 69] [Cited by in F6Publishing: 68] [Article Influence: 9.9] [Reference Citation Analysis]
104 Hayashi T, Inuzuka R, Shindo T, Hirata Y, Shimizu N, Oka A. Serum Hyaluronic Acid Concentration in Fontan Circulation: Correlation With Hepatic Function and Portal Vein Hemodynamics. Pediatr Cardiol 2014;35:608-15. [DOI: 10.1007/s00246-013-0827-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
105 Cheng J, Zhao P, Liu J, Liu X, Wu X. Preoperative aspartate aminotransferase-to-platelet ratio index (APRI) is a predictor on postoperative outcomes of hepatocellular carcinoma. Medicine (Baltimore) 2016;95:e5486. [PMID: 27902606 DOI: 10.1097/MD.0000000000005486] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 3.8] [Reference Citation Analysis]
106 Hasegawa K, Takata R, Nishikawa H, Enomoto H, Ishii A, Iwata Y, Miyamoto Y, Ishii N, Yuri Y, Nakano C, Nishimura T, Yoh K, Aizawa N, Sakai Y, Ikeda N, Takashima T, Iijima H, Nishiguchi S. Impact of Wisteria floribunda Agglutinin-Positive Mac-2-Binding Protein in Patients with Hepatitis C Virus-Related Compensated Liver Cirrhosis. Int J Mol Sci. 2016;17. [PMID: 27626413 DOI: 10.3390/ijms17091500] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
107 Roh YH, Kang BK, Jun DW, Lee CM, Kim M. Role of FIB-4 for reassessment of hepatic fibrosis burden in referral center. Sci Rep 2021;11:13616. [PMID: 34193951 DOI: 10.1038/s41598-021-93038-6] [Reference Citation Analysis]
108 Tanwar S, Trembling PM, Hogan BJ, Parkes J, Harris S, Grant P, Nastouli E, Ocker M, Wehr K, Herold C, Neureiter D, Schuppan D, Rosenberg WM. Biomarkers of Hepatic Fibrosis in Chronic Hepatitis C: A Comparison of 10 Biomarkers Using 2 Different Assays for Hyaluronic Acid. J Clin Gastroenterol 2017;51:268-77. [PMID: 27380461 DOI: 10.1097/MCG.0000000000000581] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.8] [Reference Citation Analysis]
109 Dong BT, Huang S, Lyu GR, Qin R, Gu JH. Assessment of liver fibrosis with liver and spleen stiffness measured by sound touch elastography, serum fibrosis markers in patients with chronic hepatitis B. J Dig Dis 2021;22:342-50. [PMID: 33851510 DOI: 10.1111/1751-2980.12991] [Reference Citation Analysis]
110 Ogasawara N, Kobayashi M, Akuta N, Kominami Y, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Suzuki F, Saitoh S, Suzuki Y, Arase Y, Ikeda K, Kobayashi M, Kumada H. Serial changes in liver stiffness and controlled attenuation parameter following direct-acting antiviral therapy against hepatitis C virus genotype 1b. J Med Virol 2018;90:313-9. [DOI: 10.1002/jmv.24950] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 8.8] [Reference Citation Analysis]
111 Thandassery RB, Al Kaabi S, Soofi ME, Mohiuddin SA, John AK, Al Mohannadi M, Al Ejji K, Yakoob R, Derbala MF, Wani H, Sharma M, Al Dweik N, Butt MT, Kamel YM, Sultan K, Pasic F, Singh R. Mean Platelet Volume, Red Cell Distribution Width to Platelet Count Ratio, Globulin Platelet Index, and 16 Other Indirect Noninvasive Fibrosis Scores: How Much Do Routine Blood Tests Tell About Liver Fibrosis in Chronic Hepatitis C? Journal of Clinical Gastroenterology 2016;50:518-23. [DOI: 10.1097/mcg.0000000000000489] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 2.6] [Reference Citation Analysis]
112 Matos J, Paparo F, Bacigalupo L, Cenderello G, Mussetto I, De Cesari M, Bernardi SP, Cevasco L, Forni GL, Cassola G, Rollandi GA. Noninvasive liver fibrosis assessment in chronic viral hepatitis C: agreement among 1D transient elastography, 2D shear wave elastography, and magnetic resonance elastography. Abdom Radiol (NY) 2019;44:4011-21. [PMID: 31696266 DOI: 10.1007/s00261-019-02295-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
113 Jo MH, Lim TS, Jeon MY, Lee HW, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Kim SU. Predictors of Discordance in the Assessment of Skeletal Muscle Mass between Computed Tomography and Bioimpedance Analysis. J Clin Med 2019;8:E322. [PMID: 30866538 DOI: 10.3390/jcm8030322] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
114 Kanki A, Maeba K, Sotozono H, Yasokawa K, Higaki A, Yamamoto A, Tamada T. Evaluation of liver fibrosis using hepatic extracellular volume fraction by contrast-enhanced computed tomography before and after direct-acting antiviral therapy in patients with chronic hepatitis C infection: comparison with serological liver fibrosis markers. Br J Radiol 2021;94:20210045. [PMID: 34586878 DOI: 10.1259/bjr.20210045] [Reference Citation Analysis]
115 Ma Q, Liao X, Shao C, Lin Y, Wu T, Sun Y, Feng ST, Ye J, Zhong B. Normalization of γ-glutamyl transferase levels is associated with better metabolic control in individuals with nonalcoholic fatty liver disease. BMC Gastroenterol 2021;21:215. [PMID: 33971815 DOI: 10.1186/s12876-021-01790-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
116 Mizuno K, Toyoda H, Yasuda S, Tada T, Kumada T, Sone Y, Tanaka J. The course of elderly patients with persistent hepatitis C virus infection without hepatocellular carcinoma. J Gastroenterol 2019;54:829-36. [PMID: 31161311 DOI: 10.1007/s00535-019-01595-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
117 Park SH, Plank LD, Suk KT, Park YE, Lee J, Choi JH, Heo NY, Park J, Kim TO, Moon YS, Kim HK, Jang HJ, Park HY, Kim DJ. Trends in the prevalence of chronic liver disease in the Korean adult population, 1998-2017. Clin Mol Hepatol 2020;26:209-15. [PMID: 31679316 DOI: 10.3350/cmh.2019.0065] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 15.5] [Reference Citation Analysis]
118 Abe K, Wakabayashi H, Nakayama H, Suzuki T, Kuroda M, Yoshida N, Tojo J, Kogure A, Rai T, Saito H, Mukai S, Fujita M, Hayashi M, Takahashi A, Ohira H. Factors associated with hepatocellular carcinoma occurrence after HCV eradication in patients without cirrhosis or with compensated cirrhosis. PLoS One 2020;15:e0243473. [PMID: 33284844 DOI: 10.1371/journal.pone.0243473] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
119 Hassan EM, Omran DA, El Beshlawey ML, Abdo M, El Askary A. Can transient elastography, Fib-4, Forns Index, and Lok Score predict esophageal varices in HCV-related cirrhotic patients? Gastroenterol Hepatol. 2014;37:58-65. [PMID: 24365388 DOI: 10.1016/j.gastrohep.2013.09.008] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
120 Money D, Boucoiran I, Wagner E, Dobson S, Kennedy A, Lohn Z, Krajden M, Yoshida EM. Obstetrical and neonatal outcomes among women infected with hepatitis C and their infants. J Obstet Gynaecol Can 2014;36:785-94. [PMID: 25222357 DOI: 10.1016/S1701-2163(15)30480-1] [Cited by in Crossref: 18] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
121 Wang XP, Wang Y, Ma H, Wang H, Yang DW, Zhao XY, Jin EH, Yang ZH. Assessment of liver fibrosis with liver and spleen magnetic resonance elastography, serum markers in chronic liver disease. Quant Imaging Med Surg 2020;10:1208-22. [PMID: 32550131 DOI: 10.21037/qims-19-849] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
122 Gavilán JC, Ojeda G, Arnedo R, Puerta S. Predictive factors of risk of hepatocellular carcinoma in chronic hepatitis C. European Journal of Internal Medicine 2013;24:846-51. [DOI: 10.1016/j.ejim.2013.06.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
123 Verhelst X, Dias AM, Colombel JF, Vermeire S, Van Vlierberghe H, Callewaert N, Pinho SS. Protein Glycosylation as a Diagnostic and Prognostic Marker of Chronic Inflammatory Gastrointestinal and Liver Diseases. Gastroenterology 2020;158:95-110. [PMID: 31626754 DOI: 10.1053/j.gastro.2019.08.060] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 14.0] [Reference Citation Analysis]
124 Zhang Z, Wang G, Kang K, Wu G, Wang P. The Diagnostic Accuracy and Clinical Utility of Three Noninvasive Models for Predicting Liver Fibrosis in Patients with HBV Infection. PLoS One 2016;11:e0152757. [PMID: 27050531 DOI: 10.1371/journal.pone.0152757] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
125 Chun HS, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Lee CH, Lee YB, Cho EJ, Yu SJ, Kim YJ, Yoon JH, Lee JH, Kim SU. Design and validation of risk prediction model for hepatocellular carcinoma development after sustained virological response in patients with chronic hepatitis C. Eur J Gastroenterol Hepatol. 2020;32:378-385. [PMID: 32011388 DOI: 10.1097/meg.0000000000001512] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
126 Willis SJ, Cole SR, Westreich D, Edmonds A, Hurt CB, Albrecht S, Anastos K, Augenbraun M, Fischl M, French AL, Kalapila AG, Karim R, Peters MG, Plankey M, Seaberg EC, Tien PC, Adimora AA. Chronic hepatitis C virus infection and subsequent HIV viral load among women with HIV initiating antiretroviral therapy. AIDS 2018;32:653-61. [PMID: 29334550 DOI: 10.1097/QAD.0000000000001745] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
127 Parlati L, Hollande C, Pol S. Treatment of hepatitis C virus infection. Clin Res Hepatol Gastroenterol. 2020;101578. [PMID: 33272891 DOI: 10.1016/j.clinre.2020.11.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
128 Nakagawa M, Nawa N, Takeichi E, Shimizu T, Tsuchiya J, Sato A, Miyoshi M, Kawai-kitahata F, Murakawa M, Nitta S, Itsui Y, Azuma S, Kakinuma S, Fujiwara T, Watanabe M, Tanaka Y, Asahina Y; the Ochanomizu Liver Conference Study Group. Mac-2 binding protein glycosylation isomer as a novel predictive biomarker for patient survival after hepatitis C virus eradication by DAAs. J Gastroenterol 2020;55:990-9. [DOI: 10.1007/s00535-020-01715-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
129 Zhuang Y, Ding H, Zhang Y, Sun H, Xu C, Wang W. Two-dimensional Shear-Wave Elastography Performance in the Noninvasive Evaluation of Liver Fibrosis in Patients with Chronic Hepatitis B: Comparison with Serum Fibrosis Indexes. Radiology. 2017;283:873-882. [PMID: 27982760 DOI: 10.1148/radiol.2016160131] [Cited by in Crossref: 58] [Cited by in F6Publishing: 48] [Article Influence: 11.6] [Reference Citation Analysis]
130 Kuniholm MH, Gao X, Xue X, Kovacs A, Marti D, Thio CL, Peters MG, Greenblatt RM, Goedert JJ, Cohen MH, Minkoff H, Gange SJ, Anastos K, Fazzari M, Young MA, Strickler HD, Carrington M. The relation of HLA genotype to hepatitis C viral load and markers of liver fibrosis in HIV-infected and HIV-uninfected women. J Infect Dis 2011;203:1807-14. [PMID: 21606539 DOI: 10.1093/infdis/jir192] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
131 Yasui Y, Abe T, Kurosaki M, Higuchi M, Komiyama Y, Yoshida T, Hayashi T, Kuwabara K, Takaura K, Nakakuki N, Takada H, Tamaki N, Suzuki S, Nakanishi H, Tsuchiya K, Itakura J, Takahashi Y, Hashiguchi A, Sakamoto M, Izumi N. Elastin Fiber Accumulation in Liver Correlates with the Development of Hepatocellular Carcinoma. PLoS One 2016;11:e0154558. [PMID: 27128435 DOI: 10.1371/journal.pone.0154558] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
132 Hsu WF, Sheen LY, Lin HJ, Chang HH. A Review of Western and Traditional Chinese Medical Approaches to Managing Nonalcoholic Fatty Liver Disease. Evid Based Complement Alternat Med 2016;2016:6491420. [PMID: 27872651 DOI: 10.1155/2016/6491420] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
133 Harman DJ, Ryder SD, James MW, Jelpke M, Ottey DS, Wilkes EA, Card TR, Aithal GP, Guha IN. Direct targeting of risk factors significantly increases the detection of liver cirrhosis in primary care: a cross-sectional diagnostic study utilising transient elastography. BMJ Open 2015;5:e007516. [PMID: 25941185 DOI: 10.1136/bmjopen-2014-007516] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 8.0] [Reference Citation Analysis]
134 Bharat A, Narayanan K, Golocheikine A, Steward N, Crippin J, Lisker-Melman M, Shenoy S, Lowell J, Chapman WC, Mohanakumar T. Elevated soluble CD30 characterizes patients with hepatitis C virus-induced liver allograft cirrhosis. Transplantation 2007;84:1704-7. [PMID: 18165785 DOI: 10.1097/01.tp.0000295973.31877.7b] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
135 Lee MS, Bae JM, Joo SK, Woo H, Lee DH, Jung YJ, Kim BG, Lee KL, Kim W. Prospective comparison among transient elastography, supersonic shear imaging, and ARFI imaging for predicting fibrosis in nonalcoholic fatty liver disease. PLoS One. 2017;12:e0188321. [PMID: 29176844 DOI: 10.1371/journal.pone.0188321] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 7.8] [Reference Citation Analysis]
136 Jiang ZG, Feldbrügge L, Tapper EB, Popov Y, Ghaziani T, Afdhal N, Robson SC, Mukamal KJ. Aspirin use is associated with lower indices of liver fibrosis among adults in the United States. Aliment Pharmacol Ther 2016;43:734-43. [DOI: 10.1111/apt.13515] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 6.8] [Reference Citation Analysis]
137 Elesawy BH, Abd El Hafez A, Dorgham LS, El-Askary A. Limited reliability of five non-invasive biomarkers in predicting hepatic fibrosis in chronic HCV mono-infected patients opposed to METAVIR scoring. Pathol Res Pract. 2014;210:922-928. [PMID: 25123964 DOI: 10.1016/j.prp.2014.07.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
138 Morling JR, Fallowfield JA, Guha IN, Nee LD, Glancy S, Williamson RM, Robertson CM, Strachan MW, Price JF. Using non-invasive biomarkers to identify hepatic fibrosis in people with type 2 diabetes mellitus: The Edinburgh type 2 diabetes study. Journal of Hepatology 2014;60:384-91. [DOI: 10.1016/j.jhep.2013.10.017] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 6.0] [Reference Citation Analysis]
139 Silva Junior RG, Schmillevitch J, Nascimento Mde F, Miranda ML, Brant PE, Schulz PO, Vieira A, Szutan LA. Acoustic radiation force impulse elastography and serum fibrosis markers in chronic hepatitis C. Scand J Gastroenterol. 2014;49:986-992. [PMID: 24742130 DOI: 10.3109/00365521.2014.909528] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
140 Ikeda H, Watanabe T, Okuse C, Matsumoto N, Ishii T, Yamada N, Shigefuku R, Hattori N, Matsunaga K, Nakano H. Impact of resistance-associated variant dominancy on treatment in patients with HCV genotype 1b receiving daclatasvir/asunaprevir. J Med Virol. 2017;89:99-105. [PMID: 27329864 DOI: 10.1002/jmv.24608] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
141 Nickel F, Tapking C, Benner L, Sollors J, Billeter AT, Kenngott HG, Bokhary L, Schmid M, von Frankenberg M, Fischer L. Bariatric Surgery as an Efficient Treatment for Non-Alcoholic Fatty Liver Disease in a Prospective Study with 1-Year Follow-up : BariScan Study. Obes Surg. 2018;28:1342-1350. [PMID: 29119336 DOI: 10.1007/s11695-017-3012-z] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 22.5] [Reference Citation Analysis]
142 Ok KS, Jeong SH, Jang ES, Kim YS, Lee YJ, Kim IH, Cho SB, Bae SH, Lee HC. The clinical outcomes of chronic hepatitis C in South Korea: A prospective, multicenter cohort study. Medicine (Baltimore) 2016;95:e4594. [PMID: 27583874 DOI: 10.1097/MD.0000000000004594] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
143 Naito S, Fujikawa T, Hasegawa S. Impact of preoperative aspirin continuation on bleeding complications during or after liver resection: Propensity score-matched analysis. J Hepatobiliary Pancreat Sci. 2020;27:830-838. [PMID: 32189437 DOI: 10.1002/jhbp.735] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
144 Chin J, Powell LW, Ramm LE, Hartel GF, Olynyk JK, Ramm GA. Utility of Serum Biomarker Indices for Staging of Hepatic Fibrosis Before and After Venesection in Patients With Hemochromatosis Caused by Variants in HFE. Clin Gastroenterol Hepatol 2021;19:1459-1468.e5. [PMID: 32745684 DOI: 10.1016/j.cgh.2020.07.052] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
145 Oh S, Tsujimoto T, Kim B, Uchida F, Suzuki H, Iizumi S, Isobe T, Sakae T, Tanaka K, Shoda J. Weight-loss-independent benefits of exercise on liver steatosis and stiffness in Japanese men with NAFLD. JHEP Rep 2021;3:100253. [PMID: 33898958 DOI: 10.1016/j.jhepr.2021.100253] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
146 Branchi F, Conti CB, Baccarin A, Lampertico P, Conte D, Fraquelli M. Non-invasive assessment of liver fibrosis in chronic hepatitis B. World J Gastroenterol 2014; 20(40): 14568-14580 [PMID: 25356021 DOI: 10.3748/wjg.v20.i40.14568] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 28] [Article Influence: 5.3] [Reference Citation Analysis]
147 Wu SD, Wang JY, Li L. Staging of liver fibrosis in chronic hepatitis B patients with a composite predictive model: A comparative study. World J Gastroenterol 2010; 16(4): 501-507 [PMID: 20101779 DOI: 10.3748/wjg.v16.i4.501] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 34] [Article Influence: 3.3] [Reference Citation Analysis]
148 Tokorodani R, Sumiyoshi T, Okabayashi T, Hata Y, Noda Y, Morita S, Daisaki H, Okada Y, Yasuda E. Liver fibrosis assessment using 99mTc-GSA SPECT/CT fusion imaging. Jpn J Radiol 2019;37:315-20. [DOI: 10.1007/s11604-019-00810-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
149 Martinez SM, Foucher J, Combis JM, Métivier S, Brunetto M, Capron D, Bourlière M, Bronowicki JP, Dao T, Maynard-Muet M, Lucidarme D, Merrouche W, Forns X, de Lédinghen V. Longitudinal liver stiffness assessment in patients with chronic hepatitis C undergoing antiviral therapy. PLoS One 2012;7:e47715. [PMID: 23082200 DOI: 10.1371/journal.pone.0047715] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 5.1] [Reference Citation Analysis]
150 Chen YC, Teng W, Hsieh YC, Chen WT, Jeng WJ, Huang CH, Lin CC, Chen YC, Lin SM, Lin CY, Sheen IS. Timely eradication of HCV viremia by PegIFN/RBV is crucial in prevention of post RFA recurrence in CHC-HCC patients. J Formos Med Assoc 2019;118:1239-46. [PMID: 30581103 DOI: 10.1016/j.jfma.2018.11.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
151 Turcanu A, Pitel E, Dumbrava VT, Tcaciuc E, Donscaia A, Peltec A, Pineau P. Profile of hepatocellular carcinoma in the Republic of Moldova: first-hand information on the presentation, distribution and etiologies. Rom J Intern Med 2019;57:37-46. [PMID: 30375353 DOI: 10.2478/rjim-2018-0026] [Reference Citation Analysis]
152 Li X, Xu H, Gao P. Fibrosis Index Based on 4 Factors (FIB-4) Predicts Liver Cirrhosis and Hepatocellular Carcinoma in Chronic Hepatitis C Virus (HCV) Patients. Med Sci Monit 2019;25:7243-50. [PMID: 31558693 DOI: 10.12659/MSM.918784] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
153 Pham TTT, Ho DT, Nguyen T. Usefulness of Mac-2 binding protein glycosylation isomer in non-invasive probing liver disease in the Vietnamese population. World J Hepatol 2020; 12(5): 220-229 [PMID: 32547689 DOI: 10.4254/wjh.v12.i5.220] [Reference Citation Analysis]
154 Zhang Y, Shi Y, Wu R, Wang X, Gao X, Niu J. Primary biliary cholangitis is more severe in previous hepatitis B virus infection patients. Eur J Gastroenterol Hepatol. 2018;30:682-686. [PMID: 29462025 DOI: 10.1097/meg.0000000000001100] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 2.3] [Reference Citation Analysis]
155 Androutsakos T, Schina M, Pouliakis A, Kontos A, Sipsas N, Hatzis G. Liver Fibrosis Assessment in a Cohort of Greek HIV Mono-Infected Patients by Non-Invasive Biomarkers. Curr HIV Res 2019;17:173-82. [PMID: 31549590 DOI: 10.2174/1570162X17666190809153245] [Reference Citation Analysis]
156 Giannini EG, Crespi M, Demarzo M, Bodini G, Furnari M, Marabotto E, Torre F, Zentilin P, Savarino V. Improvement in hepatitis C virus patients with advanced, compensated liver disease after sustained virological response to direct acting antivirals. Eur J Clin Invest. 2019;49:e13056. [PMID: 30474209 DOI: 10.1111/eci.13056] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 7.0] [Reference Citation Analysis]
157 Cengiz M, Ozenirler S. Comparative diagnostic accuracy of red cell distribution width-to-platelet ratio versus noninvasive fibrosis scores for the diagnosis of liver fibrosis in biopsy-proven nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol. 2015;27:1293-1299. [PMID: 26302023 DOI: 10.1097/meg.0000000000000445] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
158 Treem WR, Palmer M, Lonjon-Domanec I, Seekins D, Dimick-Santos L, Avigan MI, Marcinak JF, Dash A, Regev A, Maller E, Patwardhan M, Lewis JH, Rockey DC, Di Bisceglie AM, Freston JW, Andrade RJ, Chalasani N. Consensus Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Adults with Chronic Viral Hepatitis and Adults with Cirrhosis Secondary to Hepatitis B, C and Nonalcoholic Steatohepatitis. Drug Saf 2021;44:133-65. [PMID: 33141341 DOI: 10.1007/s40264-020-01014-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
159 Goñi Esarte S, Juanbeltz R, Zozaya JM, Úriz JI, Castilla J, Herrero JI. Modification of liver fibrosis, glucose and lipid profile after hepatitis C virus clearance with direct-acting antiviral agents. Gastroenterol Hepatol 2020;43:248-55. [PMID: 32192765 DOI: 10.1016/j.gastrohep.2019.03.017] [Reference Citation Analysis]
160 Kusakabe A, Kurosaki M, Itakura J, Joko K, Akahane T, Tsuji K, Kobashi H, Sohda T, Kimura H, Narita R, Furuta K, Izumi N. Efficacy and safety of glecaprevir/pibrentasvir as retreatment therapy for patients with genotype 2 chronic hepatitis C who failed prior sofosbuvir plus ribavirin regimen. Hepatol Res 2019;49:1121-6. [PMID: 31209976 DOI: 10.1111/hepr.13387] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
161 Beckebaum S, Iacob S, Klein CG, Dechêne A, Varghese J, Baba HA, Sotiropoulos GC, Paul A, Gerken G, Cicinnati VR. Assessment of Allograft Fibrosis by Transient Elastography and Noninvasive Biomarker Scoring Systems in Liver Transplant Patients. Transplantation 2010;89:983-93. [DOI: 10.1097/tp.0b013e3181cc66ca] [Cited by in Crossref: 53] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
162 Imai H, Kamei H, Onishi Y, Ishizu Y, Ishigami M, Goto H, Ogura Y. Diagnostic Usefulness of APRI and FIB-4 for the Prediction of Liver Fibrosis After Liver Transplantation in Patients Infected with Hepatitis C Virus. Transplant Proc 2018;50:1431-6. [PMID: 29705278 DOI: 10.1016/j.transproceed.2018.03.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
163 Sterling RK, Shin D, Shin Y, French E, Stevens MP, Bajaj JS, DeWit M, Sanyal AJ. FIB-4 Predicts Need for Mechanical Ventilation in a Multi-ethnic National cohort of COVID-19. Hepatol Commun 2021. [PMID: 34222739 DOI: 10.1002/hep4.1737] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
164 Takeuchi H, Sugimoto K, Oshiro H, Iwatsuka K, Kono S, Yoshimasu Y, Kasai Y, Furuichi Y, Sakamaki K, Itoi T. Liver fibrosis: noninvasive assessment using supersonic shear imaging and FIB4 index in patients with non-alcoholic fatty liver disease. J Med Ultrason (2001). 2018;45:243-249. [PMID: 29128938 DOI: 10.1007/s10396-017-0840-3] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
165 Sou FM, Wu CK, Chang KC, Lu SN, Wang JH, Hung CH, Chen CH, Kee KM, Yen YH, Lin MT, Tsai MC, Hu TH. Clinical characteristics and prognosis of HCC occurrence after antiviral therapy for HCV patients between sustained and non-sustained responders. J Formos Med Assoc. 2019;118:504-513. [PMID: 30527565 DOI: 10.1016/j.jfma.2018.10.017] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
166 Azzaroli F, Mazzella G, Marchesini G, Brodosi L, Petroni ML. Fatty liver in pregnancy: a narrative review of two distinct conditions. Expert Rev Gastroenterol Hepatol 2020;14:127-35. [PMID: 31928239 DOI: 10.1080/17474124.2020.1715210] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
167 Suda G, Kudo M, Nagasaka A, Furuya K, Yamamoto Y, Kobayashi T, Shinada K, Tateyama M, Konno J, Tsukuda Y, Yamasaki K, Kimura M, Umemura M, Izumi T, Tsunematsu S, Sato F, Terashita K, Nakai M, Horimoto H, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N. Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C. J Gastroenterol 2016;51:733-40. [DOI: 10.1007/s00535-016-1162-8] [Cited by in Crossref: 83] [Cited by in F6Publishing: 74] [Article Influence: 16.6] [Reference Citation Analysis]
168 Teriaky A, Reau N. Evaluation of Hepatitis C Patients in the Direct-Acting Antiviral Era. Clin Liver Dis 2015;19:591-604, v. [PMID: 26466649 DOI: 10.1016/j.cld.2015.06.001] [Reference Citation Analysis]
169 Méndez-sánchez N, Paraná R, Cheinquer H, Alves de Mattos A, Gadano A, Silva M, Pessôa MG, Gomes-ferraz ML, Soza A, Mendes-correa MC, Chávez-tapia NC, Dagher L, Padilla M, Hernandez N, Sánchez-avila JF, Contreras F, Moraes-coelho HS, Parise ER, Bessone F, Uribe M. Latin American Association for the Study of the Liver Recommendations on Treatment of Hepatitis C. Annals of Hepatology 2014;13:S4-S66. [DOI: 10.1016/s1665-2681(19)30920-2] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
170 Alfaleh FZ, Alswat K, Helmy A, Al-hamoudi W, El-sharkawy M, Omar M, Shalaby A, Bedewi MA, Hadad Q, Ali SM, Alfaleh A, Abdo AA. The natural history and long-term outcomes in patients with chronic hepatitis C genotype 4 after interferon-based therapy. Liver Int 2013;33:871-83. [PMID: 23490034 DOI: 10.1111/liv.12127] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
171 Younossi ZM, Wong VW, Anstee QM, Romero-Gomez M, Trauner MH, Harrison SA, Lawitz EJ, Okanoue T, Camargo M, Kersey K, Myers RP, Goodman Z, Stepanova M. Fatigue and Pruritus in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: The Impact on Patient-Reported Outcomes. Hepatol Commun 2020;4:1637-50. [PMID: 33163834 DOI: 10.1002/hep4.1581] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
172 van den Berg EH, Wolters AAB, Dullaart RPF, Moshage H, Zurakowski D, de Meijer VE, Blokzijl H. Prescription of statins in suspected non-alcoholic fatty liver disease and high cardiovascular risk, a population-based study. Liver Int 2019;39:1343-54. [PMID: 30968536 DOI: 10.1111/liv.14116] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
173 Endo K, Sato T, Suzuki A, Yoshida Y, Kakisaka K, Miyasaka A, Takikawa Y. Sustained virologic response by direct-acting antivirals suppresses skeletal muscle loss in hepatitis C virus infection. J Gastroenterol Hepatol. 2020;35:1602-1609. [PMID: 31975438 DOI: 10.1111/jgh.14991] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
174 Nagata H, Nakagawa M, Asahina Y, Sato A, Asano Y, Tsunoda T, Miyoshi M, Kaneko S, Otani S, Kawai-Kitahata F, Murakawa M, Nitta S, Itsui Y, Azuma S, Kakinuma S, Nouchi T, Sakai H, Tomita M, Watanabe M; Ochanomizu Liver Conference Study Group. Effect of interferon-based and -free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C. J Hepatol. 2017;67:933-939. [PMID: 28627363 DOI: 10.1016/j.jhep.2017.05.028] [Cited by in Crossref: 117] [Cited by in F6Publishing: 113] [Article Influence: 29.3] [Reference Citation Analysis]
175 Tsai YF, Liu YC, Yang CI, Chuang TM, Ke YL, Yeh TJ, Gau YC, Du JS, Wang HC, Cho SF, Hsu CM, Wu PF, Huang CI, Huang CF, Yu ML, Dai CY, Hsiao HH. Poor Prognosis of Diffuse Large B-Cell Lymphoma with Hepatitis C Infection. J Pers Med 2021;11:844. [PMID: 34575621 DOI: 10.3390/jpm11090844] [Reference Citation Analysis]
176 Ngu JH, Goh GB, Poh Z, Soetikno R. Managing non-alcoholic fatty liver disease. Singapore Med J 2016;57:368-71. [PMID: 27439352 DOI: 10.11622/smedj.2016119] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
177 Armutcu F, Akyol S, Ucar F, Erdogan S, Akyol O. Markers in Nonalcoholic Steatohepatitis. Elsevier; 2013. pp. 67-125. [DOI: 10.1016/b978-0-12-407680-8.00004-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 1.1] [Reference Citation Analysis]
178 Yamashita Y, Joshita S, Sugiura A, Yamazaki T, Kobayashi H, Wakabayashi SI, Yamada Y, Shibata S, Kunimoto H, Iwadare T, Matsumura M, Miyabayashi C, Okumura T, Ozawa S, Nozawa Y, Kobayashi N, Komatsu M, Fujimori N, Saito H, Umemura T. aMAP score prediction of hepatocellular carcinoma occurrence and incidence-free rate after a sustained virologic response in chronic hepatitis C. Hepatol Res 2021. [PMID: 34216422 DOI: 10.1111/hepr.13689] [Reference Citation Analysis]
179 Fujita K, Niki T, Nomura T, Oura K, Tadokoro T, Sakamoto T, Tani J, Yoneyama H, Morishita A, Kuroda N, Arai T, Nishimoto N, Himoto T, Hirashima M, Masaki T. Correlation between serum galectin-9 levels and liver fibrosis. J Gastroenterol Hepatol 2018;33:492-9. [PMID: 28618039 DOI: 10.1111/jgh.13851] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
180 Smith JO, Sterling RK. Systematic review: non-invasive methods of fibrosis analysis in chronic hepatitis C. Alimentary Pharmacology & Therapeutics 2009;30:557-76. [DOI: 10.1111/j.1365-2036.2009.04062.x] [Cited by in Crossref: 86] [Cited by in F6Publishing: 86] [Article Influence: 7.2] [Reference Citation Analysis]
181 Na SK, Lee SJ, Cho YK, Kim YN, Choi EK, Song BC. Aspartate Aminotransferase-to-Platelet Ratio or Fibros-4 Index Predicts the Development of Hepatocellular Carcinoma in Chronic Hepatitis C Patients with Sustained Virologic Response to Interferon Therapy. J Interferon Cytokine Res. 2019;39:703-710. [PMID: 31216229 DOI: 10.1089/jir.2019.0049] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
182 Romero-Cristóbal M, Clemente-Sánchez A, Piñeiro P, Cedeño J, Rayón L, Del Río J, Ramos C, Hernández DA, Cova M, Caballero A, Garutti I, García-Olivares P, Hortal J, Guerrero JE, García R, Bañares R, Rincón D. Possible unrecognised liver injury is associated with mortality in critically ill COVID-19 patients. Therap Adv Gastroenterol 2021;14:17562848211023410. [PMID: 34178116 DOI: 10.1177/17562848211023410] [Reference Citation Analysis]
183 Başar O, Yimaz B, Ekiz F, Giniş Z, Altinbaş A, Aktaş B, Tuna Y, Çoban S, Delibaş N, Yüksel O. Non-invasive tests in prediction of liver fibrosis in chronic hepatitis B and comparison with post-antiviral treatment results. Clin Res Hepatol Gastroenterol 2013;37:152-8. [PMID: 23391746 DOI: 10.1016/j.clinre.2012.07.003] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
184 Song DS, Chang UI, Kang SG, Song SW, Yang JM. Noninvasive Serum Fibrosis Markers are Associated with Coronary Artery Calcification in Patients with Nonalcoholic Fatty Liver Disease. Gut Liver 2019;13:658-68. [PMID: 30970434 DOI: 10.5009/gnl18439] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 13.0] [Reference Citation Analysis]
185 Lee CK, Nastasio S, Mitchell PD, Fawaz R, Elisofon SA, Vakili K, Kim HB, Nguyen D, Jonas MM. Transient elastography assessment of liver allograft fibrosis in pediatric transplant recipients. Pediatr Transplant 2020;24:e13736. [PMID: 32432836 DOI: 10.1111/petr.13736] [Reference Citation Analysis]
186 Halfon P, Munteanu M, Poynard T. FibroTest-ActiTest as a non-invasive marker of liver fibrosis. Gastroenterol Clin Biol. 2008;32:22-39. [PMID: 18973844 DOI: 10.1016/s0399-8320(08)73991-5] [Cited by in Crossref: 77] [Cited by in F6Publishing: 26] [Article Influence: 6.4] [Reference Citation Analysis]
187 Tsukano N, Miyase S, Saeki T, Mizobe K, Iwashita H, Arima N, Fujiyama S. Usefulness of virtual touch quantification for staging liver fibrosis in patients with hepatitis C, and factors affecting liver stiffness measurement failure compared with liver biopsy: Usefulness of VTQ and factors of failure. Hepatol Res 2018;48:373-82. [DOI: 10.1111/hepr.13041] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
188 McMahon BJ. Chronic hepatitis B virus infection. Med Clin North Am. 2014;98:39-54. [PMID: 24266913 DOI: 10.1016/j.mcna.2013.08.004] [Cited by in Crossref: 54] [Cited by in F6Publishing: 51] [Article Influence: 6.8] [Reference Citation Analysis]
189 Tsai IT, Hung WC, Lu YC, Wu CC, Lee TL, Hsuan CF, Yu TH, Wei CT, Chung FM, Lee YJ, Wang CP. Circulating hepassocin level in patients with stable angina is associated with fatty liver and renal function. Int J Med Sci 2021;18:1-7. [PMID: 33390768 DOI: 10.7150/ijms.50646] [Reference Citation Analysis]
190 Barocas JA, So-Armah K, Cheng DM, Lioznov D, Baum M, Gallagher K, Fuster D, Gnatienko N, Krupitsky E, Freiberg MS, Samet JH. Zinc deficiency and advanced liver fibrosis among HIV and hepatitis C co-infected anti-retroviral naïve persons with alcohol use in Russia. PLoS One 2019;14:e0218852. [PMID: 31246992 DOI: 10.1371/journal.pone.0218852] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
191 Deng Y, Zhao H, Zhou J, Yan L, Wang G; China HepB-Related Fibrosis Assessment Research Group. Angiopoietin-like protein as a novel marker for liver fibrosis in chronic hepatitis B patients with normal to minimally raised ALT. BMC Infect Dis 2017;17:650. [PMID: 28962551 DOI: 10.1186/s12879-017-2728-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
192 Jaroszewicz J, Flisiak-jackiewicz M, Lebensztejn D, Flisiak R. Current drugs in early development for treating hepatitis C virus-related hepatic fibrosis. Expert Opinion on Investigational Drugs 2015;24:1229-39. [DOI: 10.1517/13543784.2015.1057568] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
193 Wang CW, Liao KW, Chan CC, Yu ML, Chuang HY, Chiang HC, Huang PC. Association between urinary thiodiglycolic acid level and hepatic function or fibrosis index in school-aged children living near a petrochemical complex. Environ Pollut 2019;244:648-56. [PMID: 30384070 DOI: 10.1016/j.envpol.2018.10.012] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
194 Davison BA, Edwards C, Loomba R, Harrison SA, Cotter G, Alkhouri N, Koch GG, Dittrich HC. Noninvasive measure of treatment response in non-alcoholic steatohepatitis: Insights from EMMINENCE and meta-analysis. JGH Open 2021;5:740-9. [PMID: 34263067 DOI: 10.1002/jgh3.12575] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
195 Younossi ZM, Corey KE, Alkhouri N, Noureddin M, Jacobson I, Lam B, Clement S, Basu R, Gordon SC, Ravendhra N, Puri P, Rinella M, Scudera P, Singal AK, Henry L; US Members of the Global Nash Council. Clinical assessment for high-risk patients with non-alcoholic fatty liver disease in primary care and diabetology practices.Aliment Pharmacol Ther. 2020;52:513-526. [PMID: 32598051 DOI: 10.1111/apt.15830] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 12.0] [Reference Citation Analysis]
196 Zhong LK, Zhang G, Luo SY, Yin W, Song HY. The value of platelet count in evaluating the degree of liver fibrosis in patients with chronic hepatitis B. J Clin Lab Anal 2020;34:e23270. [PMID: 32363594 DOI: 10.1002/jcla.23270] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
197 Ogawa E, Furusyo N, Dohmen K, Kajiwara E, Kawano A, Nomura H, Takahashi K, Satoh T, Azuma K, Nakamuta M, Koyanagi T, Kotoh K, Shimoda S, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group. Effectiveness of triple therapy with simeprevir for chronic hepatitis C genotype 1b patients with prior telaprevir failure. J Viral Hepat 2015;22:992-1001. [PMID: 26075320 DOI: 10.1111/jvh.12427] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
198 Shirabe K, Bekki Y, Gantumur D, Araki K, Ishii N, Kuno A, Narimatsu H, Mizokami M. Mac-2 binding protein glycan isomer (M2BPGi) is a new serum biomarker for assessing liver fibrosis: more than a biomarker of liver fibrosis. J Gastroenterol 2018;53:819-26. [PMID: 29318378 DOI: 10.1007/s00535-017-1425-z] [Cited by in Crossref: 57] [Cited by in F6Publishing: 58] [Article Influence: 19.0] [Reference Citation Analysis]
199 Fujimoto K, Shiinoki T, Yuasa Y, Tanaka H. Estimation of liver elasticity using the finite element method and four-dimensional computed tomography images as a biomarker of liver fibrosis. Med Phys 2021;48:1286-98. [PMID: 33449406 DOI: 10.1002/mp.14723] [Reference Citation Analysis]
200 Sneij A, Campa A, Martinez SS, Stewart T, Baum M. Lower Plasma Zinc Levels in Hyperglycemic People Living with HIV in the MASH cohort. J AIDS Clin Res 2016;7:542. [PMID: 27182454 DOI: 10.4172/2155-6113.1000542] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
201 Nagaoki Y, Hyogo H, Ando Y, Kosaka Y, Uchikawa S, Nishida Y, Teraoka Y, Morio K, Fujino H, Ono A, Nakahara T, Murakami E, Yamauchi M, Okamoto W, Kawaoka T, Tsuge M, Hiramatsu A, Miki D, Imamura M, Takahashi S, Chayama K, Aikata H. Increasing incidence of non-HBV- and non-HCV-related hepatocellular carcinoma: single-institution 20-year study. BMC Gastroenterol 2021;21:306. [PMID: 34332532 DOI: 10.1186/s12876-021-01884-5] [Reference Citation Analysis]
202 Kuno A, Ikehara Y, Tanaka Y, Ito K, Matsuda A, Sekiya S, Hige S, Sakamoto M, Kage M, Mizokami M, Narimatsu H. A serum "sweet-doughnut" protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis. Sci Rep. 2013;3:1065. [PMID: 23323209 DOI: 10.1038/srep01065] [Cited by in Crossref: 215] [Cited by in F6Publishing: 197] [Article Influence: 26.9] [Reference Citation Analysis]
203 Xu K, Shi M, Zhang W, Shi Y, Dong Q, Shen X, Chen X, Lin J. Preoperative Fibrosis-4 (FIB-4) Evaluation May Be Helpful to Evaluate Prognosis of Gastric Cancer Patients Undergoing Operation: A Retrospective Study. Front Oncol 2021;11:655343. [PMID: 34221972 DOI: 10.3389/fonc.2021.655343] [Reference Citation Analysis]
204 Gounder PP, Bulkow LR, Snowball M, Negus S, Spradling PR, Simons BC, McMahon BJ. Nested case-control study: hepatocellular carcinoma risk after hepatitis B surface antigen seroclearance. Aliment Pharmacol Ther 2016;43:1197-207. [PMID: 27061300 DOI: 10.1111/apt.13621] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
205 Ishigami M, Hayashi K, Honda T, Kuzuya T, Ishizu Y, Ishikawa T, Nakano I, Urano F, Kumada T, Yoshioka K, Goto H, Hirooka Y. Daclatasvir and asunaprevir treatment in patients with severe liver fibrosis by hepatitis C virus genotype 1b infection: Real-world data: DEVTASV in patients with severe fibrosis. Journal of Gastroenterology and Hepatology 2017;32:1879-86. [DOI: 10.1111/jgh.13779] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
206 Hsu SJ, Chiu MC, Fang YJ, Yang TH, Yu JJ, Chen CC, Kuo CC, Lee JY, Chen CH, Chen DS, Kao JH. Real-world effectiveness and safety of glecaprevir/pibrentasvir in Asian patients with chronic hepatitis C. J Formos Med Assoc 2019;118:1187-92. [PMID: 31279502 DOI: 10.1016/j.jfma.2019.06.014] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
207 Dong J, Xu X, Ke M, Xiang J, Liu W, Liu X, Wang B, Zhang X, Lv Y. The FIB-4 score predicts postoperative short-term outcomes of hepatocellular carcinoma fulfilling the milan criteria. European Journal of Surgical Oncology (EJSO) 2016;42:722-7. [DOI: 10.1016/j.ejso.2016.02.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
208 Castera L. Invasive and non-invasive methods for the assessment of fibrosis and disease progression in chronic liver disease. Best Pract Res Clin Gastroenterol. 2011;25:291-303. [PMID: 21497746 DOI: 10.1016/j.bpg.2011.02.003] [Cited by in Crossref: 91] [Cited by in F6Publishing: 79] [Article Influence: 9.1] [Reference Citation Analysis]
209 Fujita K, Yamasaki K, Morishita A, Shi T, Tani J, Nishiyama N, Kobara H, Himoto T, Yatsuhashi H, Masaki T. Albumin platelet product as a novel score for liver fibrosis stage and prognosis. Sci Rep 2021;11:5345. [PMID: 33674669 DOI: 10.1038/s41598-021-84719-3] [Reference Citation Analysis]
210 Paggi S, Colli A, Fraquelli M, Viganò M, Poggio PD, Facciotto C, Colombo M, Ronchi G, Conte D. A non-invasive algorithm accurately predicts advanced fibrosis in hepatitis C: A comparison using histology with internal–external validation. Journal of Hepatology 2008;49:564-71. [DOI: 10.1016/j.jhep.2008.07.007] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
211 Baranova A, Lal P, Birerdinc A, Younossi ZM. Non-invasive markers for hepatic fibrosis. BMC Gastroenterol. 2011;11:91. [PMID: 21849046 DOI: 10.1186/1471-230x-11-91] [Cited by in Crossref: 181] [Cited by in F6Publishing: 78] [Article Influence: 18.1] [Reference Citation Analysis]
212 Yabe Y, Kim T, Oh S, Shida T, Oshida N, Hasegawa N, Okada K, Someya N, Mizokami Y, Shoda J. Relationships of Dietary Habits and Physical Activity Status with Non-Alcoholic Fatty Liver Disease Featuring Advanced Fibrosis. Int J Environ Res Public Health 2021;18:8918. [PMID: 34501508 DOI: 10.3390/ijerph18178918] [Reference Citation Analysis]
213 Hanai T, Hiraoka A, Shiraki M, Sugimoto R, Taniki N, Hiramatsu A, Nakamoto N, Iwasa M, Chayama K, Shimizu M. Utility of the SARC-F Questionnaire for Sarcopenia Screening in Patients with Chronic Liver Disease: A Multicenter Cross-Sectional Study in Japan. J Clin Med 2021;10:3448. [PMID: 34362231 DOI: 10.3390/jcm10153448] [Reference Citation Analysis]
214 Bourgi K, Brar I, Baker-Genaw K. Health Disparities in Hepatitis C Screening and Linkage to Care at an Integrated Health System in Southeast Michigan. PLoS One 2016;11:e0161241. [PMID: 27525983 DOI: 10.1371/journal.pone.0161241] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 7.0] [Reference Citation Analysis]
215 Kumada T, Toyoda H, Yasuda S, Sone Y, Ogawa S, Takeshima K, Tada T, Ito T, Sumida Y, Tanaka J. Prediction of Hepatocellular Carcinoma by Liver Stiffness Measurements Using Magnetic Resonance Elastography After Eradicating Hepatitis C Virus. Clin Transl Gastroenterol 2021;12:e00337. [PMID: 33888672 DOI: 10.14309/ctg.0000000000000337] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
216 Huang YT, Hsieh YY, Chen WM, Tung SY, Wei KL, Shen CH, Chang KC, Lu CK, Yen CW, Lu SN, Hung CH, Chang TS. Sofosbuvir/velpatasvir is an effective treatment for patients with hepatitis C and advanced fibrosis or cirrhosis in a real-world setting in Taiwan. BMC Gastroenterol 2021;21:259. [PMID: 34118889 DOI: 10.1186/s12876-021-01837-y] [Reference Citation Analysis]
217 Suda G, Nagasaka A, Yamamoto Y, Furuya K, Kumagai K, Kudo M, Terashita K, Kobayashi T, Tsunematsu I, Yoshida J, Meguro T, Kimura M, Ito J, Umemura M, Izumi T, Tsunematsu S, Sato F, Tsukuda Y, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N; NORTE Study Group. Safety and efficacy of daclatasvir and asunaprevir in hepatitis C virus-infected patients with renal impairment. Hepatol Res 2017;47:1127-36. [PMID: 27943523 DOI: 10.1111/hepr.12851] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 7.0] [Reference Citation Analysis]
218 de Lédinghen V, Poynard T, Wartelle C, Rosenthal E. [Non-invasive evaluation of liver fibrosis in hepatitis C]. Gastroenterol Clin Biol 2008;32:S90-5. [PMID: 18675186 DOI: 10.1016/S0399-8320(08)73271-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
219 Yong SH, Leem AY, Kim YS, Park MS, Chang J, Kim SU, Jung JY. Hepatic Fibrosis Assessed Using Fibrosis-4 Index Is Predictive of All-Cause Mortality in Patients with Chronic Obstructive Pulmonary Disease. Int J Chron Obstruct Pulmon Dis 2020;15:831-9. [PMID: 32368029 DOI: 10.2147/COPD.S242863] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
220 Usluer G, Erben N, Aykin N, Dagli O, Aydogdu O, Barut S, Cevik F, Ormen B. Comparison of non-invasive fibrosis markers and classical liver biopsy in chronic hepatitis C. Eur J Clin Microbiol Infect Dis. 2012;31:1873-1878. [PMID: 22231498 DOI: 10.1007/s10096-011-1513-6] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.7] [Reference Citation Analysis]
221 Yang HR, Kim HR, Kim MJ, Ko JS, Seo JK. Noninvasive Parameters and hepatic fibrosis scores in children with nonalcoholic fatty liver disease. World J Gastroenterol 2012; 18(13): 1525-1530 [PMID: 22509085 DOI: 10.3748/wjg.v18.i13.1525] [Cited by in CrossRef: 54] [Cited by in F6Publishing: 48] [Article Influence: 6.0] [Reference Citation Analysis]
222 Bolte FJ, O'Keefe AC, Webb LM, Serti E, Rivera E, Liang TJ, Ghany M, Rehermann B. Intra-Hepatic Depletion of Mucosal-Associated Invariant T Cells in Hepatitis C Virus-Induced Liver Inflammation. Gastroenterology. 2017;153:1392-1403.e2. [PMID: 28780074 DOI: 10.1053/j.gastro.2017.07.043] [Cited by in Crossref: 51] [Cited by in F6Publishing: 53] [Article Influence: 12.8] [Reference Citation Analysis]
223 Castera L. Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterology. 2012;142:1293-1302.e4. [PMID: 22537436 DOI: 10.1053/j.gastro.2012.02.017] [Cited by in Crossref: 411] [Cited by in F6Publishing: 366] [Article Influence: 45.7] [Reference Citation Analysis]
224 Isfordink CJ, van Erpecum KJ, van der Valk M, Mauser-Bunschoten EP, Makris M. Viral hepatitis in haemophilia: historical perspective and current management. Br J Haematol 2021. [PMID: 33955555 DOI: 10.1111/bjh.17438] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
225 Shida T, Oshida N, Oh S, Okada K, Shoda J. Progressive reduction in skeletal muscle mass to visceral fat area ratio is associated with a worsening of the hepatic conditions of non-alcoholic fatty liver disease. Diabetes Metab Syndr Obes 2019;12:495-503. [PMID: 31114278 DOI: 10.2147/DMSO.S185705] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
226 Dharan NJ, Neuhaus J, Rockstroh JK, Peters L, Gordin F, Arenas-Pinto A, Emerson C, Marks K, Hidalgo J, Sarmento-Castro R, Stephan C, Kumarasamy N, Emery S, Matthews GV; INSIGHT START Study Group. Benefit of Early versus Deferred Antiretroviral Therapy on Progression of Liver Fibrosis among People with HIV in the START Randomized Trial. Hepatology 2019;69:1135-50. [PMID: 30298608 DOI: 10.1002/hep.30296] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
227 Marella HK, Reddy YK, Jiang Y, Ganguli S, Podila PSB, Snell PD, Kovalic AJ, Cholankeril G, Singal AK, Nair S, Maliakkal B, Satapathy SK. Accuracy of Noninvasive Fibrosis Scoring Systems in African American and White Patients With Nonalcoholic Fatty Liver Disease. Clin Transl Gastroenterol 2020;11:e00165. [PMID: 32352687 DOI: 10.14309/ctg.0000000000000165] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
228 Li X, Guo Y, Wang X, Ge A, Wang H, Fan K, Guo C. Clinical significance of serum miR-487b in HBV-related hepatocellular carcinoma and its potential mechanism. Infect Dis (Lond) 2021;53:546-54. [PMID: 33783293 DOI: 10.1080/23744235.2021.1901981] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
229 Itokawa N, Atsukawa M, Tsubota A, Ikegami T, Shimada N, Kato K, Abe H, Okubo T, Arai T, Iwashita AN, Kondo C, Mikami S, Asano T, Matsuzaki Y, Toyoda H, Kumada T, Iio E, Tanaka Y, Iwakiri K. Efficacy of direct-acting antiviral treatment in patients with compensated liver cirrhosis: A multicenter study. Hepatol Res 2019;49:125-35. [PMID: 30307682 DOI: 10.1111/hepr.13256] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
230 Kang S, Moon MK, Kim W, Koo BK. Association between muscle strength and advanced fibrosis in non-alcoholic fatty liver disease: a Korean nationwide survey. J Cachexia Sarcopenia Muscle 2020;11:1232-41. [PMID: 32638541 DOI: 10.1002/jcsm.12598] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
231 Boursier J, Brochard C, Bertrais S, Michalak S, Gallois Y, Fouchard-Hubert I, Oberti F, Rousselet MC, Calès P. Combination of blood tests for significant fibrosis and cirrhosis improves the assessment of liver-prognosis in chronic hepatitis C. Aliment Pharmacol Ther. 2014;40:178-188. [PMID: 24889599 DOI: 10.1111/apt.12813] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 4.1] [Reference Citation Analysis]
232 Zhang GM, Xia YJ. Reference Intervals of Fibrosis Index Based on Four Indicators in Healthy Elderly Chinese. J Clin Lab Anal 2016;30:645-8. [PMID: 26953257 DOI: 10.1002/jcla.21916] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
233 Wong GL. Non-invasive assessments for liver fibrosis: The crystal ball we long for: Assessments for liver fibrosis. Journal of Gastroenterology and Hepatology 2018;33:1009-15. [DOI: 10.1111/jgh.14103] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
234 Sebastiani G, Castera L, Halfon P, Pol S, Mangia A, Di Marco V, Pirisi M, Voiculescu M, Bourliere M, Alberti A. The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers: an international study of 2411 cases: Liver fibrosis biomarkers, aetiology and fibrosis stages. Alimentary Pharmacology & Therapeutics 2011;34:1202-16. [DOI: 10.1111/j.1365-2036.2011.04861.x] [Cited by in Crossref: 86] [Cited by in F6Publishing: 83] [Article Influence: 8.6] [Reference Citation Analysis]
235 Bonder A, Tapper EB, Afdhal NH. Contemporary Assessment of Hepatic Fibrosis. Clinics in Liver Disease 2015;19:123-34. [DOI: 10.1016/j.cld.2014.09.007] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
236 Soriano V, Mcmahon B. Strategic use of lamivudine in the management of chronic hepatitis B. Antiviral Research 2013;100:435-8. [DOI: 10.1016/j.antiviral.2013.08.026] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
237 Tomeno W, Yoneda M, Imajo K, Suzuki K, Ogawa Y, Shinohara Y, Mawatari H, Fujita K, Shibata W, Kirikoshi H, Maeda S, Nakajima A, Saito S. Evaluation of the Liver Fibrosis Index calculated by using real-time tissue elastography for the non-invasive assessment of liver fibrosis in chronic liver diseases. Hepatol Res. 2013;43:735-742. [PMID: 23216963 DOI: 10.1111/hepr.12023] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
238 Papaluca T, Craigie A, McDonald L, Edwards A, MacIsaac M, Holmes JA, Jarman M, Lee T, Huang H, Chan A, Lai M, Sundararajan V, Doyle JS, Hellard M, Stoove M, Howell J, Desmond P, Iser D, Thompson AJ. Non-invasive fibrosis algorithms are clinically useful for excluding cirrhosis in prisoners living with hepatitis C. PLoS One 2020;15:e0242101. [PMID: 33206696 DOI: 10.1371/journal.pone.0242101] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
239 Li Q, Huang C, Xu W, Hu Q, Chen L. Accuracy of FibroScan in analysis of liver fibrosis in patients with concomitant chronic Hepatitis B and nonalcoholic fatty liver disease. Medicine (Baltimore) 2020;99:e20616. [PMID: 32502037 DOI: 10.1097/MD.0000000000020616] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
240 Chiang H, Lee C, Hu T, Hung C, Wang J, Lu S, Lai H, Su W, Lin C, Peng C, Chen C. A combination of the on-treatment FIB-4 and alpha-foetoprotein predicts clinical outcomes in cirrhotic patients receiving entecavir. Liver Int 2018;38:1997-2005. [DOI: 10.1111/liv.13889] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
241 Mallet V, Dhalluin-Venier V, Roussin C, Bourliere M, Pettinelli ME, Giry C, Vallet-Pichard A, Fontaine H, Pol S. The accuracy of the FIB-4 index for the diagnosis of mild fibrosis in chronic hepatitis B. Aliment Pharmacol Ther. 2009;29:409-415. [PMID: 19035983 DOI: 10.1111/j.1365-2036.2008.03895.x] [Cited by in Crossref: 63] [Cited by in F6Publishing: 65] [Article Influence: 4.8] [Reference Citation Analysis]
242 Marjot T, Moolla A, Cobbold JF, Hodson L, Tomlinson JW. Nonalcoholic Fatty Liver Disease in Adults: Current Concepts in Etiology, Outcomes, and Management. Endocr Rev. 2020;41. [PMID: 31629366 DOI: 10.1210/endrev/bnz009] [Cited by in Crossref: 30] [Cited by in F6Publishing: 35] [Article Influence: 30.0] [Reference Citation Analysis]
243 Del Bello D, Cha A, Sorbera M, Bichoupan K, Levine C, Doyle E, Harty A, Patel N, Ng M, Gardenier D. Real-World Sustained Virologic Response Rates of Sofosbuvir-Containing Regimens in Patients Coinfected With Hepatitis C and HIV. Clin Infect Dis. 2016;62:1497-1504. [PMID: 26936665 DOI: 10.1093/cid/ciw119] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 4.2] [Reference Citation Analysis]
244 Jackson JA, Konomi JV, Mendoza MV, Krasinskas A, Jin R, Caltharp S, Mouzaki M, Vos MB. Performance of fibrosis prediction scores in paediatric non-alcoholic fatty liver disease: Fibrosis scores in fatty liver disease. J Paediatr Child Health 2018;54:172-6. [DOI: 10.1111/jpc.13689] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
245 Liu X, Xu H, Zhan M, Niu J. The Potential Effects of Diabetes Mellitus on Liver Fibrosis in Patients with Primary Biliary Cholangitis. Med Sci Monit 2019;25:6174-80. [PMID: 31420961 DOI: 10.12659/MSM.916107] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
246 Kumada T, Toyoda H, Yasuda S, Tada T, Ito T, Tanaka J. Long-term outcomes of viral eradication in patients with hepatitis C virus infection and mild hepatic fibrosis. J Viral Hepat 2021;28:1293-303. [PMID: 34185932 DOI: 10.1111/jvh.13562] [Reference Citation Analysis]
247 Lim TS, Lee HW, Lee JI, Kim IH, Lee CH, Jang BK, Chung WJ, Yim HJ, Suh SJ, Seo YS, Lee HA, Yu JH, Lee J, Kim SG, Kim YS, Park SY, Tak WY, Kim SS, Cheong JY, Jeong SW, Jang JY, Rou WS, Lee BS, Kim SU; The Korean Transient Elastography Study Group. Predictive score for hepatocellular carcinoma after hepatitis B e antigen loss in patients treated with entecavir or tenofovir. J Viral Hepat 2020;27:1052-60. [DOI: 10.1111/jvh.13316] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
248 Chindamo MC, Boursier J, Luiz RR, Fouchard-Hubert I, Pannain VLN, de Araújo Neto JM, Coelho HSM, de Mello Perez R, Calès P, Villela-Nogueira CA. Fibrosis assessment using FibroMeter combined to first generation tests in hepatitis C. World J Hepatol 2017; 9(6): 310-317 [PMID: 28293380 DOI: 10.4254/wjh.v9.i6.310] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
249 Schreiner AD, Zhang J, Durkalski-Mauldin V, Livingston S, Marsden J, Bian J, Mauldin PD, Moran WP, Rockey DC. Advanced liver fibrosis and the metabolic syndrome in a primary care setting. Diabetes Metab Res Rev 2021. [PMID: 33759300 DOI: 10.1002/dmrr.3452] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
250 Oono T, Yamasaki T, Zaitsu J, Saeki I, Iwamoto T, Harima Y, Marumoto Y, Hidaka I, Urata Y, Ishikawa T, Takami T, Segawa M, Uchida K, Terai S, Kunitugu I, Tanabe T, Sakaida I. Association of tyrosine with insulin resistance in hepatitis C virus-related chronic liver disease. Hepatol Res 2014;44:E54-62. [PMID: 23905687 DOI: 10.1111/hepr.12213] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
251 Sekimoto T, Maruyama H, Kondo T, Shimada T, Takahashi M, Yokosuka O, Otsuka M, Miyazaki M, Mine Y. Virtual laparoscopy: Initial experience with three-dimensional ultrasonography to characterize hepatic surface features. European Journal of Radiology 2013;82:929-34. [DOI: 10.1016/j.ejrad.2013.01.015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
252 Wang Z, Bertot LC, Jeffrey GP, Joseph J, Garas G, de Boer B, Huang Y, MacQuillan G, Wallace M, Smith B, Adams LA. Serum Fibrosis Tests Guide Prognosis in Metabolic Dysfunction-Associated Fatty Liver Disease Patients Referred From Primary Care. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01055-7. [PMID: 34624564 DOI: 10.1016/j.cgh.2021.09.040] [Reference Citation Analysis]
253 Galal G, Tammam H, Abdel Aal A, Fahmy N, Sheneef A, Ahmed N, Zaghloul A. Role of Lymphotoxin-α Gene Polymorphism in Hepatitis C Virus-Related Chronic Liver Disorders. Infect Drug Resist 2021;14:1921-30. [PMID: 34079302 DOI: 10.2147/IDR.S306879] [Reference Citation Analysis]
254 Qi X, An W, Liu F, Qi R, Wang L, Liu Y, Liu C, Xiang Y, Hui J, Liu Z, Qi X, Liu C, Peng B, Ding H, Yang Y, He X, Hou J, Tian J, Li Z. Virtual Hepatic Venous Pressure Gradient with CT Angiography (CHESS 1601): A Prospective Multicenter Study for the Noninvasive Diagnosis of Portal Hypertension. Radiology. 2019;290:370-377. [PMID: 30457484 DOI: 10.1148/radiol.2018180425] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
255 Bichoupan K, Tandon N, Martel-Laferriere V, Patel NM, Sachs D, Ng M, Schonfeld EA, Pappas A, Crismale J, Stivala A, Khaitova V, Gardenier D, Linderman M, Olson W, Perumalswami PV, Schiano TD, Odin JA, Liu LU, Dieterich DT, Branch AD. Factors associated with success of telaprevir- and boceprevir-based triple therapy for hepatitis C virus infection. World J Hepatol 2017; 9(11): 551-561 [PMID: 28469811 DOI: 10.4254/wjh.v9.i11.551] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
256 Kallwitz ER, Tayo BO, Kuniholm MH, Cai J, Daviglus M, Cooper RS, Cotler SJ. American Ancestry Is a Risk Factor for Suspected Nonalcoholic Fatty Liver Disease in Hispanic/Latino Adults. Clin Gastroenterol Hepatol. 2019;17:2301-2309. [PMID: 30743004 DOI: 10.1016/j.cgh.2019.02.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
257 Seki N, Sugita T, Aida Y, Itagaki M, Ishiguro H, Sutoh S, Abe H, Tsubota A, Matsushima M, Aizawa Y. Assessment of the features of serum apolipoprotein profiles in chronic HCV infection: difference between HCV genotypes 1b and 2. Hepatol Int. 2014;8:550-559. [PMID: 26202760 DOI: 10.1007/s12072-014-9572-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
258 Montano-Loza AJ, Thandassery RB, Czaja AJ. Targeting Hepatic Fibrosis in Autoimmune Hepatitis. Dig Dis Sci. 2016;61:3118-3139. [PMID: 27435327 DOI: 10.1007/s10620-016-4254-7] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
259 Yoshikawa K, Iwasa M, Eguchi A, Kojima S, Yoshizawa N, Tempaku M, Sugimoto R, Yamamoto N, Sugimoto K, Kobayashi Y, Hasegawa H, Takei Y. Neutrophil gelatinase-associated lipocalin level is a prognostic factor for survival in rat and human chronic liver diseases. Hepatol Commun 2017;1:946-56. [PMID: 29404502 DOI: 10.1002/hep4.1109] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
260 Choi J, Choi GH, Lee D, Shim JH, Lim YS, Lee HC, Chung YH, Lee YS, Kim KM. Long-term clinical outcomes in patients with autoimmune hepatitis according to treatment response in Asian country. Liver Int 2019;39:985-94. [PMID: 30821090 DOI: 10.1111/liv.14082] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
261 Liang KH, Cheng ML, Lo CJ, Lin YH, Lai MW, Lin WR, Yeh CT. Plasma phenylalanine and glutamine concentrations correlate with subsequent hepatocellular carcinoma occurrence in liver cirrhosis patients: an exploratory study. Sci Rep 2020;10:10926. [PMID: 32616821 DOI: 10.1038/s41598-020-67971-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
262 Atsukawa M, Tsubota A, Okubo T, Arai T, Nakagawa A, Itokawa N, Kondo C, Kato K, Hatori T, Hano H, Oikawa T, Emoto N, Abe M, Kage M, Iwakiri K. Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein more reliably distinguishes liver fibrosis stages in non-alcoholic fatty liver disease than serum Mac-2 binding protein. Hepatol Res. 2018;48:424-432. [PMID: 29274190 DOI: 10.1111/hepr.13046] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
263 Tada T, Kumada T, Okushin H, Tani J, Takaguchi K, Tsutsui A, Toyoda H, Yasuda S, Dohmen K, Hiraoka A, Michitaka K, Nouso K, Kariyama K, Kim SR, Kim SK, Fujioka S, Mikami S, Watanabe Y, Tamai T, Atsukawa M, Itokawa N, Tanaka H, Tsuji K, Ishikawa T, Imai M, Itobayashi E, Shibata H, Shimada N. Real-World Virological Efficacy and Safety of Ledipasvir and Sofosbuvir in Patients with Chronic Hepatitis C Virus Genotype 2 Infection: A Multicenter Study. Infect Dis Ther 2021;10:269-80. [PMID: 33141401 DOI: 10.1007/s40121-020-00364-9] [Reference Citation Analysis]
264 Fairfield CJ, Drake TM, Pius R, Bretherick AD, Campbell A, Clark DW, Fallowfield JA, Hayward C, Henderson NC, Joshi PK, Mills NL, Porteous DJ, Ramachandran P, Semple RK, Shaw CA, Sudlow CLM, Timmers PRHJ, Wilson JF, Wigmore SJ, Harrison EM, Spiliopoulou A. Genome-Wide Association Study of NAFLD Using Electronic Health Records. Hepatol Commun 2021. [PMID: 34535985 DOI: 10.1002/hep4.1805] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
265 Shibata N, Kondo T, Kazama S, Kimura Y, Oishi H, Arao Y, Kato H, Yamaguchi S, Kuwayama T, Hiraiwa H, Morimoto R, Okumura T, Sumi T, Sawamura A, Shimizu K, Murohara T. Impact of predictive value of Fibrosis-4 index in patients hospitalized for acute heart failure. Int J Cardiol 2021;324:90-5. [PMID: 33007325 DOI: 10.1016/j.ijcard.2020.09.056] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
266 Lu W, Zhang YP, Zhu HG, Zhang T, Zhang L, Gao N, Chang DY, Yin J, Zhou XY, Li MY, Li YT, Li ZZ, He Q, Geng Y. Evaluation and comparison of the diagnostic performance of routine blood tests in predicting liver fibrosis in chronic hepatitis B infection. Br J Biomed Sci. 2019;76:137-142. [PMID: 31062646 DOI: 10.1080/09674845.2019.1615717] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
267 Backus LI, Belperio PS, Shahoumian TA, Cheung R, Mole LA. Comparative effectiveness of the hepatitis C virus protease inhibitors boceprevir and telaprevir in a large U.S. cohort. Aliment Pharmacol Ther. 2014;39:93-103. [PMID: 24206566 DOI: 10.1111/apt.12546] [Cited by in Crossref: 39] [Cited by in F6Publishing: 42] [Article Influence: 4.9] [Reference Citation Analysis]
268 Blackard JT, Welge JA, Taylor LE, Mayer KH, Klein RS, Celentano DD, Jamieson DJ, Gardner L, Sherman KE. HIV mono-infection is associated with FIB-4 - A noninvasive index of liver fibrosis - in women. Clin Infect Dis. 2011;52:674-680. [PMID: 21248367 DOI: 10.1093/cid/ciq199] [Cited by in Crossref: 64] [Cited by in F6Publishing: 64] [Article Influence: 6.4] [Reference Citation Analysis]
269 Yarnykh VL, Tartaglione EV, Ioannou GN. Fast macromolecular proton fraction mapping of the human liver in vivo for quantitative assessment of hepatic fibrosis. NMR Biomed 2015;28:1716-25. [PMID: 26503401 DOI: 10.1002/nbm.3437] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
270 Lurie Y, Webb M, Cytter-Kuint R, Shteingart S, Lederkremer GZ. Non-invasive diagnosis of liver fibrosis and cirrhosis. World J Gastroenterol 2015; 21(41): 11567-11583 [PMID: 26556987 DOI: 10.3748/wjg.v21.i41.11567] [Cited by in CrossRef: 120] [Cited by in F6Publishing: 105] [Article Influence: 20.0] [Reference Citation Analysis]
271 Ikeda H, Watanabe T, Atsukawa M, Toyoda H, Takaguchi K, Nakamuta M, Matsumoto N, Okuse C, Tada T, Tsutsui A, Yamashita N, Kondo C, Hayama K, Kato K, Itokawa N, Arai T, Shimada N, Asano T, Uojima H, Ogawa C, Mikami S, Ikegami T, Fukunishi S, Asai A, Iio E, Tsubota A, Hiraoka A, Nozaki A, Okubo H, Tachi Y, Moriya A, Oikawa T, Matsumoto Y, Tsuruoka S, Tani J, Kikuchi K, Iwakiri K, Tanaka Y, Kumada T. Evaluation of 8-week glecaprevir/pibrentasvir treatment in direct-acting antiviral-naïve noncirrhotic HCV genotype 1 and 2infected patients in a real-world setting in Japan. J Viral Hepat 2019;26:1266-75. [PMID: 31278795 DOI: 10.1111/jvh.13170] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
272 Chin JL, Pavlides M, Moolla A, Ryan JD. Non-invasive Markers of Liver Fibrosis: Adjuncts or Alternatives to Liver Biopsy? Front Pharmacol. 2016;7:159. [PMID: 27378924 DOI: 10.3389/fphar.2016.00159] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 5.6] [Reference Citation Analysis]
273 Atsukawa M, Tsubota A, Koushima Y, Ikegami T, Watanabe K, Shimada N, Sato S, Kato K, Abe H, Okubo T, Arai T, Itokawa N, Kondo C, Mikami S, Asano T, Chuganji Y, Matsuzaki Y, Iwakiri K. Efficacy and safety of ombitasvir/paritaprevir/ritonavir in dialysis patients with genotype 1b chronic hepatitis C: Ombitasvir/paritaprevir/ritonavir for dialysis patients. Hepatol Res 2017;47:1429-37. [DOI: 10.1111/hepr.12910] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 8.0] [Reference Citation Analysis]
274 Karlas T, Hempel M, Tröltzsch M, Huster D, Günther P, Tenckhoff H, Mössner J, Berg T, Keim V, Wiegand J. Non-invasive evaluation of hepatic manifestation in Wilson disease with transient elastography, ARFI, and different fibrosis scores. Scand J Gastroenterol. 2012;47:1353-1361. [PMID: 22943453 DOI: 10.3109/00365521.2012.719924] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
275 Backus LI, Belperio PS, Shahoumian TA, Loomis TP, Mole LA. Comparative effectiveness of ledipasvir/sofosbuvir ± ribavirin vs. ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in 6961 genotype 1 patients treated in routine medical practice. Aliment Pharmacol Ther 2016;44:400-10. [DOI: 10.1111/apt.13696] [Cited by in Crossref: 54] [Cited by in F6Publishing: 48] [Article Influence: 10.8] [Reference Citation Analysis]
276 Hwang J, Yoon HM, Jung AY, Lee JS, Kim KM, Oh SH, Cho YA. Diagnostic Performance of Ultrasound Elastography and Serologic Fibrosis Indices for Evaluation of Hepatic Involvement in Wilson Disease. J Ultrasound Med 2020;39:2231-42. [PMID: 32401363 DOI: 10.1002/jum.15334] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
277 Hsu CW, Liang KH, Huang SF, Tsao KC, Yeh CT. Development of a non-invasive fibrosis test for chronic hepatitis B patients and comparison with other unpatented scores. BMC Res Notes 2013;6:212. [PMID: 23706143 DOI: 10.1186/1756-0500-6-212] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
278 Zhou P, Chen B, Miao X, Zhou J, Xiong L, Wen Y, Zou H. Comparison of FIB-4 Index and Child-Pugh Score in Predicting the Outcome of Hepatic Resection for Hepatocellular Carcinoma. J Gastrointest Surg 2020;24:823-31. [DOI: 10.1007/s11605-019-04123-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
279 Salama M, Nomir M, Fahmi M, El-gayar A, El-shishtawy M. Potential Role of Microfibrillar-Associated Protein 4, Fibrotic Indices and Oxidative Stress in Hepatocellular Carcinoma. Sci Pharm 2018;86:44. [DOI: 10.3390/scipharm86040044] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
280 Cheah MC, McCullough AJ, Goh GB. Current Modalities of Fibrosis Assessment in Non-alcoholic Fatty Liver Disease. J Clin Transl Hepatol. 2017;5:261-271. [PMID: 28936407 DOI: 10.14218/jcth.2017.00009] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
281 Kim D, Kim WR, Kim HJ, Therneau TM. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology. 2013;57:1357-1365. [PMID: 23175136 DOI: 10.1002/hep.26156] [Cited by in Crossref: 410] [Cited by in F6Publishing: 382] [Article Influence: 51.3] [Reference Citation Analysis]
282 Frulio N, Trillaud H. Ultrasound elastography in liver. Diagn Interv Imaging. 2013;94:515-534. [PMID: 23623211 DOI: 10.1016/j.diii.2013.02.005] [Cited by in Crossref: 110] [Cited by in F6Publishing: 89] [Article Influence: 13.8] [Reference Citation Analysis]
283 Strazzulla A, Coppolino G, Di Fatta C, Giancotti F, D’Onofrio G, Postorino MC, Mazzitelli M, Mammone SV, Gentile I, Rivoli L, Palella E, Gravina T, Costa C, Pisani V, De Maria V, Barreca GS, Marascio N, Focà A, Fuiano G, Gulletta E, Torti C. Is neutrophil gelatinase associated lipocalin useful in hepatitis C virus infection? World J Hepatol 2016; 8(19): 815-824 [PMID: 27429717 DOI: 10.4254/wjh.v8.i19.815] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
284 Izadi N, Goetz MB, Graber CJ. Inverse correlation of initial CD8 lymphocyte count and CD4 lymphocyte response to combination antiretroviral therapy in treatment-naive HIV-infected patients. J Acquir Immune Defic Syndr 2012;59:e1-3. [PMID: 22156822 DOI: 10.1097/QAI.0b013e31823d3277] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
285 Liu XD, Wu JL, Liang J, Zhang T, Sheng QS. Globulin-platelet model predicts minimal fibrosis and cirrhosis in chronic hepatitis B virus infected patients. World J Gastroenterol 2012; 18(22): 2784-2792 [PMID: 22719186 DOI: 10.3748/wjg.v18.i22.2784] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 30] [Article Influence: 3.8] [Reference Citation Analysis]
286 Marques V, Afonso MB, Bierig N, Duarte-Ramos F, Santos-Laso Á, Jimenez-Agüero R, Eizaguirre E, Bujanda L, Pareja MJ, Luís R, Costa A, Machado MV, Alonso C, Arretxe E, Alustiza JM, Krawczyk M, Lammert F, Tiniakos DG, Flehmig B, Cortez-Pinto H, Banales JM, Castro RE, Normann A, Rodrigues CMP. Adiponectin, Leptin, and IGF-1 Are Useful Diagnostic and Stratification Biomarkers of NAFLD. Front Med (Lausanne) 2021;8:683250. [PMID: 34249975 DOI: 10.3389/fmed.2021.683250] [Reference Citation Analysis]
287 Yoo HW, Kim YS, Kim SG, Yoo J, Jeong SW, Jang JY, Lee SH, Kim HS, Kim YD, Cheon GJ, Jun B, Kim BS. Usefulness of noninvasive methods including assessment of liver stiffness by 2-dimensional shear wave elastography for predicting esophageal varices. Digestive and Liver Disease 2019;51:1706-12. [DOI: 10.1016/j.dld.2019.06.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
288 Xu F, Leidner AJ, Tong X, Holmberg SD. Estimating the Number of Patients Infected With Chronic HCV in the United States Who Meet Highest or High-Priority Treatment Criteria. Am J Public Health 2015;105:1285-9. [PMID: 25973816 DOI: 10.2105/AJPH.2015.302652] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
289 Khatun M, Ray RB. Mechanisms Underlying Hepatitis C Virus-Associated Hepatic Fibrosis. Cells 2019;8:E1249. [PMID: 31615075 DOI: 10.3390/cells8101249] [Cited by in Crossref: 43] [Cited by in F6Publishing: 33] [Article Influence: 21.5] [Reference Citation Analysis]
290 Fayed HM, Mahmoud HS, Elaiw Mohamed Ali A. The Utility of Retinol-Binding Protein 4 in Predicting Liver Fibrosis in Chronic Hepatitis C Patients in Response to Direct-Acting Antivirals. Clin Exp Gastroenterol 2020;13:53-63. [PMID: 32110084 DOI: 10.2147/CEG.S229689] [Reference Citation Analysis]
291 Madsen BS, Thiele M, Detlefsen S, Kjaergaard M, Møller LS, Trebicka J, Nielsen MJ, Gudmann NS, Leeming DJ, Karsdal MA, Krag A; GALAXY consortium. PRO-C3 and ADAPT algorithm accurately identify patients with advanced fibrosis due to alcohol-related liver disease. Aliment Pharmacol Ther 2021;54:699-708. [PMID: 34251031 DOI: 10.1111/apt.16513] [Reference Citation Analysis]
292 Zhang M, Zhang L, Li H, Chen Z, Luo A, Liu B, Chen M, Peng M, Ren H, Hu P. Circulating T follicular helper cells are associated with rapid virological response in chronic hepatitis C patients undergoing peginterferon therapy. Int Immunopharmacol 2016;34:235-43. [PMID: 26971227 DOI: 10.1016/j.intimp.2016.03.005] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
293 Hasegawa K, Nishikawa H, Enomoto H, Iwata Y, Sakai Y, Ikeda N, Takashima T, Aizawa N, Takata R, Yoh K, Ishii N, Yuri Y, Nishimura T, Iijima H, Hatano E, Fujimoto J, Nishiguchi S. Proposed model for the prediction of intrahepatic covalently closed circular DNA level in patients with chronic hepatitis B. Hepatol Res 2018;49:271-83. [DOI: 10.1111/hepr.13280] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
294 Moini M, Onofrio F, Hansen BE, Adeyi O, Khalili K, Patel K. Combination of FIB-4 with ultrasound surface nodularity or elastography as predictors of histologic advanced liver fibrosis in chronic liver disease. Sci Rep 2021;11:19275. [PMID: 34588540 DOI: 10.1038/s41598-021-98776-1] [Reference Citation Analysis]
295 Itami-Matsumoto S, Hayakawa M, Uchida-Kobayashi S, Enomoto M, Tamori A, Mizuno K, Toyoda H, Tamura T, Akutsu T, Ochiya T, Kawada N, Murakami Y. Circulating Exosomal miRNA Profiles Predict the Occurrence and Recurrence of Hepatocellular Carcinoma in Patients with Direct-Acting Antiviral-Induced Sustained Viral Response. Biomedicines 2019;7:E87. [PMID: 31684167 DOI: 10.3390/biomedicines7040087] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
296 Park HE, Lee H, Choi S, Kwak M, Yang JI, Yim JY, Chung GE. Clinical significance of hepatic steatosis according to coronary plaque morphology: assessment using controlled attenuation parameter. J Gastroenterol 2019;54:271-80. [DOI: 10.1007/s00535-018-1516-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
297 Tandon P, Bishay K, Fisher S, Yelle D, Carrigan I, Wooller K, Kelly E. Comparison of clinical outcomes between variceal and non-variceal gastrointestinal bleeding in patients with cirrhosis: Outcomes of UGIB in cirrhosis. Journal of Gastroenterology and Hepatology 2018;33:1773-9. [DOI: 10.1111/jgh.14147] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
298 Knop V, Hofmann WP, Buggisch P, Klinker H, Mauss S, Günther R, Hinrichsen H, Hüppe D, Pfeiffer-Vornkahl H, Simon KG, Berg T, Manns MP, Friedrich-Rust M; German Hepatitis C-Registry. Estimation of liver fibrosis by noncommercial serum markers in comparison with transient elastography in patients with chronic hepatitis C virus infection receiving direct-acting antiviral treatment. J Viral Hepat 2019;26:224-30. [PMID: 30315694 DOI: 10.1111/jvh.13021] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
299 Uribe M, Gutiérrez-grobe Y, Kobashi-margáin RA, Méndez-sánchez N. Noninvasive markers of liver fibrosis in Latin America and Mexico. Annals of Hepatology 2010;9:S43-8. [DOI: 10.1016/s1665-2681(19)31723-5] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
300 Wakui N, Nagai H, Yoshimine N, Amanuma M, Kobayashi K, Ogino Y, Matsui D, Mukozu T, Matsukiyo Y, Matsui T, Daido Y, Momiyama K, Shinohara M, Kudo T, Maruyama K, Sumino Y, Igarashi Y. Flash Imaging Used in the Post-vascular Phase of Contrast-Enhanced Ultrasonography is Useful for Assessing the Progression in Patients with Hepatitis C Virus-Related Liver Disease. Ultrasound Med Biol. 2019;45:1654-1662. [PMID: 31031037 DOI: 10.1016/j.ultrasmedbio.2019.03.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
301 Sharma S, Khalili K, Nguyen GC. Non-invasive diagnosis of advanced fibrosis and cirrhosis. World J Gastroenterol 2014; 20(45): 16820-16830 [PMID: 25492996 DOI: 10.3748/wjg.v20.i45.16820] [Cited by in CrossRef: 93] [Cited by in F6Publishing: 67] [Article Influence: 13.3] [Reference Citation Analysis]
302 Chapelle T, Op de Beeck B, Driessen A, Roeyen G, Bracke B, Hartman V, Huyghe I, Morrison S, Ysebaert D, Francque S. Estimation of the future remnant liver function is a better tool to predict post-hepatectomy liver failure than platelet-based liver scores. Eur J Surg Oncol 2017;43:2277-84. [PMID: 28988766 DOI: 10.1016/j.ejso.2017.08.009] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
303 Feng J, Qu Z, Wu B, Sun D, Jiang Y. The preoperative fibrosis score 4 predicts posthepatectomy liver failure in patients with hepatocellular carcinoma. Annals of Hepatology 2019;18:701-7. [DOI: 10.1016/j.aohep.2019.04.017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
304 Pham TTT, Ho DT, Nguyen T. Usefulness of Mac-2 binding protein glycosylation isomer in non-invasive probing liver disease in the Vietnamese population. WJH 2020;12:210-9. [DOI: 10.4254/wjh.v12.i5.210] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
305 Tada T, Kumada T, Toyoda H, Mizuno K, Sone Y, Kataoka S, Hashinokuchi S. Improvement of liver stiffness in patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response. J Gastroenterol Hepatol. 2017;32:1982-1988. [PMID: 28299813 DOI: 10.1111/jgh.13788] [Cited by in Crossref: 69] [Cited by in F6Publishing: 62] [Article Influence: 23.0] [Reference Citation Analysis]
306 Crystal H, Kleyman I, Anastos K, Lazar J, Cohen M, Liu C, Pearce L, Golub E, Valcour V, Ho A, Strickler H, Peters M, Kovacs A, Holman S, Kreek MJ, Manly J. Effects of hepatitis C and HIV on cognition in women: data from the Women's Interagency HIV Study. J Acquir Immune Defic Syndr 2012;59:149-54. [PMID: 22107817 DOI: 10.1097/QAI.0b013e318240566b] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
307 Abdollahi M, Pouri A, Ghojazadeh M, Estakhri R, Somi M. Non-invasive serum fibrosis markers: A study in chronic hepatitis. Bioimpacts. 2015;5:17-23. [PMID: 25901293 DOI: 10.15171/bi.2015.05] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
308 Kumagai E, Mano Y, Yoshio S, Shoji H, Sugiyama M, Korenaga M, Ishida T, Arai T, Itokawa N, Atsukawa M, Hyogo H, Chayama K, Ohashi T, Ito K, Yoneda M, Kawaguchi T, Torimura T, Nozaki Y, Watanabe S, Mizokami M, Kanto T. Serum YKL-40 as a marker of liver fibrosis in patients with non-alcoholic fatty liver disease. Sci Rep 2016;6:35282. [PMID: 27739482 DOI: 10.1038/srep35282] [Cited by in Crossref: 48] [Cited by in F6Publishing: 46] [Article Influence: 9.6] [Reference Citation Analysis]
309 Abdelsameea E, Alsebaey A, Abdel-Razek W, Ehsan N, Morad W, Salama M, Waked I. Elastography and serum markers of fibrosis versus liver biopsy in 1270 Egyptian patients with hepatitis C. Eur J Gastroenterol Hepatol 2020;32:1553-8. [PMID: 31972660 DOI: 10.1097/MEG.0000000000001672] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
310 Yu SJ, Kim D, Lee J, Chung GE, Yim JY, Park MJ, Kim YJ, Yoon J, Jang J, Lee H. Validation of P2/MS and Other Noninvasive Fibrosis Scoring Systems in the Korean Population with Nonalcoholic Fatty Liver Disease. Korean J Gastroenterol 2011;57:19. [DOI: 10.4166/kjg.2011.57.1.19] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
311 Matsuda T, Mccombs JS, Tonnu-mihara I, Mcginnis J, Fox DS. The Impact of Delayed Hepatitis C Viral Load Suppression on Patient Risk: Historical Evidence from the Veterans Administration. Forum for Health Economics and Policy 2016;19:333-51. [DOI: 10.1515/fhep-2015-0041] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
312 Stasi C, Salomoni E, Arena U, Corti G, Montalto P, Bartalesi F, Marra F, Laffi G, Milani S, Zignego AL. Non-invasive assessment of liver fibrosis in patients with HBV-related chronic liver disease undergoing antiviral treatment: A preliminary study. Eur J Pharmacol. 2017;806:105-109. [PMID: 28414057 DOI: 10.1016/j.ejphar.2017.03.063] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
313 Johnson K, Green PK, Ioannou GN. Implications of HCV RNA level at week 4 of direct antiviral treatments for hepatitis C. J Viral Hepat 2017;24:966-75. [PMID: 28585416 DOI: 10.1111/jvh.12731] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
314 Sumida Y, Yoneda M, Hyogo H, Itoh Y, Ono M, Fujii H, Eguchi Y, Suzuki Y, Aoki N, Kanemasa K, Fujita K, Chayama K, Saibara T, Kawada N, Fujimoto K, Kohgo Y, Yoshikawa T, Okanoue T;  Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD). Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population. BMC Gastroenterol. 2012;12:2. [PMID: 22221544 DOI: 10.1186/1471-230x-12-2] [Cited by in Crossref: 181] [Cited by in F6Publishing: 104] [Article Influence: 20.1] [Reference Citation Analysis]
315 Sebastiani G, Gkouvatsos K, Plebani M. Non-invasive assessment of liver fibrosis: it is time for laboratory medicine. Clin Chem Lab Med. 2011;49:13-32. [PMID: 20961196 DOI: 10.1515/cclm.2011.001] [Cited by in Crossref: 16] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
316 Varchetta S, Mele D, Lombardi A, Oliviero B, Mantovani S, Tinelli C, Spreafico M, Prati D, Ludovisi S, Ferraioli G, Filice C, Aghemo A, Lampertico P, Facchetti F, Bernuzzi F, Invernizzi P, Mondelli MU. Lack of Siglec-7 expression identifies a dysfunctional natural killer cell subset associated with liver inflammation and fibrosis in chronic HCV infection. Gut 2016;65:1998-2006. [PMID: 26674359 DOI: 10.1136/gutjnl-2015-310327] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 5.7] [Reference Citation Analysis]
317 Tamaki N, Kurosaki M, Tanaka K, Suzuki Y, Hoshioka Y, Kato T, Yasui Y, Hosokawa T, Ueda K, Tsuchiya K, Nakanishi H, Itakura J, Asahina Y, Izumi N. Noninvasive estimation of fibrosis progression overtime using the FIB-4 index in chronic hepatitis C. J Viral Hepat 2013;20:72-6. [PMID: 23231087 DOI: 10.1111/j.1365-2893.2012.01635.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 3.6] [Reference Citation Analysis]
318 Martini S, Sacco M, Strona S, Arese D, Tandoi F, Dell Olio D, Stradella D, Cocchis D, Mirabella S, Rizza G, Magistroni P, Moschini P, Ottobrelli A, Amoroso A, Rizzetto M, Salizzoni M, Saracco GM, Romagnoli R. Impact of viral eradication with sofosbuvir-based therapy on the outcome of post-transplant hepatitis C with severe fibrosis. Liver Int 2017;37:62-70. [PMID: 27344058 DOI: 10.1111/liv.13193] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 4.6] [Reference Citation Analysis]
319 Guaraldi G, Squillace N, Stentarelli C, Orlando G, D’Amico R, Ligabue G, Fiocchi F, Zona S, Loria P, Esposito R. Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors. Clin Infect Dis. 2008;47:250-257. [PMID: 18532884 DOI: 10.1086/589294] [Cited by in Crossref: 145] [Cited by in F6Publishing: 137] [Article Influence: 11.2] [Reference Citation Analysis]
320 Sebastiani G, Alshaalan R, Wong P, Rubino M, Salman A, Metrakos P, Deschenes M, Ghali P. Prognostic Value of Non-Invasive Fibrosis and Steatosis Tools, Hepatic Venous Pressure Gradient (HVPG) and Histology in Nonalcoholic Steatohepatitis. PLoS One. 2015;10:e0128774. [PMID: 26083565 DOI: 10.1371/journal.pone.0128774] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 5.8] [Reference Citation Analysis]
321 Kelly EM, Dodge JL, Bacchetti P, Sarkar M, French AL, Tien PC, Glesby MJ, Golub ET, Augenbraun M, Plankey M, Peters MG. Moderate Alcohol Use Is Not Associated With Fibrosis Progression in Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Women: A Prospective Cohort Study. Clin Infect Dis. 2017;65:2050-2056. [PMID: 29020382 DOI: 10.1093/cid/cix716] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
322 Stasi C, Milani S. Non-invasive assessment of liver fibrosis: Between prediction/prevention of outcomes and cost-effectiveness. World J Gastroenterol 2016; 22(4): 1711-1720 [PMID: 26819535 DOI: 10.3748/wjg.v22.i4.1711] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 33] [Article Influence: 8.2] [Reference Citation Analysis]
323 Ahmad W, Ijaz B, Gull S, Asad S, Khaliq S, Jahan S, Sarwar MT, Kausar H, Sumrin A, Shahid I. A brief review on molecular, genetic and imaging techniques for HCV fibrosis evaluation. Virol J. 2011;8:53. [PMID: 21299910 DOI: 10.1186/1743-422x-8-53] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
324 Sirinawasatien A, Techasirioangkun T. The Prevalence and Determinants of Hepatic Steatosis Assessed by Controlled Attenuation Parameter in Thai Chronic Hepatitis C Patients. Gastroenterol Res Pract 2020;2020:8814135. [PMID: 33204256 DOI: 10.1155/2020/8814135] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
325 Sun HY, Cheng PN, Tseng CY, Tsai WJ, Chiu YC, Young KC. Favouring modulation of circulating lipoproteins and lipid loading capacity by direct antiviral agents grazoprevir/elbasvir or ledipasvir/sofosbuvir treatment against chronic HCV infection. Gut. 2018;67:1342-1350. [PMID: 28615303 DOI: 10.1136/gutjnl-2017-313832] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
326 Wu S, Ni Y, Liu L, Li H, Lu L, Wang J. Establishment and validation of a simple noninvasive model to predict significant liver fibrosis in patients with chronic hepatitis B. Hepatol Int 2012;6:360-8. [DOI: 10.1007/s12072-011-9328-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
327 Zarski JP, Sturm N, Guechot J, Zafrani ES, Vaubourdolle M, Thoret S, Margier J, David-Tchouda S, Bosson JL. Contribution of the ELFG test in algorithms of non-invasive markers towards the diagnosis of significant fibrosis in chronic hepatitis C. PLoS One. 2013;8:e59088. [PMID: 23555619 DOI: 10.1371/journal.pone.0059088.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
328 Morling JR, Fallowfield JA, Williamson RM, Robertson CM, Glancy S, Guha IN, Strachan MW, Price JF. γ-Glutamyltransferase, but not markers of hepatic fibrosis, is associated with cardiovascular disease in older people with type 2 diabetes mellitus: the Edinburgh Type 2 Diabetes Study. Diabetologia 2015;58:1484-93. [PMID: 25820150 DOI: 10.1007/s00125-015-3575-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
329 Wandrer F, Han B, Liebig S, Schlue J, Manns MP, Schulze-Osthoff K, Bantel H. Senescence mirrors the extent of liver fibrosis in chronic hepatitis C virus infection. Aliment Pharmacol Ther 2018;48:270-80. [PMID: 29863282 DOI: 10.1111/apt.14802] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
330 Syed-Abdul MM, Jacome-Sosa M, Hu Q, Gaballah AH, Winn NC, Lee NT, Mucinski JM, Manrique-Acevedo C, Lastra G, Anderson JM, Al Juboori A, Bartholow BD, Parks EJ. The Tailgate Study: Differing metabolic effects of a bout of excessive eating and drinking. Alcohol 2021;90:45-55. [PMID: 33232792 DOI: 10.1016/j.alcohol.2020.11.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
331 Mahajan R, Xing J, Liu SJ, Ly KN, Moorman AC, Rupp L, Xu F, Holmberg SD; Chronic Hepatitis Cohort Study (CHeCS) Investigators. Mortality among persons in care with hepatitis C virus infection: the Chronic Hepatitis Cohort Study (CHeCS), 2006-2010. Clin Infect Dis. 2014;58:1055-1061. [PMID: 24523214 DOI: 10.1093/cid/ciu077] [Cited by in Crossref: 86] [Cited by in F6Publishing: 80] [Article Influence: 12.3] [Reference Citation Analysis]
332 Lee YH, Jung KS, Kim SU, Yoon HJ, Yun YJ, Lee BW, Kang ES, Han KH, Lee HC, Cha BS. Sarcopaenia is associated with NAFLD independently of obesity and insulin resistance: Nationwide surveys (KNHANES 2008-2011). J Hepatol. 2015;63:486-493. [PMID: 25772036 DOI: 10.1016/j.jhep.2015.02.051] [Cited by in Crossref: 162] [Cited by in F6Publishing: 154] [Article Influence: 27.0] [Reference Citation Analysis]
333 Yanavich C, Pacheco AG, Cardoso SW, Nunes EP, Chaves U, Freitas G, Santos R, Morata M, Veloso VG, Grinsztejn B, Perazzo H. Diagnostic value of serological biomarkers for detection of non-alcoholic fatty liver disease (NAFLD) and/or advanced liver fibrosis in people living with HIV. HIV Med 2021;22:445-56. [PMID: 33529485 DOI: 10.1111/hiv.13060] [Reference Citation Analysis]
334 Catanzaro R, Aleo A, Sciuto M, Zanoli L, Balakrishnan B, Marotta F. FIB-4 and APRI scores for predicting severe liver fibrosis in chronic hepatitis HCV patients: a monocentric retrospective study. Clin Exp Hepatol 2021;7:111-6. [PMID: 34027123 DOI: 10.5114/ceh.2021.104543] [Reference Citation Analysis]
335 Long MT, Zhang X, Xu H, Liu CT, Corey KE, Chung RT, Loomba R, Benjamin EJ. Hepatic Fibrosis Associates With Multiple Cardiometabolic Disease Risk Factors: The Framingham Heart Study. Hepatology 2021;73:548-59. [PMID: 33125745 DOI: 10.1002/hep.31608] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
336 Ohira S, Kanayama N, Toratani M, Ueda Y, Koike Y, Karino T, Shunsuke O, Miyazaki M, Koizumi M, Teshima T. Stereotactic body radiation therapy planning for liver tumors using functional images from dual-energy computed tomography. Radiother Oncol 2020;145:56-62. [PMID: 31923710 DOI: 10.1016/j.radonc.2019.12.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
337 Toson EA, Shiha GE, El-Mezayen HA, Samir W, El-Khininy MM. Noninvasive estimation of liver fibrosis in biopsy-proven hepatitis C virus-infected patients: angiogenic fibrogenic link. Eur J Gastroenterol Hepatol 2017;29:199-207. [PMID: 27930387 DOI: 10.1097/MEG.0000000000000775] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
338 Conti F, Serra C, Vukotic R, Felicani C, Mazzotta E, Gitto S, Vitale G, D’errico A, Andreone P. Assessment of Liver Fibrosis With Elastography Point Quantification vs Other Noninvasive Methods. Clinical Gastroenterology and Hepatology 2019;17:510-517.e3. [DOI: 10.1016/j.cgh.2018.06.027] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
339 Schiavon LL, Narciso-Schiavon JL, Carvalho-Filho RJ. Non-invasive diagnosis of liver fibrosis in chronic hepatitis C. World J Gastroenterol 2014; 20(11): 2854-2866 [PMID: 24659877 DOI: 10.3748/wjg.v20.i11.2854] [Cited by in CrossRef: 47] [Cited by in F6Publishing: 44] [Article Influence: 6.7] [Reference Citation Analysis]
340 Osakabe K, Ichino N, Nishikawa T, Sugiyama H, Kato M, Shibata A, Asada W, Kawabe N, Hashimoto S, Murao M, Nakano T, Shimazaki H, Kan T, Nakaoka K, Takagawa Y, Ohki M, Kurashita T, Takamura T, Yoshioka K. Changes of shear-wave velocity by interferon-based therapy in chronic hepatitis C. World J Gastroenterol 2015; 21(35): 10215-10223 [PMID: 26401087 DOI: 10.3748/wjg.v21.i35.10215] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
341 López-Martínez R, Arias-García A, Rodríguez-Algarra F, Castellote-Bellés L, Rando-Segura A, Tarraso G, Vargas-Accarino E, Montserrat-Lloan I, Blanco-Grau A, Caballero-Garralda A, Ferrer-Costa R, Pumarola-Sunye T, Buti-Ferret M, Esteban-Mur R, Quer J, Casis-Saez E, Rodríguez-Frías F. Significant Improvement in Diagnosis of Hepatitis C Virus Infection by a One-Step Strategy in a Central Laboratory: an Optimal Tool for Hepatitis C Elimination? J Clin Microbiol 2019;58:e01815-19. [PMID: 31694971 DOI: 10.1128/JCM.01815-19] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
342 Chen Q, Li Q, Li D, Chen X, Liu Z, Hu G, Wang J, Ling W. Association between liver fibrosis scores and the risk of mortality among patients with coronary artery disease. Atherosclerosis 2020;299:45-52. [PMID: 32240838 DOI: 10.1016/j.atherosclerosis.2020.03.010] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 11.0] [Reference Citation Analysis]
343 Han E, Cho Y, Kim KW, Lee YH, Kang ES, Cha BS, Lee BW. Hepatic fibrosis is associated with total proteinuria in Korean patients with type 2 diabetes. Medicine (Baltimore) 2020;99:e21038. [PMID: 32871978 DOI: 10.1097/MD.0000000000021038] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
344 Hsieh YC, Lee KC, Su CW, Lan KH, Huo TI, Wang YJ, Huang HC, Lin HC, Chu CJ, Huang YH, Hou MC. Persistent liver inflammation in chronic hepatitis C patients with advanced fibrosis after direct-acting antivirals induced sustained virological response. J Chin Med Assoc 2021;84:472-7. [PMID: 33742989 DOI: 10.1097/JCMA.0000000000000517] [Reference Citation Analysis]
345 Nishikawa H, Hasegawa K, Ishii A, Takata R, Enomoto H, Yoh K, Kishino K, Shimono Y, Iwata Y, Nakano C, Nishimura T, Aizawa N, Sakai Y, Ikeda N, Takashima T, Iijima H, Nishiguchi S. A proposed predictive model for advanced fibrosis in patients with chronic hepatitis B and its validation. Medicine (Baltimore) 2016;95:e4679. [PMID: 27583895 DOI: 10.1097/MD.0000000000004679] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
346 Sebastiani G, Gkouvatsos K, Pantopoulos K. Chronic hepatitis C and liver fibrosis. World J Gastroenterol 2014; 20(32): 11033-11053 [PMID: 25170193 DOI: 10.3748/wjg.v20.i32.11033] [Cited by in CrossRef: 117] [Cited by in F6Publishing: 96] [Article Influence: 16.7] [Reference Citation Analysis]
347 Hahn JA, Murnane PM, Vittinghoff E, Muyindike WR, Emenyonu NI, Fatch R, Chamie G, Haberer JE, Francis JM, Kapiga S, Jacobson K, Myers B, Couture MC, DiClemente RJ, Brown JL, So-Armah K, Sulkowski M, Marcus GM, Woolf-King S, Cook RL, Richards VL, Molina P, Ferguson T, Welsh D, Piano MR, Phillips SA, Stewart S, Afshar M, Page K, McGinnis K, Fiellin DA, Justice AC, Bryant K, Saitz R. Factors associated with phosphatidylethanol (PEth) sensitivity for detecting unhealthy alcohol use: An individual patient data meta-analysis. Alcohol Clin Exp Res 2021;45:1166-87. [PMID: 33837975 DOI: 10.1111/acer.14611] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
348 Kawamura Y, Ikeda K, Arase Y, Sorin Y, Fukushima T, Kunimoto H, Hosaka T, Kobayashi M, Saitoh S, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Kumada H. New discriminant score to predict the fibrotic stage of non-alcoholic steatohepatitis in Japan. Hepatol Int. 2015;9:269-277. [PMID: 25788193 DOI: 10.1007/s12072-014-9605-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
349 Li Z, Li S, Tao H, Zhan Y, Ni K, Gong J, Li G. Higher titer hepatitis B core antibody predicts a higher risk of liver metastases and worse survival in patients with colorectal cancer. World J Surg Oncol 2021;19:251. [PMID: 34446030 DOI: 10.1186/s12957-021-02369-1] [Reference Citation Analysis]
350 Zhang Z, Li J, Wang P, He T, Ouyang Y, Huang Y. Nomogram for cirrhosis in patients with chronic hepatitis B: A simple self-assessed scale for individual risk of cirrhosis. Sci Rep 2017;7:17493. [PMID: 29235488 DOI: 10.1038/s41598-017-17685-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
351 Yang L, Ling W, He D, Lu C, Ma L, Tang L, Luo Y, Chen S. Shear wave-based sound touch elastography in liver fibrosis assessment for patients with autoimmune liver diseases. Quant Imaging Med Surg 2021;11:1532-42. [PMID: 33816189 DOI: 10.21037/qims-20-521] [Reference Citation Analysis]
352 Park H, Jun DW, Park HK, Kim M. Clinical implications of serum Mac-2-binding protein glycan isomer as a novel biomarker of advanced hepatic fibrosis in diabetes. Ann Transl Med 2020;8:1583. [PMID: 33437782 DOI: 10.21037/atm-20-5216] [Reference Citation Analysis]
353 Vignier N, Esmat G, Elsharkawy A, Hassany M, Bonnard P, Delarocque-Astagneau E, Said M, Raafat R, El-Hoseiny M, Fontanet A, Mohamed MK, Vray M. Reproducibility of liver stiffness measurements in hepatitis C virus (HCV)-infected patients in Egypt. J Viral Hepat 2011;18:e358-65. [PMID: 21692948 DOI: 10.1111/j.1365-2893.2010.01433.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
354 Zachou K, Gabeta S, Shums Z, Gatselis NK, Koukoulis GK, Norman GL, Dalekos GN. COMP serum levels: A new non-invasive biomarker of liver fibrosis in patients with chronic viral hepatitis. Eur J Intern Med. 2017;38:83-88. [PMID: 28100410 DOI: 10.1016/j.ejim.2017.01.007] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
355 Levick C, Phillips-Hughes J, Collier J, Banerjee R, Cobbold JF, Wang LM, Piechnik SK, Robson MD, Neubauer S, Barnes E, Pavlides M. Non-invasive assessment of portal hypertension by multi-parametric magnetic resonance imaging of the spleen: A proof of concept study. PLoS One 2019;14:e0221066. [PMID: 31430314 DOI: 10.1371/journal.pone.0221066] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 8.5] [Reference Citation Analysis]
356 Tada T, Kumada T, Toyoda H, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Kitabatake S, Yama T, Tanaka J. Post-treatment levels of α-fetoprotein predict long-term hepatocellular carcinoma development after sustained virological response in patients with hepatitis C: AFP predicts HCC development in SVR patients. Hepatol Res 2017;47:1021-31. [DOI: 10.1111/hepr.12839] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
357 Fox DS, McGinnis JJ, Tonnu-Mihara IQ, McCombs JS. Comparative treatment effectiveness of direct acting antiviral regimens for hepatitis C: Data from the Veterans administration. J Gastroenterol Hepatol 2017;32:1136-42. [PMID: 27869323 DOI: 10.1111/jgh.13652] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 5.3] [Reference Citation Analysis]
358 Tawada A, Maruyama H, Kamezaki H, Shimada T, Ishibashi H, Takahashi M, Kanda T, Fujiwara K, Imazeki F, Yokosuka O. Magnitude of contrast-enhanced ultrasonography as a noninvasive predictor for hepatic fibrosis: comparison with liver stiffness measurement and serum-based models. Hepatol Int 2013;7:749-57. [PMID: 26201810 DOI: 10.1007/s12072-012-9370-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
359 Enomoto H, Aizawa N, Nakamura H, Sakai Y, Iwata Y, Tanaka H, Ikeda N, Aoki T, Yuri Y, Yoh K. An Increased Ratio of Glycated Albumin to HbA1c Is Associated with the Degree of Liver Fibrosis in Hepatitis B Virus-Positive Patients. Gastroenterol Res Pract. 2014;2014:351396. [PMID: 24693282 DOI: 10.1155/2014/351396] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
360 Cheong JY, Um SH, Seo YS, Kim DJ, Hwang SG, Lee YJ, Cho M, Yang JM, Kim YB, Park YN. Non-invasive index for predicting significant liver fibrosis: comparison of diagnostic performances in patients with chronic hepatitis B and C. Dig Dis Sci. 2011;56:555-563. [PMID: 20585981 DOI: 10.1007/s10620-010-1305-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
361 Maieron A, Salzl P, Peck-Radosavljevic M, Trauner M, Hametner S, Schöfl R, Ferenci P, Ferlitsch M. Von Willebrand Factor as a new marker for non-invasive assessment of liver fibrosis and cirrhosis in patients with chronic hepatitis C. Aliment Pharmacol Ther. 2014;39:331-338. [PMID: 24308724 DOI: 10.1111/apt.12564] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 5.0] [Reference Citation Analysis]
362 Obach D, Deuffic-Burban S, Esmat G, Anwar WA, Dewedar S, Canva V, Cousien A, Doss W, Mostafa A, Pol S, Buti M, Siebert U, Fontanet A, Mohamed MK, Yazdanpanah Y. Effectiveness and cost-effectiveness of immediate versus delayed treatment of hepatitis C virus-infected patients in a country with limited resources: the case of Egypt. Clin Infect Dis 2014;58:1064-71. [PMID: 24510934 DOI: 10.1093/cid/ciu066] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 4.1] [Reference Citation Analysis]
363 Umbleja T, Brown TT, Overton ET, Ribaudo HJ, Schrack JA, Fitch KV, Douglas PS, Grinspoon SK, Henn S, Arduino RC, Rodriguez B, Benson CA, Erlandson KM. Physical Function Impairment and Frailty in Middle-Aged People Living With Human Immunodeficiency Virus in the REPRIEVE Trial Ancillary Study PREPARE. J Infect Dis 2020;222:S52-62. [PMID: 32645163 DOI: 10.1093/infdis/jiaa249] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
364 Fahmy DM, Shokeir M, El Zeiny SM, Jonas MM, Abdallah A. Changes in Liver Stiffness and Noninvasive Fibrosis Scores in Egyptian Adolescents Successfully Treated with Ledipasvir-Sofosbuvir for Chronic Hepatitis C Virus Infection. J Pediatr 2021;231:110-6. [PMID: 33347957 DOI: 10.1016/j.jpeds.2020.12.031] [Reference Citation Analysis]
365 Wang HW, Peng CY, Lai HC, Su WP, Lin CH, Chuang PH, Chen SH, Chen CH, Hsu WF, Huang GT. New noninvasive index for predicting liver fibrosis in Asian patients with chronic viral hepatitis. Sci Rep 2017;7:3259. [PMID: 28607450 DOI: 10.1038/s41598-017-03589-w] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
366 Tada T, Toyoda H, Yasuda S, Kumada T, Kurisu A, Ohisa M, Akita T, Tanaka J. Long‐term prognosis of liver disease in patients with eradicated chronic hepatitis C virus: An analysis using a Markov chain model. Hepatol Res. [DOI: 10.1111/hepr.13512] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
367 Nishikawa H, Nishijima N, Enomoto H, Sakamoto A, Nasu A, Komekado H, Nishimura T, Kita R, Kimura T, Iijima H, Nishiguchi S, Osaki Y. Comparison of FIB-4 index and aspartate aminotransferase to platelet ratio index on carcinogenesis in chronic hepatitis B treated with entecavir. J Cancer. 2017;8:152-161. [PMID: 28243319 DOI: 10.7150/jca.16523] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
368 Benhammou JN, Dong TS, May FP, Kawamoto J, Dixit R, Jackson S, Dixit V, Bhattacharya D, Han SB, Pisegna JR. Race affects SVR12 in a large and ethnically diverse hepatitis C-infected patient population following treatment with direct-acting antivirals: Analysis of a single-center Department of Veterans Affairs cohort. Pharmacol Res Perspect. 2018;6:e00379. [PMID: 29484189 DOI: 10.1002/prp2.379] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
369 Borrelli A, Bonelli P, Tuccillo FM, Goldfine ID, Evans JL, Buonaguro FM, Mancini A. Role of gut microbiota and oxidative stress in the progression of non-alcoholic fatty liver disease to hepatocarcinoma: Current and innovative therapeutic approaches. Redox Biol 2018;15:467-79. [PMID: 29413959 DOI: 10.1016/j.redox.2018.01.009] [Cited by in Crossref: 81] [Cited by in F6Publishing: 81] [Article Influence: 27.0] [Reference Citation Analysis]
370 Okubo H, Kitamura T, Ando H, Fukada H, Igusa Y, Kokubu S, Miyazaki A, Fujimura A, Shiina S, Watanabe S. Gadoxetic Acid-Enhanced MR Imaging Predicts Simeprevir-Induced Hyperbilirubinemia During Hepatitis C Virus Treatment: A Pilot Study. J Clin Pharmacol 2017;57:369-75. [PMID: 27530761 DOI: 10.1002/jcph.811] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
371 Tetangco EP, Silva RG, Lerma EV. Portal hypertension: Etiology, evaluation, and management. Dis Mon 2016;62:411-26. [PMID: 27788916 DOI: 10.1016/j.disamonth.2016.08.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.2] [Reference Citation Analysis]
372 Jaruvongvanich V, Sempokuya T, Wong L. Is there an optimal staging system or liver reserve model that can predict outcome in hepatocellular carcinoma? J Gastrointest Oncol 2018;9:750-61. [PMID: 30151272 DOI: 10.21037/jgo.2018.05.11] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
373 Calzadilla-Bertot L, Vilar-Gomez E, Wong VW, Romero-Gomez M, Aller-de la Fuente R, Wong GL, Castellanos M, Eslam M, Desai AP, Jeffrey GP, George J, Chalasani N, Adams LA. ABIDE: An Accurate Predictive Model of Liver Decompensation in Patients With Nonalcoholic Fatty Liver-Related Cirrhosis. Hepatology 2021;73:2238-50. [PMID: 32978796 DOI: 10.1002/hep.31576] [Reference Citation Analysis]
374 Dong B, Lyu G, Chen Y, Lin G, Wang H, Qin R, Gu J. Comparison of two-dimensional shear wave elastography, magnetic resonance elastography, and three serum markers for diagnosing fibrosis in patients with chronic hepatitis B: a meta-analysis. Expert Rev Gastroenterol Hepatol 2021;15:1077-89. [PMID: 33487039 DOI: 10.1080/17474124.2021.1880894] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
375 Martínez-mier G, Esquivel-torres S, Casanova-sánchez I, Escobar-ríos A, Troche-gutiérrez J, Yoldi-aguirre C. Carcinoma hepatocelular en hígado no cirrótico: características clínicas y resultados en Veracruz, México. Revista de Gastroenterología de México 2021;86:4-12. [DOI: 10.1016/j.rgmx.2019.11.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
376 Beiser ME, Smith K, Ingemi M, Mulligan E, Baggett TP. Hepatitis C treatment outcomes among homeless-experienced individuals at a community health centre in Boston. Int J Drug Policy 2019;72:129-37. [PMID: 30962036 DOI: 10.1016/j.drugpo.2019.03.017] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 11.0] [Reference Citation Analysis]
377 Ishikawa T, Sasaki R, Nishimura T, Matsuda T, Maeda M, Iwamoto T, Saeki I, Hidaka I, Takami T, Sakaida I. Liver stiffness measured by transient elastography as predictor of prognoses following portosystemic shunt occlusion. J Gastroenterol Hepatol 2019;34:215-23. [PMID: 30070412 DOI: 10.1111/jgh.14410] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
378 Tsuji K, Kurosaki M, Itakura J, Mori N, Takaki S, Hasebe C, Akahane T, Joko K, Yagisawa H, Takezawa J, Nakata R, Kusakabe A, Kojima Y, Kimura H, Tamada T, Kobashi H, Mitsuda A, Kondou M, Ogawa C, Uchida Y, Sohda T, Narita R, Izumi N. Real-world efficacy and safety of ledipasvir and sofosbuvir in patients with hepatitis C virus genotype 1 infection: a nationwide multicenter study by the Japanese Red Cross Liver Study Group. J Gastroenterol 2018;53:1142-50. [PMID: 29626296 DOI: 10.1007/s00535-018-1455-1] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 9.0] [Reference Citation Analysis]
379 Sebastiani G, Tempesta D, Fattovich G, Castera L, Halfon P, Bourliere M, Noventa F, Angeli P, Saggioro A, Alberti A. Prediction of oesophageal varices in hepatic cirrhosis by simple serum non-invasive markers: Results of a multicenter, large-scale study. J Hepatol 2010;53:630-8. [PMID: 20615567 DOI: 10.1016/j.jhep.2010.04.019] [Cited by in Crossref: 80] [Cited by in F6Publishing: 69] [Article Influence: 7.3] [Reference Citation Analysis]
380 Rath MM, Panigrahi MK, Pattnaik K, Bhuyan P, Kar SK, Misra B, Misra D, Meher C, Agrawal O, Rath J, Singh SP. Histological Evaluation of Non-alcoholic Fatty Liver Disease and Its Correlation with Different Noninvasive Scoring Systems with Special Reference to Fibrosis: A Single Center Experience. J Clin Exp Hepatol 2016;6:291-6. [PMID: 28003718 DOI: 10.1016/j.jceh.2016.08.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
381 Suda G, Kurosaki M, Itakura J, Izumi N, Uchida Y, Mochida S, Hasebe C, Abe M, Haga H, Ueno Y, Masakane I, Abe K, Takahashi A, Ohira H, Furuya K, Baba M, Yamamoto Y, Kobayashi T, Kawakami A, Kumagai K, Terasita K, Ohara M, Kawagishi N, Umemura M, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N; NORTE Study Group. Safety and efficacy of elbasvir and grazoprevir in Japanese hemodialysis patients with genotype 1b hepatitis C virus infection. J Gastroenterol 2019;54:78-86. [PMID: 30019127 DOI: 10.1007/s00535-018-1495-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
382 Lisotti A, Azzaroli F, Buonfiglioli F, Montagnani M, Cecinato P, Turco L, Calvanese C, Simoni P, Guardigli M, Arena R, Cucchetti A, Colecchia A, Festi D, Golfieri R, Mazzella G. Indocyanine green retention test as a noninvasive marker of portal hypertension and esophageal varices in compensated liver cirrhosis. Hepatology. 2014;59:643-650. [PMID: 24038116 DOI: 10.1002/hep.26700] [Cited by in Crossref: 64] [Cited by in F6Publishing: 55] [Article Influence: 8.0] [Reference Citation Analysis]
383 Shiha G, Seif S, Eldesoky A, Elbasiony M, Soliman R, Metwally A, Zalata K, Mikhail N. A simple bedside blood test (Fibrofast; FIB-5) is superior to FIB-4 index for the differentiation between non-significant and significant fibrosis in patients with chronic hepatitis C. Hepatol Int 2017;11:286-91. [PMID: 28425016 DOI: 10.1007/s12072-017-9796-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
384 Wu S, Tseng Y, Xu N, Yin X, Xie X, Zhang L, Wu W, Zhu W, Wu W, Yao J, Wu Y. Evaluation of transient elastography in assessing liver fibrosis in patients with advanced schistosomiasis japonica. Parasitol Int 2018;67:302-8. [PMID: 29355611 DOI: 10.1016/j.parint.2018.01.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
385 Bertot LC, Jeffrey GP, Wallace M, MacQuillan G, Garas G, Ching HL, Adams LA. Nonalcoholic fatty liver disease-related cirrhosis is commonly unrecognized and associated with hepatocellular carcinoma. Hepatol Commun 2017;1:53-60. [PMID: 29404433 DOI: 10.1002/hep4.1018] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 8.0] [Reference Citation Analysis]
386 Li DK, Yan P, Abou-Samra AB, Chung RT, Butt AA. Proton pump inhibitors are associated with accelerated development of cirrhosis, hepatic decompensation and hepatocellular carcinoma in noncirrhotic patients with chronic hepatitis C infection: results from ERCHIVES. Aliment Pharmacol Ther 2018;47:246-58. [PMID: 29105111 DOI: 10.1111/apt.14391] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
387 Han E, Lee YH, Kim YD, Kim BK, Park JY, Kim DY, Ahn SH, Lee BW, Kang ES, Cha BS, Han KH, Nam HS, Heo JH, Kim SU. Nonalcoholic Fatty Liver Disease and Sarcopenia Are Independently Associated With Cardiovascular Risk. Am J Gastroenterol. 2020;115:584-595. [PMID: 32141917 DOI: 10.14309/ajg.0000000000000572] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 14.0] [Reference Citation Analysis]
388 Toyoda H, Kumada T, Tada T, Yama T, Mizuno K, Sone Y, Maeda A, Kaneoka Y, Akita T, Tanaka J. Differences in the impact of prognostic factors for hepatocellular carcinoma over time. Cancer Sci 2017;108:2438-44. [PMID: 28945309 DOI: 10.1111/cas.13406] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
389 Taneja S, Tohra S, Duseja A, Dhiman RK, Chawla YK. Noninvasive Assessment of Liver Fibrosis By Transient Elastography and FIB4/APRI for Prediction of Treatment Response in Chronic Hepatitis C-An Experience from a Tertiary Care Hospital. J Clin Exp Hepatol 2016;6:282-90. [PMID: 28003717 DOI: 10.1016/j.jceh.2016.08.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
390 Weiskirchen R, Tacke F. Combining GP73 with liver stiffness measurements: A proof-of-concept for non-invasive fibrosis assessment in antiviral-naïve HBV patients. Liver Int 2017;37:1605-7. [PMID: 29065256 DOI: 10.1111/liv.13563] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
391 Suda G, Ogawa K, Yamamoto Y, Katagiri M, Furuya K, Kumagai K, Konno J, Kimura M, Kawagishi N, Ohara M. Retreatment with sofosbuvir, ledipasvir, and add-on ribavirin for patients who failed daclatasvir and asunaprevir combination therapy. J Gastroenterol. 2017;52:1122-1129. [PMID: 28315983 DOI: 10.1007/s00535-017-1328-z] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 6.5] [Reference Citation Analysis]
392 Gu J, Zhang E, Liang B, Zhang Z, Chen X, Huang Z. Effectiveness comparison of indocyanine green retention test with the cirrhotic severity scoring in evaluating the pathological severity of liver cirrhosis in patients with hepatocellular carcinoma and Child-Pugh grade A liver function. World J Surg Oncol 2020;18:79. [PMID: 32326968 DOI: 10.1186/s12957-020-01854-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
393 Wadhva RK, Haque MM, Luck NH, Tasneem AA, Abbas Z, Mubarak M. Diagnostic Accuracy of Aspartate Aminotransferase to Platelet Ratio Index and Fibrosis 4 Scores in Predicting Advanced Liver Fibrosis in Patients with End-stage Renal Disease and Chronic Viral Hepatitis: Experience from Pakistan. J Transl Int Med 2018;6:38-42. [PMID: 29607303 DOI: 10.2478/jtim-2018-0008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
394 Hyun Kim K, Kyung Kim B, Yong Park J, Young Kim D, Hoon Ahn S, Han KH, Kim SU. Sarcopenia assessed using bioimpedance analysis is associated independently with significant liver fibrosis in patients with chronic liver diseases. Eur J Gastroenterol Hepatol 2020;32:58-65. [PMID: 31283527 DOI: 10.1097/MEG.0000000000001475] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
395 Sayiner M, Lam B, Golabi P, Younossi ZM. Advances and challenges in the management of advanced fibrosis in nonalcoholic steatohepatitis. Therap Adv Gastroenterol 2018;11:1756284818811508. [PMID: 30479664 DOI: 10.1177/1756284818811508] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
396 Gidwani-marszowski R, Owens DK, Lo J, Goldhaber-fiebert JD, Asch SM, Barnett PG. The Costs of Hepatitis C by Liver Disease Stage: Estimates from the Veterans Health Administration. Appl Health Econ Health Policy 2019;17:513-21. [DOI: 10.1007/s40258-019-00468-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
397 Kaneko S, Kurosaki M, Inada K, Kirino S, Hayakawa Y, Yamashita K, Osawa L, Sekiguchi S, Higuchi M, Takaura K, Maeyashiki C, Tamaki N, Yasui Y, Itakura J, Takahashi Y, Tsuchiya K, Nakanishi H, Izumi N. Hepatitis B core-related antigen predicts disease progression and hepatocellular carcinoma in hepatitis B e antigen-negative chronic hepatitis B patients. J Gastroenterol Hepatol 2021. [PMID: 34057248 DOI: 10.1111/jgh.15563] [Reference Citation Analysis]
398 Kim J, Kang W, Sinn DH, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. Substantial risk of recurrence even after 5 recurrence-free years in early-stage hepatocellular carcinoma patients. Clin Mol Hepatol 2020;26:516-28. [PMID: 32911589 DOI: 10.3350/cmh.2020.0016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
399 Zhang W, Wang L, Wang L, Li G, Huang A, Yin P, Yang Z, Ling C, Wang L. Liver stiffness measurement, better than APRI, Fibroindex, Fib-4, and NBI gastroscopy, predicts portal hypertension in patients with cirrhosis. Cell Biochem Biophys 2015;71:865-73. [PMID: 25417057 DOI: 10.1007/s12013-014-0275-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
400 Silva‐sepulveda JA, Fonseca Y, Vodkin I, Vaughn G, Newbury R, Vavinskaya V, Dwek J, Perry JC, Reshamwala P, Baehling C, Lyon J, Davis C, Lee JW, El‐sabrout H, Shahbah D, Alshawabkeh L, Moore JW, El‐said H. Evaluation of Fontan liver disease: Correlation of transjugular liver biopsy with magnetic resonance and hemodynamics. Congenital Heart Disease 2019;14:600-8. [DOI: 10.1111/chd.12770] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 11.0] [Reference Citation Analysis]
401 方正亚, 张国顺, 刘斌, 孟冬梅. 乙型肝炎相关性肝硬化的无创性诊断. 世界华人消化杂志 2016; 24(29): 4092-4101 [DOI: 10.11569/wcjd.v24.i29.4092] [Reference Citation Analysis]
402 Tan LJ, Jung H, Kim SA, Shin S. The Association Between Coffee Consumption and Nonalcoholic Fatty Liver Disease in the South Korean General Population. Mol Nutr Food Res 2021;:e2100356. [PMID: 34319647 DOI: 10.1002/mnfr.202100356] [Reference Citation Analysis]
403 Liu C, Jia BS, Zou BW, Du H, Yan LN, Yang JY, Jiang L, Wen TF, Lu WS. Neutrophil-to-lymphocyte and aspartate-to-alanine aminotransferase ratios predict hepatocellular carcinoma prognosis after transarterial embolization. Medicine (Baltimore). 2017;96:e8512. [PMID: 29137051 DOI: 10.1097/md.0000000000008512] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
404 Ichikawa T, Miyaaki H, Miuma S, Motoyoshi Y, Yamashima M, Yamamichi S, Koike M, Honda T, Yajima H, Uehara R, Miyazaki O, Hino N, Hirata R, Taura N, Nakao K. Calculated body muscle mass as a useful screening marker for low skeletal muscle mass and sarcopenia in chronic liver disease. Hepatol Res 2020;50:704-14. [PMID: 32061107 DOI: 10.1111/hepr.13492] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
405 Alem SA, Abdellatif Z, Mabrouk M, Zayed N, Elsharkawy A, Khairy M, Musa S, Anwar I, Yosry A. Diagnostic accuracy of acoustic radiation force impulse elastography (ARFI) in comparison to other non-invasive modalities in staging of liver fibrosis in chronic HCV patients: single-center experience. Abdom Radiol (NY). 2019;44:2751-2758. [PMID: 31028432 DOI: 10.1007/s00261-019-02031-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
406 Schmoyer CJ, Kumar D, Gupta G, Sterling RK. Diagnostic Accuracy of Noninvasive Tests to Detect Advanced Hepatic Fibrosis in Patients With Hepatitis C and End-Stage Renal Disease. Clin Gastroenterol Hepatol 2020;18:2332-2339.e1. [PMID: 32084602 DOI: 10.1016/j.cgh.2020.02.019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
407 Scaglia E, Sockalingum GD, Schmitt J, Gobinet C, Schneider N, Manfait M, Thiéfin G. Noninvasive assessment of hepatic fibrosis in patients with chronic hepatitis C using serum Fourier transform infrared spectroscopy. Anal Bioanal Chem 2011;401:2919-25. [DOI: 10.1007/s00216-011-5402-8] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
408 Mayo R, Crespo J, Martínez-Arranz I, Banales JM, Arias M, Mincholé I, Aller de la Fuente R, Jimenez-Agüero R, Alonso C, de Luis DA, Vitek L, Stritesky J, Caballería J, Romero-Gómez M, Martín-Duce A, Mugüerza Huguet JM, Busteros-Moraza JI, Idowu MO, Castro A, Martínez-Chantar ML, Ortiz P, Bruha R, Lu SC, Bedossa P, Noureddin M, Sanyal AJ, Mato JM. Metabolomic-based noninvasive serum test to diagnose nonalcoholic steatohepatitis: Results from discovery and validation cohorts. Hepatol Commun 2018;2:807-20. [PMID: 30027139 DOI: 10.1002/hep4.1188] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 14.7] [Reference Citation Analysis]
409 Guo G, Lei Z, Tang X, Ma W, Si A, Yang P, Li Q, Geng Z, Zhou J, Cheng Z. External Validation of Six Liver Functional Reserve Models to predict Posthepatectomy Liver Failure after Major Resection for Hepatocellular Carcinoma. J Cancer 2021;12:5260-7. [PMID: 34335942 DOI: 10.7150/jca.58726] [Reference Citation Analysis]
410 Trivedi HD, Patwardhan VR, Malik R. Chronic hepatitis C infection — Noninvasive assessment of liver fibrosis in the era of direct acting antivirals. Digestive and Liver Disease 2019;51:183-9. [DOI: 10.1016/j.dld.2018.11.016] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
411 Inoue‐shinomiya E, Murakawa M, Asahina Y, Nakagawa M, Tsuchiya J, Sato A, Tsunoda T, Miyoshi M, Nitta S, Kawai‐kitahata F, Itsui Y, Azuma S, Kakinuma S, Murata K, Mizokami M, Watanabe M. Association of serum interferon‐λ3 levels with hepatocarcinogenesis in chronic hepatitis C patients treated with direct‐acting antiviral agents. Hepatol Res 2019;49:500-11. [DOI: 10.1111/hepr.13307] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
412 Dong B, Huang S, Chang J, Chen X, Yan J. Comparison of Sound Touch Elastography, Sound Touch Quantify, and 4 Serum Fibrosis Indexes for the Diagnosis of Liver Fibrosis in Patients With Chronic Hepatitis B. Ultrasound Q 2021;37:123-8. [PMID: 34057912 DOI: 10.1097/RUQ.0000000000000485] [Reference Citation Analysis]
413 Zhu MY, Chen PZ, Li J, Yu DM, Huang D, Zhu XJ, Han Y, Chen J, Huang W, Chen YY, Gong QM, Jiang JH, Zhang DH, Zhang Y, Zhang JM, Zhang XX. Serum M2BPGi level is a novel predictive biomarker for the responses to pegylated interferon-α treatment in HBeAg-positive chronic hepatitis B patients. J Med Virol 2018;90:721-9. [PMID: 29247529 DOI: 10.1002/jmv.25010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
414 Osada M, Kaneko M, Sakamoto M, Endoh M, Takigawa K, Suzuki-Inoue K, Inoue O, Satoh K, Enomoto N, Yatomi Y, Ozaki Y. Causes of thrombocytopenia in chronic hepatitis C viral infection. Clin Appl Thromb Hemost 2012;18:272-80. [PMID: 22327815 DOI: 10.1177/1076029611429124] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
415 Beste LA, Green PK, Ioannou GN. Boceprevir and telaprevir-based regimens for the treatment of hepatitis C virus in HIV/HCV coinfected patients. Eur J Gastroenterol Hepatol 2015;27:123-9. [PMID: 25503739 DOI: 10.1097/MEG.0000000000000241] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
416 Pan AN, Xu WW, Luo YL, Yu HH, Hu YB, Sun QF, Ding JG, Wu YH. A novel system for predicting liver histopathology in patients with chronic hepatitis B. Medicine (Baltimore) 2017;96:e6465. [PMID: 28383410 DOI: 10.1097/MD.0000000000006465] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
417 Joo SK, Kim W, Kim D, Kim JH, Oh S, Lee KL, Chang MS, Jung YJ, So YH, Lee MS, Bae JM, Kim BG. Steatosis severity affects the diagnostic performances of noninvasive fibrosis tests in nonalcoholic fatty liver disease. Liver Int. 2018;38:331-341. [PMID: 28796410 DOI: 10.1111/liv.13549] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 5.5] [Reference Citation Analysis]
418 Kanwal F, Kramer JR, Asch SM, Cao Y, Li L, El-Serag HB. Long-Term Risk of Hepatocellular Carcinoma in HCV Patients Treated With Direct Acting Antiviral Agents. Hepatology. 2020;71:44-55. [PMID: 31222774 DOI: 10.1002/hep.30823] [Cited by in Crossref: 68] [Cited by in F6Publishing: 63] [Article Influence: 34.0] [Reference Citation Analysis]
419 Mallet V, Parlati L, Vallet-Pichard A, Terris B, Tsochatzis E, Sogni P, Pol S. [FIB-4 index to rule-out advanced liver fibrosis in NAFLD patients]. Presse Med 2019;48:1484-8. [PMID: 31767251 DOI: 10.1016/j.lpm.2019.10.017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
420 Tada T, Kumada T, Toyoda H, Tsuji K, Hiraoka A, Tanaka J. Impact of FIB-4 index on hepatocellular carcinoma incidence during nucleos(t)ide analogue therapy in patients with chronic hepatitis B: An analysis using time-dependent receiver operating characteristic: HCC development in CHB during NA therapy. Journal of Gastroenterology and Hepatology 2017;32:451-8. [DOI: 10.1111/jgh.13473] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
421 Sagnelli C, Martini S, Pisaturo M, Pasquale G, Macera M, Zampino R, Coppola N, Sagnelli E. Liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfection: Diagnostic methods and clinical impact. World J Hepatol 2015; 7(24): 2510-2521 [PMID: 26523204 DOI: 10.4254/wjh.v7.i24.2510] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
422 Kennedy P, Wagner M, Castéra L, Hong CW, Johnson CL, Sirlin CB, Taouli B. Quantitative Elastography Methods in Liver Disease: Current Evidence and Future Directions. Radiology 2018;286:738-63. [PMID: 29461949 DOI: 10.1148/radiol.2018170601] [Cited by in Crossref: 119] [Cited by in F6Publishing: 106] [Article Influence: 39.7] [Reference Citation Analysis]
423 Morozov VA, Lagaye S. Hepatitis C virus: Morphogenesis, infection and therapy. World J Hepatol 2018; 10(2): 186-212 [PMID: 29527256 DOI: 10.4254/wjh.v10.i2.186] [Cited by in Crossref: 49] [Cited by in F6Publishing: 40] [Article Influence: 16.3] [Reference Citation Analysis]
424 Ichikawa T, Miyaaki H, Miuma S, Motoyoshi Y, Yamashima M, Yamamichi S, Koike M, Takahashi Y, Honda T, Yajima H, Uehara R, Hino N, Hirata R, Taura N, Nakao K. Indices calculated by serum creatinine and cystatin C as predictors of liver damage, muscle strength and sarcopenia in liver disease. Biomed Rep 2020;12:89-98. [PMID: 32042417 DOI: 10.3892/br.2020.1273] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
425 Calès P, Boursier J, Oberti F, Hubert I, Gallois Y, Rousselet MC, Dib N, Moal V, Macchi L, Chevailler A. FibroMeters: a family of blood tests for liver fibrosis. Gastroenterol Clin Biol. 2008;32:40-51. [PMID: 18973845 DOI: 10.1016/s0399-8320(08)73992-7] [Cited by in Crossref: 31] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
426 Darweesh SK, Elsabaawy MA, Eltahawy MA, Ghanem HS, Abdel-Razek W. Serum ammonia as a non-invasive marker for early prediction of esophageal varices. Eur J Gastroenterol Hepatol 2021;32:230-6. [PMID: 32243345 DOI: 10.1097/MEG.0000000000001715] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
427 Harrison SA, Ratziu V, Boursier J, Francque S, Bedossa P, Majd Z, Cordonnier G, Sudrik FB, Darteil R, Liebe R, Magnanensi J, Hajji Y, Brozek J, Roudot A, Staels B, Hum DW, Megnien SJ, Hosmane S, Dam N, Chaumat P, Hanf R, Anstee QM, Sanyal AJ. A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol 2020;5:970-85. [PMID: 32763196 DOI: 10.1016/S2468-1253(20)30252-1] [Cited by in Crossref: 26] [Cited by in F6Publishing: 11] [Article Influence: 26.0] [Reference Citation Analysis]
428 Yu SJ, Lee JH, Chung GE, Lee CH, Cho EJ, Jang ES, Kwak MS, Kim YJ, Yoon JH, Jang JJ, Lee HS. Validation of P2/MS for reflecting hepatic fibrosis in patients with hepatocellular carcinoma. Korean J Hepatol 2010;16:389-96. [PMID: 21415583 DOI: 10.3350/kjhep.2010.16.4.389] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
429 Bhat M, Tazari M, Sebastiani G. Performance of transient elastography and serum fibrosis biomarkers for non-invasive evaluation of recurrent fibrosis after liver transplantation: A meta-analysis. PLoS One. 2017;12:e0185192. [PMID: 28953939 DOI: 10.1371/journal.pone.0185192] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
430 Huang CM, Hu TH, Chang KC, Tseng PL, Lu SN, Chen CH, Wang JH, Lee CM, Tsai MC, Lin MT, Yen YH, Hung CH, Cho CL, Wu CK. Dynamic noninvasive markers predict hepatocellular carcinoma in chronic hepatitis C patients without sustained virological response after interferon-based therapy: Prioritize who needs urgent direct-acting antiviral agents. Medicine (Baltimore) 2017;96:e8696. [PMID: 29145306 DOI: 10.1097/MD.0000000000008696] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
431 Osakabe K, Ichino N, Nishikawa T, Sugiyama H, Kato M, Kitahara S, Hashimoto S, Kawabe N, Harata M, Nitta Y, Murao M, Nakano T, Shimazaki H, Arima Y, Suzuki K, Yoshioka K. Reduction of liver stiffness by antiviral therapy in chronic hepatitis B. J Gastroenterol. 2011;46:1324-1334. [PMID: 21822591 DOI: 10.1007/s00535-011-0444-4] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 3.9] [Reference Citation Analysis]
432 Mai R, Lu H, Bai T, Liang R, Lin Y, Ma L, Xiang B, Wu G, Li L, Ye J. Artificial neural network model for preoperative prediction of severe liver failure after hemihepatectomy in patients with hepatocellular carcinoma. Surgery 2020;168:643-52. [DOI: 10.1016/j.surg.2020.06.031] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
433 Fujita K, Kuroda N, Morishita A, Oura K, Tadokoro T, Nomura T, Yoneyama H, Arai T, Himoto T, Watanabe S, Masaki T. Fibrosis Staging Using Direct Serum Biomarkers is Influenced by Hepatitis Activity Grading in Hepatitis C Virus Infection. J Clin Med. 2018;7. [PMID: 30208564 DOI: 10.3390/jcm7090267] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
434 Wang J, Wu M, Linghu R, Chang J, Wu M, Feng C, Ren X, Liu C, Lin J, Song T, Gu J, Zhang Y, Fang Y, Ma S, Hu P, Wu L, Han X, Chen K, Shi Q, Zhang R, Zhou Q, Du R, Gao Y, Jing X, Yang S, Zhou C, Zheng J, Liang P, Zheng RQ. Usefulness of New Shear Wave Elastography Technique for Noninvasive Assessment of Liver Fibrosis in Patients with Chronic Hepatitis B: A Prospective Multicenter Study. Ultraschall Med 2021. [PMID: 33910257 DOI: 10.1055/a-1376-6734] [Reference Citation Analysis]
435 Soubrane O, Brouquet A, Zalinski S, Terris B, Brézault C, Mallet V, Goldwasser F, Scatton O. Predicting high grade lesions of sinusoidal obstruction syndrome related to oxaliplatin-based chemotherapy for colorectal liver metastases: correlation with post-hepatectomy outcome. Ann Surg. 2010;251:454-460. [PMID: 20160638 DOI: 10.1097/sla.0b013e3181c79403] [Cited by in Crossref: 122] [Cited by in F6Publishing: 46] [Article Influence: 11.1] [Reference Citation Analysis]
436 Belmonte I, Nuñez A, Barrecheguren M, Esquinas C, Pons M, López-Martínez RM, Ruiz G, Blanco-Grau A, Ferrer R, Genescà J, Miravitlles M, Rodríguez-Frías F. Trends in Diagnosis of Alpha-1 Antitrypsin Deficiency Between 2015 and 2019 in a Reference Laboratory. Int J Chron Obstruct Pulmon Dis 2020;15:2421-31. [PMID: 33116457 DOI: 10.2147/COPD.S269641] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
437 Gordon SC, Lamerato LE, Rupp LB, Holmberg SD, Moorman AC, Spradling PR, Teshale E, Xu F, Boscarino JA, Vijayadeva V, Schmidt MA, Oja-Tebbe N, Lu M. Prevalence of cirrhosis in hepatitis C patients in the Chronic Hepatitis Cohort Study (CHeCS): a retrospective and prospective observational study. Am J Gastroenterol 2015;110:1169-77; quiz 1178. [PMID: 26215529 DOI: 10.1038/ajg.2015.203] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 4.3] [Reference Citation Analysis]
438 Alghamdi AS, Sanai FM, Ismail M, Alghamdi H, Alswat K, Alqutub A, Altraif I, Shah H, Alfaleh FZ; Saudi Association for the Study of Liver Diseases and Transplantation. SASLT practice guidelines: management of hepatitis C virus infection. Saudi J Gastroenterol 2012;18 Suppl:S1-32. [PMID: 23006491 DOI: 10.4103/1319-3767.101155] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
439 Sarkar M, Dodge JL, Greenblatt RM, Kuniholm MH, DeHovitz J, Plankey M, Kovacs A, French AL, Seaberg EC, Ofotokun I, Fischl M, Overton E, Kelly E, Bacchetti P, Peters MG; Women’s Interagency HIV Study. Reproductive Aging and Hepatic Fibrosis Progression in Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Women. Clin Infect Dis 2017;65:1695-702. [PMID: 29020239 DOI: 10.1093/cid/cix643] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
440 Li J, Venkatesh SK, Yin M. Advances in Magnetic Resonance Elastography of Liver. Magn Reson Imaging Clin N Am 2020;28:331-40. [PMID: 32624152 DOI: 10.1016/j.mric.2020.03.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
441 Chang Y, Cho YK, Kim Y, Sung E, Ahn J, Jung H, Yun KE, Shin H, Ryu S. Nonheavy Drinking and Worsening of Noninvasive Fibrosis Markers in Nonalcoholic Fatty Liver Disease: A Cohort Study: Hepatology. Hepatology 2019;69:64-75. [DOI: 10.1002/hep.30170] [Cited by in Crossref: 48] [Cited by in F6Publishing: 53] [Article Influence: 16.0] [Reference Citation Analysis]
442 Cross TJ, Rizzi P, Berry PA, Bruce M, Portmann B, Harrison PM. King's Score: an accurate marker of cirrhosis in chronic hepatitis C. Eur J Gastroenterol Hepatol. 2009;21:730-738. [PMID: 19430302 DOI: 10.1097/meg.0b013e32830dfcb3] [Cited by in Crossref: 78] [Cited by in F6Publishing: 35] [Article Influence: 7.1] [Reference Citation Analysis]
443 Wu YM, Xu N, Hu JY, Xu XF, Wu WX, Gao SX, Zhu WJ, Wu WL, Shen XZ, Wang JY, Wu SD. A simple noninvasive index to predict significant liver fibrosis in patients with advanced schistosomiasis japonica. Parasitol Int 2013;62:283-8. [PMID: 23466574 DOI: 10.1016/j.parint.2013.02.005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
444 Richard J, Lingvay I. Hepatic steatosis and Type 2 diabetes: current and future treatment considerations. Expert Rev Cardiovasc Ther. 2011;9:321-328. [PMID: 21438811 DOI: 10.1586/erc.11.15] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 3.2] [Reference Citation Analysis]
445 Moorman AC, Xing J, Ko S, Rupp LB, Xu F, Gordon SC, Lu M, Spradling PR, Teshale EH, Boscarino JA, Vijayadeva V, Schmidt MA, Holmberg SD; CHeCS Investigators. Late diagnosis of hepatitis C virus infection in the Chronic Hepatitis Cohort Study (CHeCS): Missed opportunities for intervention. Hepatology 2015;61:1479-84. [PMID: 25131217 DOI: 10.1002/hep.27365] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 5.5] [Reference Citation Analysis]
446 Toyoda H, Yasuda S, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Kitabatake S, Yamamoto S, Shiota S, Furoi M, Koyabu T, Furukawa D, Kumada T, Sumida Y. Impact of COVID-19 pandemic on surveillance of hepatocellular carcinoma: a study in patients with chronic hepatitis C after sustained virologic response. GastroHep 2020. [PMID: 32837333 DOI: 10.1002/ygh2.418] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
447 Itani T, Ishihara T. Efficacy of canagliflozin against nonalcoholic fatty liver disease: a prospective cohort study. Obes Sci Pract. 2018;4:477-482. [PMID: 30338118 DOI: 10.1002/osp4.294] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 11.0] [Reference Citation Analysis]
448 Debroy P, Lake JE, Malagoli A, Guaraldi G. Relationship between Grip Strength and Nonalcoholic Fatty Liver Disease in Men Living with HIV Referred to a Metabolic Clinic. J Frailty Aging 2019;8:150-3. [PMID: 31237317 DOI: 10.14283/jfa.2018.37] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
449 Golabi P, Sayiner M, Fazel Y, Koenig A, Henry L, Younossi ZM. Current complications and challenges in nonalcoholic steatohepatitis screening and diagnosis. Expert Rev Gastroenterol Hepatol. 2016;10:63-71. [PMID: 26469309 DOI: 10.1586/17474124.2016.1099433] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 5.7] [Reference Citation Analysis]
450 Varchetta S, Mele D, D'Ambrosio R, Perbellini R, Lombardi A, Rojas A, Paolucci S, Baldanti F, Oliviero B, Mantovani S, Tinelli C, De Silvestri A, Romero Gomez M, Lampertico P, Mondelli MU. A new algorithm shows superior ability to discriminate liver fibrosis stages in chronic hepatitis C. J Viral Hepat 2021. [PMID: 34228858 DOI: 10.1111/jvh.13570] [Reference Citation Analysis]
451 Zou X, Zhu MY, Yu DM, Li W, Zhang DH, Lu FJ, Gong QM, Liu F, Jiang JH, Zheng MH, Kuno A, Narimatsu H, Zhang Y, Zhang XX. Serum WFA+ -M2BP levels for evaluation of early stages of liver fibrosis in patients with chronic hepatitis B virus infection. Liver Int 2017;37:35-44. [PMID: 27300763 DOI: 10.1111/liv.13188] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 8.6] [Reference Citation Analysis]
452 Qiao L, Tan W, Wang X, Zheng X, Huang Y, Li B, Meng Z, Gao Y, Qian Z, Liu F, Lu X, Shang J, Liu J, Yan H, Gu W, Zhang Y, Xiang X, Hou Y, Zhang Q, Xiong Y, Zou C, Chen J, Huang Z, Jiang X, Luo S, Chen Y, Gao N, Liu C, Yuan W, Mei X, Li J, Li T, Zheng R, Zhou X, Chen J, Deng G, Zhang W, Li H. Different Effects of Total Bilirubin on 90-Day Mortality in Hospitalized Patients With Cirrhosis and Advanced Fibrosis: A Quantitative Analysis. Front Med (Lausanne) 2021;8:704452. [PMID: 34249983 DOI: 10.3389/fmed.2021.704452] [Reference Citation Analysis]
453 Liu Y, Ning Z, Örmeci N, An W, Yu Q, Han K, Huang Y, Liu D, Liu F, Li Z, Ding H, Luo H, Zuo C, Liu C, Wang J, Zhang C, Ji J, Wang W, Wang Z, Wang W, Yuan M, Li L, Zhao Z, Wang G, Li M, Liu Q, Lei J, Liu C, Tang T, Akçalar S, Çelebioğlu E, Üstüner E, Bilgiç S, Ellik Z, Asiller ÖÖ, Liu Z, Teng G, Chen Y, Hou J, Li X, He X, Dong J, Tian J, Liang P, Ju S, Zhang Y, Qi X. Deep Convolutional Neural Network-Aided Detection of Portal Hypertension in Patients With Cirrhosis. Clin Gastroenterol Hepatol 2020;18:2998-3007.e5. [PMID: 32205218 DOI: 10.1016/j.cgh.2020.03.034] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
454 Furlan A, Tublin ME, Yu L, Chopra KB, Lippello A, Behari J. Comparison of 2D Shear Wave Elastography, Transient Elastography, and MR Elastography for the Diagnosis of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.AJR Am J Roentgenol. 2020;214:W20-W26. [PMID: 31714842 DOI: 10.2214/AJR.19.21267] [Cited by in Crossref: 23] [Cited by in F6Publishing: 14] [Article Influence: 11.5] [Reference Citation Analysis]
455 Lee SH, Shin HP, Lee JI. Real-world single-center experience with direct-acting antivirals for improvement of the liver fibrosis after chronic hepatitis C treatment. Antivir Chem Chemother 2020;28:2040206620974835. [PMID: 33215505 DOI: 10.1177/2040206620974835] [Reference Citation Analysis]
456 Izumi T, Sho T, Morikawa K, Shigesawa T, Suzuki K, Nakamura A, Ohara M, Kawagishi N, Umemura M, Shimazaki T, Kimura M, Nakai M, Suda G, Natsuizaka M, Ogawa K, Kudo Y, Nishida M, Ono K, Baba M, Furuya K, Sakamoto N. Assessing the risk of hepatocellular carcinoma by combining liver stiffness and the controlled attenuation parameter. Hepatol Res. 2019;49:1207-1217. [PMID: 31219667 DOI: 10.1111/hepr.13391] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
457 Na SK, Song BC. Development and surveillance of hepatocellular carcinoma in patients with sustained virologic response after antiviral therapy for chronic hepatitis C. Clin Mol Hepatol 2019;25:234-44. [PMID: 30661334 DOI: 10.3350/cmh.2018.0108] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
458 Becker L, Salameh W, Sferruzza A, Zhang K, ng Chen R, Malik R, Reitz R, Nasser I, Afdhal NH. Validation of hepascore, compared with simple indices of fibrosis, in patients with chronic hepatitis C virus infection in United States. Clin Gastroenterol Hepatol. 2009;7:696-701. [PMID: 19514117 DOI: 10.1016/j.cgh.2009.01.010] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 3.9] [Reference Citation Analysis]
459 Fallatah HI. Noninvasive Biomarkers of Liver Fibrosis: An Overview. Advances in Hepatology 2014;2014:1-15. [DOI: 10.1155/2014/357287] [Cited by in Crossref: 28] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
460 Jung JY, Park SK, Oh CM, Chung PW, Ryoo JH. Non-Alcoholic Fatty Liver Disease and Its Association with Depression in Korean General Population. J Korean Med Sci 2019;34:e199. [PMID: 31373184 DOI: 10.3346/jkms.2019.34.e199] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
461 Khairy M, Abdel-Rahman M, El-Raziky M, El-Akel W, Zayed N, Khatab H, Esmat G. Non-invasive prediction of hepatic fibrosis in patients with chronic HCV based on the routine pre-treatment workup. Hepat Mon 2012;12:e6718. [PMID: 23346149 DOI: 10.5812/hepatmon.6718] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
462 Kurosaki M, Izumi N. External validation of FIB-4: Diagnostic accuracy is limited in elderly populations. Hepatology 2008;47:352-352. [DOI: 10.1002/hep.21978] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
463 Leung JC, Loong TC, Pang J, Wei JL, Wong VW. Invasive and non-invasive assessment of portal hypertension. Hepatol Int 2018;12:44-55. [PMID: 28361299 DOI: 10.1007/s12072-017-9795-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
464 Weis A, Marquart L, Calvopina DA, Genz B, Ramm GA, Skoien R. Serum MicroRNAs as Biomarkers in Hepatitis C: Preliminary Evidence of a MicroRNA Panel for the Diagnosis of Hepatocellular Carcinoma. Int J Mol Sci. 2019;20. [PMID: 30781550 DOI: 10.3390/ijms20040864] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
465 AbdAllah M, Alboraie M, Abdel-Razek W, Hassany M, Ammar I, Kamal E, Alalfy M, Okasha A, El Akel W, Shaaban E, Elbaz T, Hefny Z, Gomaa A, El-Bendary M, El-Serafy M, Esmat G, Doss W, El-Sayed MH. Pregnancy outcome of anti-HCV direct-acting antivirals: Real-life data from an Egyptian cohort. Liver Int 2021;41:1494-7. [PMID: 33905164 DOI: 10.1111/liv.14913] [Reference Citation Analysis]
466 Squillace N, Lorenzini P, Lapadula G, Bandera A, Cozzi-Lepri A, Rusconi S, Puoti M, Castagna A, Antinori A, Gori A, d'Arminio Monforte A; Icona Foundation Study Group. Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART. J Antimicrob Chemother 2016;71:2663-9. [PMID: 27272727 DOI: 10.1093/jac/dkw185] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
467 Fuster D, García-Calvo X, Zuluaga P, Bolao F, Muga R. Assessment of liver disease in patients with chronic hepatitis C and unhealthy alcohol use. World J Gastroenterol 2021; 27(23): 3223-3237 [PMID: 34163107 DOI: 10.3748/wjg.v27.i23.3223] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
468 McPherson S, Anstee QM, Henderson E, Day CP, Burt AD. Are simple noninvasive scoring systems for fibrosis reliable in patients with NAFLD and normal ALT levels? Eur J Gastroenterol Hepatol. 2013;25:652-658. [PMID: 23325287 DOI: 10.1097/meg.0b013e32835d72cf] [Cited by in Crossref: 49] [Cited by in F6Publishing: 24] [Article Influence: 6.1] [Reference Citation Analysis]
469 Barnett PG, Joyce VR, Lo J, Gidwani-Marszowski R, Goldhaber-Fiebert JD, Desai M, Asch SM, Holodniy M, Owens DK. Effect of Interferon-Free Regimens on Disparities in Hepatitis C Treatment of US Veterans. Value Health 2018;21:921-30. [PMID: 30098669 DOI: 10.1016/j.jval.2017.12.025] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
470 Mitchell LR, Shah N, Selwyn PA. Palliative Care in the Management of Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome in the Primary Care Setting. Prim Care 2019;46:433-45. [PMID: 31375191 DOI: 10.1016/j.pop.2019.05.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
471 Noguchi R, Kaji K, Namisaki T, Moriya K, Kitade M, Takeda K, Kawaratani H, Okura Y, Aihara Y, Furukawa M, Mitoro A, Yoshiji H. Serum angiotensin-converting enzyme level for evaluating significant fibrosis in chronic hepatitis B. World J Gastroenterol 2017; 23(36): 6705-6714 [PMID: 29085215 DOI: 10.3748/wjg.v23.i36.6705] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
472 Drazilova S, Janicko M, Skladany L, Kristian P, Oltman M, Szantova M, Krkoska D, Mazuchova E, Piesecka L, Vahalova V, Rac M, Schreter I, Virag L, Koller T, Liptakova A, Ondrasova M, Jarcuska P. Glucose Metabolism Changes in Patients with Chronic Hepatitis C Treated with Direct Acting Antivirals. Can J Gastroenterol Hepatol 2018;2018:6095097. [PMID: 30402450 DOI: 10.1155/2018/6095097] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
473 Sebastiani G, Alberti A. How far is noninvasive assessment of liver fibrosis from replacing liver biopsy in hepatitis C? J Viral Hepat. 2012;19 Suppl 1:18-32. [PMID: 22233410 DOI: 10.1111/j.1365-2893.2011.01518.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 3.2] [Reference Citation Analysis]
474 Chang XJ, Sun C, Chen Y, Li XD, Yu ZJ, Dong Z, Bai WL, Wang XD, Li ZQ, Chen D, Du WJ, Liao H, Jiang QY, Sun LJ, Li YY, Zhang CH, Xu DP, Chen YP, Li Q, Yang YP. On-treatment monitoring of liver fibrosis with serum hepatitis B core-related antigen in chronic hepatitis B. World J Gastroenterol 2019; 25(32): 4764-4778 [PMID: 31528100 DOI: 10.3748/wjg.v25.i32.4764] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
475 Collazos J, Cartón JA, Asensi V. Immunological status does not influence hepatitis c virus or liver fibrosis in HIV-hepatitis C virus-coinfected patients. AIDS Res Hum Retroviruses. 2011;27:383-389. [PMID: 20977357 DOI: 10.1089/aid.2010.0168] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
476 Pissaia A Jr, Borderie D, Bernard D, Scatton O, Calmus Y, Conti F. APRI and FIB-4 Scores Are Useful After Liver Transplantation Independently of Etiology. Transplant Proc. 2009;41:679-681. [PMID: 19328955 DOI: 10.1016/j.transproceed.2008.12.014] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]
477 Yu JH, Kim JK, Lee KS, Lee JI. Antiviral Therapy in Patients With Chronic Hepatitis C-related Hepatocellular Carcinoma Responding to Palliative Treatment. J Clin Gastroenterol 2018;52:557-62. [PMID: 28863014 DOI: 10.1097/MCG.0000000000000923] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
478 Shin SK, Lee JW, Ra H, Kwon OS, Shin JB, Jin YJ, Lee S, Han KJ, Kim YN, Kim TH, Kim YS, Kim JH. Durability of Sustained Virologic Response and Improvement of Fibrosis Markers after Daclatasvir and Asunaprevir Treatment in Genotype 1b Hepatitis C Virus-Infected Patients: a Real Life and Multicenter Study. J Korean Med Sci 2019;34:e264. [PMID: 31650719 DOI: 10.3346/jkms.2019.34.e264] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
479 Liu CH, Yang SS, Peng CY, Lin WT, Liu CJ, Su TH, Tseng TC, Chen PJ, Chen DS, Kao JH. Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairment. J Viral Hepat 2020;27:568-75. [PMID: 31981264 DOI: 10.1111/jvh.13265] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
480 Hsu CW, Liang KH, Lin CL, Wang TH, Yeh CT. Platelet counts modulate the quantitative relationship between hepatitis B viral DNA and surface antigen concentrations: a cross-sectional study of hematological, histological and viral factors. BMC Infect Dis 2017;17:9. [PMID: 28056849 DOI: 10.1186/s12879-016-2121-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
481 Vahedian-Azimi A, Shojaie S, Banach M, Heidari F, Cicero AFG, Khoshfetrat M, Jamialahmadi T, Sahebkar A. Statin therapy in chronic viral hepatitis: a systematic review and meta-analysis of nine studies with 195,602 participants. Ann Med 2021;53:1227-42. [PMID: 34296976 DOI: 10.1080/07853890.2021.1956686] [Reference Citation Analysis]
482 Ho SY, Liu PH, Hsu CY, Hsia CY, Lee YH, Lee RC, Huang YH, Lee FY, Hou MC, Tsai YJ, Huo TI. Prognostic role of noninvasive liver reserve markers in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. PLoS One. 2017;12:e0180408. [PMID: 28672011 DOI: 10.1371/journal.pone.0180408] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
483 Sasaki R, Miyaaki H, Narita S, Fukushima M, Haraguchi M, Miuma S, Hidaka M, Eguchi S, Okudaira S, Abe K, Nakao K. Serum Mac-2 binding protein glycosylation isomer as a biomarker of fibrosis in living donor liver transplant graft. Clin Transplant 2021;35:e14175. [PMID: 33247961 DOI: 10.1111/ctr.14175] [Reference Citation Analysis]
484 Trang T, Petersen JR, Snyder N. Non-invasive markers of hepatic fibrosis in patients co-infected with HCV and HIV: comparison of the APRI and FIB-4 index. Clin Chim Acta. 2008;397:51-54. [PMID: 18692034 DOI: 10.1016/j.cca.2008.07.009] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 1.9] [Reference Citation Analysis]
485 Ogawa E, Furusyo N, Kajiwara E, Nomura H, Kawano A, Takahashi K, Dohmen K, Satoh T, Azuma K, Nakamuta M. Comparative effectiveness and safety study of triple therapy with simeprevir or telaprevir for non-cirrhotic patients with chronic hepatitis C virus genotype 1b infection. J Gastroenterol Hepatol. 2015;30:1759-1767. [PMID: 26095167 DOI: 10.1111/jgh.13016] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
486 Kuo MT, Tseng PL, Chou YP, Chang KC, Tsai MC, Kuo YH, Hu TH, Hung CH, Wang JH, Lu SN, Chen CH. Role of hepatitis B surface antigen in hepatitis B virus relapse after entecavir or tenofovir prophylaxis in patients undergoing cancer chemotherapy. J Gastroenterol Hepatol 2018;33:1766-72. [PMID: 29514418 DOI: 10.1111/jgh.14142] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
487 Sandrasegaran K, Akisik FM, Lin C, Tahir B, Rajan J, Saxena R, Aisen AM. Value of diffusion-weighted MRI for assessing liver fibrosis and cirrhosis. AJR Am J Roentgenol. 2009;193:1556-1560. [PMID: 19933647 DOI: 10.2214/ajr.09.2436] [Cited by in Crossref: 147] [Cited by in F6Publishing: 49] [Article Influence: 13.4] [Reference Citation Analysis]
488 Waldron PR, Holodniy M. Peripheral Blood Mononuclear Cell Gene Expression Remains Broadly Altered Years after Successful Interferon-Based Hepatitis C Virus Treatment. J Immunol Res 2015;2015:958231. [PMID: 26568966 DOI: 10.1155/2015/958231] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
489 Adler M, Gulbis B, Moreno C, Evrard S, Verset G, Golstein P, Frotscher B, Nagy N, Thiry P. The predictive value of FIB-4 versus FibroTest, APRI, FibroIndex and Forns index to noninvasively estimate fibrosis in hepatitis C and nonhepatitis C liver diseases. Hepatology. 2008;47:762-763; author reply 763. [PMID: 18220307 DOI: 10.1002/hep.22085] [Cited by in Crossref: 64] [Cited by in F6Publishing: 62] [Article Influence: 4.9] [Reference Citation Analysis]
490 Nishikawa H, Takata R, Enomoto H, Yoh K, Kishino K, Shimono Y, Iwata Y, Hasegawa K, Nakano C, Nishimura T, Aizawa N, Sakai Y, Ikeda N, Takashima T, Ishii A, Iijima H, Nishiguchi S. Proposal of a predictive model for advanced fibrosis containing Wisteria floribunda agglutinin-positive Mac-2-binding protein in chronic hepatitis C: Predictive model, liver fibrosis and WFA + -M2BP. Hepatol Res 2017;47:E74-84. [DOI: 10.1111/hepr.12724] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
491 Khalili H, Dayyeh BA, Friedman LS. Assessment of Liver Function in Clinical Practice. In: Ginès P, Kamath PS, Arroyo V, editors. Chronic Liver Failure. Totowa: Humana Press; 2011. pp. 47-76. [DOI: 10.1007/978-1-60761-866-9_3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
492 Ichikawa T, Miyaaki H, Miuma S, Motoyoshi Y, Yamashima M, Yamamichi S, Koike M, Nakano Y, Honda T, Yajima H, Uehara R, Miyazaki O, Kuribayashi Y, Kira K, Taura N, Nakao K. Direct-acting Antivirals Improved the Quality of Life, Ameliorated Disease-related Symptoms, and Augmented Muscle Volume Three Years Later in Patients with Hepatitis C Virus. Intern Med 2020;59:2653-60. [PMID: 33132304 DOI: 10.2169/internalmedicine.5102-20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
493 Levy JJ, Azizgolshani N, Andersen MJ Jr, Suriawinata A, Liu X, Lisovsky M, Ren B, Bobak CA, Christensen BC, Vaickus LJ. A large-scale internal validation study of unsupervised virtual trichrome staining technologies on nonalcoholic steatohepatitis liver biopsies. Mod Pathol 2021;34:808-22. [PMID: 33299110 DOI: 10.1038/s41379-020-00718-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
494 Cho Y, Kabata D, Ehara E, Yamamoto A, Mizuochi T, Mushiake S, Kusano H, Kuwae Y, Suzuki T, Uchida-Kobayashi S, Morikawa H, Amano-Teranishi Y, Kioka K, Jogo A, Isoura Y, Hamazaki T, Murakami Y, Tokuhara D. Assessing liver stiffness with conventional cut-off values overestimates liver fibrosis staging in patients who received the Fontan procedure. Hepatol Res 2021;51:593-602. [PMID: 33677839 DOI: 10.1111/hepr.13627] [Reference Citation Analysis]
495 Masugi Y, Abe T, Tsujikawa H, Effendi K, Hashiguchi A, Abe M, Imai Y, Hino K, Hige S, Kawanaka M, Yamada G, Kage M, Korenaga M, Hiasa Y, Mizokami M, Sakamoto M. Quantitative assessment of liver fibrosis reveals a nonlinear association with fibrosis stage in nonalcoholic fatty liver disease. Hepatol Commun 2018;2:58-68. [PMID: 29404513 DOI: 10.1002/hep4.1121] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
496 Tama M, Naylor P, Patel S, Altawil J, Gulati D, Antaki F, Mutchnick MG, Ehrinpreis M. Overestimate of Fibrosis by FIBROSpect® II in African Americans Complicates the Management of their Chronic Hepatitis C. J Clin Transl Hepatol 2016;4:12-9. [PMID: 27047767 DOI: 10.14218/JCTH.2015.00053] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
497 Kileng H, Gutteberg T, Goll R, Paulssen EJ. Screening for hepatitis C in a general adult population in a low-prevalence area: the Tromsø study. BMC Infect Dis 2019;19:189. [PMID: 30808290 DOI: 10.1186/s12879-019-3832-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
498 Ikenaga H, Uchida-Kobayashi S, Tamori A, Odagiri N, Yoshida K, Kotani K, Motoyama H, Kozuka R, Kawamura E, Hagihara A, Fujii H, Enomoto M, Kawada N. Direct-acting antivirals reduce the risk of tumour progression of hepatocellular carcinoma after curative treatment. J Viral Hepat 2021. [PMID: 34695288 DOI: 10.1111/jvh.13627] [Reference Citation Analysis]
499 McPherson S, Hardy T, Dufour JF, Petta S, Romero-Gomez M, Allison M, Oliveira CP, Francque S, Van Gaal L, Schattenberg JM, Tiniakos D, Burt A, Bugianesi E, Ratziu V, Day CP, Anstee QM. Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis. Am J Gastroenterol. 2017;112:740-751. [PMID: 27725647 DOI: 10.1038/ajg.2016.453] [Cited by in Crossref: 208] [Cited by in F6Publishing: 206] [Article Influence: 41.6] [Reference Citation Analysis]
500 Fracanzani AL, Pisano G, Consonni D, Tiraboschi S, Baragetti A, Bertelli C, Norata GD, Dongiovanni P, Valenti L, Grigore L, Tonella T, Catapano A, Fargion S. Epicardial Adipose Tissue (EAT) Thickness Is Associated with Cardiovascular and Liver Damage in Nonalcoholic Fatty Liver Disease. PLoS One. 2016;11:e0162473. [PMID: 27627804 DOI: 10.1371/journal.pone.0162473] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
501 European Association for Study of Liver. Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63:237-264. [PMID: 25911335 DOI: 10.1016/j.jhep.2015.04.006] [Cited by in Crossref: 918] [Cited by in F6Publishing: 787] [Article Influence: 153.0] [Reference Citation Analysis]
502 Wang L, Fan YX, Dou XG. Declining diagnostic accuracy of non-invasive fibrosis tests is associated with elevated alanine aminotransferase in chronic hepatitis B. World J Clin Cases 2018; 6(12): 521-530 [PMID: 30397608 DOI: 10.12998/wjcc.v6.i12.521] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
503 Poustchi H, Eslami M, Ostovaneh MR, Modabbernia A, Saeedian FS, Taslimi S, George J, Malekzadeh R, Zamani F. Transient elastography in hepatitis C virus-infected patients with beta-thalassemia for assessment of fibrosis: Transient elastography in beta-thalassemia. Hepatol Res 2013;43:1276-83. [DOI: 10.1111/hepr.12088] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
504 Emamaullee J, Khan S, Weaver C, Goldbeck C, Yanni G, Kohli R, Genyk Y, Zhou S, Shillingford N, Sullivan PM, Takao C, Detterich J, Kantor PF, Cleveland JD, Herrington C, Ram Kumar S, Starnes V, Badran S, Patel ND. Non-invasive biomarkers of Fontan-associated liver disease. JHEP Rep 2021;3:100362. [PMID: 34693238 DOI: 10.1016/j.jhepr.2021.100362] [Reference Citation Analysis]
505 Suda G, Furusyo N, Toyoda H, Kawakami Y, Ikeda H, Suzuki M, Arataki K, Mori N, Tsuji K, Katamura Y, Takaguchi K, Ishikawa T, Tsuji K, Shimada N, Hiraoka A, Yamsaki S, Nakai M, Sho T, Morikawa K, Ogawa K, Kudo M, Nagasaka A, Furuya K, Yamamoto Y, Kato K, Ueno Y, Iio E, Tanaka Y, Kurosaki M, Kumada T, Chayama K, Sakamoto N. Daclatasvir and asunaprevir in hemodialysis patients with hepatitis C virus infection: a nationwide retrospective study in Japan. J Gastroenterol 2018;53:119-28. [PMID: 28560477 DOI: 10.1007/s00535-017-1353-y] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 8.8] [Reference Citation Analysis]
506 Hsieh YC, Lee KC, Wang YW, Yang YY, Hou MC, Huo TI, Lin HC. Correlation and prognostic accuracy between noninvasive liver fibrosismarkers and portal pressure in cirrhosis: Role of ALBI score. PLoS One 2018;13:e0208903. [PMID: 30540824 DOI: 10.1371/journal.pone.0208903] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
507 Fouad SA, Esmat S, Omran D, Rashid L, Kobaisi MH. Noninvasive assessment of hepatic fibrosis in Egyptian patients with chronic hepatitis C virus infection. World J Gastroenterol 2012; 18(23): 2988-2994 [PMID: 22736923 DOI: 10.3748/wjg.v18.i23.2988] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 29] [Article Influence: 3.2] [Reference Citation Analysis]
508 Stasi C, Leoncini L, Biagini MR, Arena U, Madiai S, Laffi G, Marra F, Milani S. Assessment of liver fibrosis in primary biliary cholangitis: Comparison between indirect serum markers and fibrosis morphometry. Dig Liver Dis. 2016;48:298-301. [PMID: 26632448 DOI: 10.1016/j.dld.2015.10.024] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
509 Pfeifer L, Adler W, Zopf S, Siebler J, Wildner D, Goertz RS, Schellhaas B, Neurath MF, Strobel D. Acoustic radiation force impulse elastography: comparison and combination with other noninvasive tests for the diagnosis of compensated liver cirrhosis. European Journal of Gastroenterology & Hepatology 2017;29:524-30. [DOI: 10.1097/meg.0000000000000827] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
510 Su T, Liao C, Liu C, Huang K, Tseng T, Yang H, Liu C, Chen P, Chen D, Kao J. Acoustic Radiation Force Impulse US Imaging: Liver Stiffness in Patients with Chronic Hepatitis B with and without Antiviral Therapy. Radiology 2018;288:293-9. [DOI: 10.1148/radiol.2018171116] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
511 Ng KJ, Tseng CW, Chang TT, Tzeng SJ, Hsieh YH, Hung TH, Huang HT, Wu SF, Tseng KC. Aspartate aminotransferase to platelet ratio index and sustained virologic response are associated with progression from hepatitis C associated liver cirrhosis to hepatocellular carcinoma after treatment with pegylated interferon plus ribavirin. Clin Interv Aging. 2016;11:1035-1041. [PMID: 27536084 DOI: 10.2147/cia.s108589] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
512 Wang TZ, Lin DD, Jin BX, Sun XY, Li N. Plasma microRNA: A novel non-invasive biomarker for HBV-associated liver fibrosis staging. Exp Ther Med. 2019;17:1919-1929. [PMID: 30783469 DOI: 10.3892/etm.2018.7117] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
513 Kawagishi N, Suda G, Onozawa M, Kimura M, Maehara O, Ohara M, Izumi T, Umemura M, Ito J, Nakai M. Comparing the risk of hepatitis B virus reactivation between direct-acting antiviral therapies and interferon-based therapies for hepatitis C. J Viral Hepat. 2017;24:1098-1106. [PMID: 28632923 DOI: 10.1111/jvh.12737] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
514 Lopez-Sanchez I, Dunkel Y, Roh YS, Mittal Y, De Minicis S, Muranyi A, Singh S, Shanmugam K, Aroonsakool N, Murray F, Ho SB, Seki E, Brenner DA, Ghosh P. GIV/Girdin is a central hub for profibrogenic signalling networks during liver fibrosis. Nat Commun 2014;5:4451. [PMID: 25043713 DOI: 10.1038/ncomms5451] [Cited by in Crossref: 69] [Cited by in F6Publishing: 64] [Article Influence: 9.9] [Reference Citation Analysis]
515 Boyle M, Tiniakos D, Schattenberg JM, Ratziu V, Bugianessi E, Petta S, Oliveira CP, Govaere O, Younes R, McPherson S, Bedossa P, Nielsen MJ, Karsdal M, Leeming D, Kendrick S, Anstee QM. Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease. JHEP Rep 2019;1:188-98. [PMID: 32039369 DOI: 10.1016/j.jhepr.2019.06.004] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 15.5] [Reference Citation Analysis]
516 Sakamaki A, Kamimura K, Fukui N, Watanabe H, Sakai N, Tominaga K, Mizuno K, Takamura M, Kawai H, Sugai T, Yamagiwa S, Someya T, Terai S. A case report of psychiatric symptoms following direct-acting antiviral and ribavirin combination therapy for chronic hepatitis C in a patient with innate anxiety. BMC Gastroenterol 2019;19:85. [PMID: 31195993 DOI: 10.1186/s12876-019-1013-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
517 Akiyama T, Miyamoto Y, Imai K, Yamashita Y, Nomoto D, Daitoku N, Sakamoto Y, Kiyozumi Y, Tokunaga R, Eto K, Harada K, Hiyoshi Y, Iwatsuki M, Nagai Y, Iwagami S, Baba Y, Yoshida N, Baba H. Fibrosis-4 Index, a Noninvasive Fibrosis Marker, Predicts Survival Outcomes After Hepatectomy for Colorectal Cancer Liver Metastases. Ann Surg Oncol 2020;27:3534-41. [PMID: 32648180 DOI: 10.1245/s10434-020-08828-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
518 Cheng PN, Chiu HC, Chiu YC, Chen SC, Chen Y. Comparison of FIB-4 and transient elastography in evaluating liver fibrosis of chronic hepatitis C subjects in community. PLoS One 2018;13:e0206947. [PMID: 30403744 DOI: 10.1371/journal.pone.0206947] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
519 Lesko CR, Nance RM, Lau B, Fojo AT, Hutton HE, Delaney JAC, Crane HM, Cropsey KL, Mayer KH, Napravnik S, Geng E, Mathews WC, McCaul ME, Chander G; CNICS. Changing Patterns of Alcohol Use and Probability of Unsuppressed Viral Load Among Treated Patients with HIV Engaged in Routine Care in the United States. AIDS Behav 2021;25:1072-82. [PMID: 33064249 DOI: 10.1007/s10461-020-03065-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
520 Kilany S, Ata L, Gomaa A, Sabry A, Nada A, Tharwa ES, Badra G, Abogabal A, Elwaraky M, Moaz E, Ezzat S, Elsharawy A, Waked I. Decreased Incidence of Hepatocellular Carcinoma after Directly Acting Antiviral Therapy in Patients with Hepatitis C-Related Advanced Fibrosis and Cirrhosis. J Hepatocell Carcinoma 2021;8:925-35. [PMID: 34408991 DOI: 10.2147/JHC.S295330] [Reference Citation Analysis]
521 Fusco M, Piselli P, Virdone S, Di Cicco P, Scognamiglio P, De Paoli P, Ciullo V, Verdirosi D, D'Orazio M, Dal Maso L, Girardi E, Franceschi S, Serraino D. Infection with hepatitis viruses, FIB-4 index and risk of hepatocellular carcinoma in southern Italy: a population-based cohort study. Infect Agent Cancer. 2016;11:54. [PMID: 27822295 DOI: 10.1186/s13027-016-0101-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
522 Jeng JE, Tsai JF, Chuang LY, Ho MS, Lin ZY, Hsieh MY, Chen SC, Chuang WL, Wang LY, Yu ML, Dai CY, Chang JG. Tumor necrosis factor-alpha 308.2 polymorphism is associated with advanced hepatic fibrosis and higher risk for hepatocellular carcinoma. Neoplasia 2007;9:987-92. [PMID: 18030367 DOI: 10.1593/neo.07781] [Cited by in Crossref: 68] [Cited by in F6Publishing: 58] [Article Influence: 4.9] [Reference Citation Analysis]
523 Lombardi R, Lever R, Smith C, Marshall N, Rodger A, Bhagani S, Tsochatzis E. Liver test abnormalities in patients with HIV mono-infection: assessment with simple noninvasive fibrosis markers. Ann Gastroenterol 2017;30:349-56. [PMID: 28469366 DOI: 10.20524/aog.2017.0141] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
524 Bessissow T, Le NH, Rollet K, Afif W, Bitton A, Sebastiani G. Incidence and Predictors of Nonalcoholic Fatty Liver Disease by Serum Biomarkers in Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2016;22:1937-1944. [PMID: 27379445 DOI: 10.1097/mib.0000000000000832] [Cited by in Crossref: 41] [Cited by in F6Publishing: 19] [Article Influence: 13.7] [Reference Citation Analysis]
525 Takaguchi K, Toyoda H, Tsutsui A, Suzuki Y, Nakamuta M, Imamura M, Senoh T, Nagano T, Tada T, Tachi Y, Hiraoka A, Michitaka K, Shibata H, Joko K, Okubo H, Tsuji K, Takaki S, Watanabe T, Ogawa C, Chayama K, Kumada T, Kudo M, Kumada H. Real-world virological efficacy and safety of daclatasvir/asunaprevir/beclabuvir in patients with chronic hepatitis C virus genotype 1 infection in Japan. J Gastroenterol 2019;54:742-51. [DOI: 10.1007/s00535-019-01568-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
526 Ostovaneh MR, Ambale-Venkatesh B, Fuji T, Bakhshi H, Shah R, Murthy VL, Tracy RP, Guallar E, Wu CO, Bluemke DA, Lima JAC. Association of Liver Fibrosis With Cardiovascular Diseases in the General Population: The Multi-Ethnic Study of Atherosclerosis (MESA). Circ Cardiovasc Imaging 2018;11:e007241. [PMID: 29523555 DOI: 10.1161/CIRCIMAGING.117.007241] [Cited by in Crossref: 28] [Cited by in F6Publishing: 14] [Article Influence: 14.0] [Reference Citation Analysis]
527 Liu R, Guo J, Lu Y, Zhang L, Shen G, Wu S, Chang M, Hu L, Hao H, Li M, Xie Y. Changes in APRI and FIB-4 in HBeAg-negative treatment-naive chronic hepatitis B patients with significant liver histological lesions receiving 5-year entecavir therapy. Clin Exp Med 2019;19:309-20. [PMID: 31111345 DOI: 10.1007/s10238-019-00560-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
528 Song BG, Sinn DH, Chi S, Kim K, Kang W, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. Additional role of liver stiffness measurement in stratifying residual hepatocellular carcinoma risk predicted by serum biomarkers in chronic hepatitis B patients under antiviral therapy. Eur J Gastroenterol Hepatol. 2018;30:1447-1452. [PMID: 30063482 DOI: 10.1097/meg.0000000000001226] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
529 Oshida N, Shida T, Oh S, Kim T, Isobe T, Okamoto Y, Kamimaki T, Okada K, Suzuki H, Ariizumi SI, Yamamoto M, Shoda J. Urinary Levels of Titin-N Fragment, a Skeletal Muscle Damage Marker, are Increased in Subjects with Nonalcoholic Fatty Liver Disease. Sci Rep. 2019;9:19498. [PMID: 31862937 DOI: 10.1038/s41598-019-56121-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
530 Qi X, Han G, Ye C, Zhang Y, Dai J, Peng Y, Deng H, Li J, Hou F, Ning Z, Zhao J, Zhang X, Wang R, Guo X. Splenectomy Causes 10-Fold Increased Risk of Portal Venous System Thrombosis in Liver Cirrhosis Patients. Med Sci Monit. 2016;22:2528-2550. [PMID: 27432511 DOI: 10.12659/msm.898866] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 3.4] [Reference Citation Analysis]
531 Pandya P, Rzouq F, Oni O. Sustained virologic response and other potential genotype-specific roles of statins among patients with hepatitis C-related chronic liver diseases. Clin Res Hepatol Gastroenterol. 2015;39:555-565. [PMID: 25835493 DOI: 10.1016/j.clinre.2015.02.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
532 Wiegand J, Berg T. The etiology, diagnosis and prevention of liver cirrhosis: part 1 of a series on liver cirrhosis. Dtsch Arztebl Int 2013;110:85-91. [PMID: 23451000 DOI: 10.3238/arztebl.2013.0085] [Cited by in Crossref: 16] [Cited by in F6Publishing: 36] [Article Influence: 2.0] [Reference Citation Analysis]
533 D'Ambrosio R, Degasperi E, Aghemo A, Fraquelli M, Lampertico P, Rumi MG, Facchetti F, Grassi E, Casazza G, Rosenberg W, Bedossa P, Colombo M. Serological Tests Do Not Predict Residual Fibrosis in Hepatitis C Cirrhotics with a Sustained Virological Response to Interferon. PLoS One 2016;11:e0155967. [PMID: 27304619 DOI: 10.1371/journal.pone.0155967] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
534 Miyasaka A, Yoshida Y, Yoshida T, Murakami A, Abe K, Ohuchi K, Kawakami T, Watanabe D, Hoshino T, Sawara K, Takikawa Y. The Real-world Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir for Hepatitis C Genotype 1. Intern Med 2018;57:2807-12. [PMID: 29780135 DOI: 10.2169/internalmedicine.0810-18] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
535 Aizawa N, Enomoto H, Imanishi H, Saito M, Iwata Y, Tanaka H, Ikeda N, Sakai Y, Takashima T, Iwai T. Elevation of the glycated albumin to glycated hemoglobin ratio during the progression of hepatitis C virus related liver fibrosis. World J Hepatol. 2012;4:11-17. [PMID: 22312451 DOI: 10.5754/hge12064] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
536 Park HE, Lee H, Choi SY, Kim HS, Chung GE. The risk of atrial fibrillation in patients with non-alcoholic fatty liver disease and a high hepatic fibrosis index. Sci Rep 2020;10:5023. [PMID: 32193478 DOI: 10.1038/s41598-020-61750-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
537 Attallah AM, Omran MM, Farid K, El-Bendary M, Emran TM, Albannan MS, El-Dosoky I. Development of a novel score for liver fibrosis staging and comparison with eight simple laboratory scores in large numbers of HCV-monoinfected patients. Clin Chim Acta. 2012;413:1725-1730. [PMID: 22759976 DOI: 10.1016/j.cca.2012.06.031] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
538 Lee HJ, Lee DC, Kim CO. Association Between 10-Year Fracture Probability and Nonalcoholic Fatty Liver Disease With or Without Sarcopenia in Korean Men: A Nationwide Population-Based Cross-Sectional Study. Front Endocrinol (Lausanne) 2021;12:599339. [PMID: 33868162 DOI: 10.3389/fendo.2021.599339] [Reference Citation Analysis]
539 Kim HM, Kim BS, Cho YK, Kim BI, Sohn CI, Jeon WK, Kim HJ, Park DI, Park JH, Joo KJ. Elevated red cell distribution width is associated with advanced fibrosis in NAFLD. Clin Mol Hepatol. 2013;19:258-265. [PMID: 24133663 DOI: 10.3350/cmh.2013.19.3.258] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
540 Kelly ML, Riordan SM, Bopage R, Lloyd AR, Post JJ. Capacity of non-invasive hepatic fibrosis algorithms to replace transient elastography to exclude cirrhosis in people with hepatitis C virus infection: A multi-centre observational study. PLoS One 2018;13:e0192763. [PMID: 29438397 DOI: 10.1371/journal.pone.0192763] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
541 Cross T, Antoniades C, Harrison P. Non-invasive markers for the prediction of fibrosis in chronic hepatitis C infection. Hepatol Res 2008;38:762-9. [PMID: 18462378 DOI: 10.1111/j.1872-034X.2008.00364.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
542 Wang C, Liu C, Lin C, Wang P, Tseng T, Lin HH, Kao J. Fibrosis index based on four factors better predicts advanced fibrosis or cirrhosis than aspartate aminotransferase/platelet ratio index in chronic hepatitis C patients. Journal of the Formosan Medical Association 2015;114:923-8. [DOI: 10.1016/j.jfma.2015.07.004] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
543 Zhang C, Yang M. Current Options and Future Directions for NAFLD and NASH Treatment. Int J Mol Sci 2021;22:7571. [PMID: 34299189 DOI: 10.3390/ijms22147571] [Reference Citation Analysis]
544 Valkov I, Ivanova R, Alexiev A, Antonov K, Mateva L. Association of Serum Lipids with Hepatic Steatosis, Stage of Liver Fibrosis and Viral Load in Chronic Hepatitis C. J Clin Diagn Res 2017;11:OC15-20. [PMID: 28969178 DOI: 10.7860/JCDR/2017/28609.10459] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
545 Kishore R, Loomba R, Sterling RK. Editorial: A New Spin on Magnetic Resonance Elastography. American Journal of Gastroenterology 2016;111:834-7. [DOI: 10.1038/ajg.2016.134] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
546 Abbas SH, Pickett E, Lomas DA, Thorburn D, Gooptu B, Hurst JR, Marshall A. Non-invasive testing for liver pathology in alpha-1 antitrypsin deficiency. BMJ Open Respir Res 2020;7:e000820. [PMID: 33323365 DOI: 10.1136/bmjresp-2020-000820] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
547 Deng H, Qi X, Guo X. Diagnostic Accuracy of APRI, AAR, FIB-4, FI, King, Lok, Forns, and FibroIndex Scores in Predicting the Presence of Esophageal Varices in Liver Cirrhosis: A Systematic Review and Meta-Analysis. Medicine (Baltimore). 2015;94:e1795. [PMID: 26496312 DOI: 10.1097/md.0000000000001795] [Cited by in Crossref: 55] [Cited by in F6Publishing: 28] [Article Influence: 11.0] [Reference Citation Analysis]
548 Li X, Xing Y, Zhou D, Xiao H, Zhou Z, Han Z, Sun X, Li S, Zhang L, Li Z, Zhang P, Zhang J, Zhang N, Cao X, Zao X, Du H, Tong G, Chi X, Gao Y, Ye Y. A Non-invasive Model for Predicting Liver Inflammation in Chronic Hepatitis B Patients With Normal Serum Alanine Aminotransferase Levels. Front Med (Lausanne) 2021;8:688091. [PMID: 34150818 DOI: 10.3389/fmed.2021.688091] [Reference Citation Analysis]
549 Galvin Z, Rajakumar R, Chen E, Adeyi O, Selzner M, Grant D, Sapisochin G, Greig P, Cattral M, McGilvray I, Ghanekar A, Selzner N, Lilly L, Patel K, Bhat M. Predictors of De Novo Nonalcoholic Fatty Liver Disease After Liver Transplantation and Associated Fibrosis. Liver Transpl. 2019;25:56-67. [PMID: 30609189 DOI: 10.1002/lt.25338] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
550 Lin J, Hsieh T, Wu C, Chen P, Chueh T, Chang W, Chu H. Association Between Chronic Hepatitis C Virus Infection and Bone Mineral Density. Calcif Tissue Int 2012;91:423-9. [DOI: 10.1007/s00223-012-9653-y] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
551 Wu SD, Liu LL, Cheng JL, Liu Y, Cheng LS, Wang SQ, Ma W, Chen LP, Tseng YJ, Wang JY, Shen XZ, Jiang W. Longitudinal monitoring of liver fibrosis status by transient elastography in chronic hepatitis B patients during long-term entecavir treatment. Clin Exp Med. 2018;18:433-443. [PMID: 29696462 DOI: 10.1007/s10238-018-0501-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
552 Bavu E, Gennisson JL, Couade M, Bercoff J, Mallet V, Fink M, Badel A, Vallet-Pichard A, Nalpas B, Tanter M, Pol S. Noninvasive in vivo liver fibrosis evaluation using supersonic shear imaging: a clinical study on 113 hepatitis C virus patients. Ultrasound Med Biol. 2011;37:1361-1373. [PMID: 21775051 DOI: 10.1016/j.ultrasmedbio.2011.05.016] [Cited by in Crossref: 305] [Cited by in F6Publishing: 237] [Article Influence: 30.5] [Reference Citation Analysis]
553 Leuştean A, Popescu C, Nichita L, Tilişcan C, Aramă V. Dynamics of APRI and FIB-4 in HCV cirrhotic patients who achieved SVR after DAA therapy. Exp Ther Med 2021;21:99. [PMID: 33363610 DOI: 10.3892/etm.2020.9531] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
554 Kumada T, Toyoda H, Yasuda S, Tada T, Ogawa S, Takeshima K, Tanaka J, Chayama K, Johnson PJ. Impact of the introduction of direct-acting anti-viral drugs on hepatocarcinogenesis: a prospective serial follow-up MRI study. Aliment Pharmacol Ther 2020;52:359-70. [PMID: 32519782 DOI: 10.1111/apt.15825] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
555 Han E, Lee YH, Kim BK, Park JY, Kim DY, Ahn SH, Lee BW, Kang ES, Cha BS, Han KH, Kim SU. Sarcopenia is associated with the risk of significant liver fibrosis in metabolically unhealthy subjects with chronic hepatitis B. Aliment Pharmacol Ther 2018;48:300-12. [PMID: 29920701 DOI: 10.1111/apt.14843] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 7.3] [Reference Citation Analysis]
556 Zarski JP, Sturm N, Guechot J, Paris A, Zafrani ES, Asselah T, Boisson RC, Bosson JL, Guyader D, Renversez JC, Bronowicki JP, Gelineau MC, Tran A, Trocme C, De Ledinghen V, Lasnier E, Poujol-Robert A, Ziegler F, Bourliere M, Voitot H, Larrey D, Rosenthal-Allieri MA, Fouchard Hubert I, Bailly F, Vaubourdolle M;  ANRS HCEP 23 Fibrostar Group. Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: the ANRS HCEP-23 study. J Hepatol. 2012;56:55-62. [PMID: 21781944 DOI: 10.1016/j.jhep.2011.05.024] [Cited by in Crossref: 142] [Cited by in F6Publishing: 126] [Article Influence: 14.2] [Reference Citation Analysis]
557 Tani J, Morishita A, Sakamoto T, Takuma K, Nakahara M, Fujita K, Oura K, Tadokoro T, Mimura S, Nomura T, Yoneyama H, Kobara H, Himoto T, Tsutsui A, Senoh T, Nagano T, Ogawa C, Moriya A, Deguchi A, Takaguchi K, Masaki T. Simple scoring system for prediction of hepatocellular carcinoma occurrence after hepatitis C virus eradication by direct-acting antiviral treatment: All Kagawa Liver Disease Group Study. Oncol Lett. 2020;19:2205-2212. [PMID: 32194718 DOI: 10.3892/ol.2020.11341] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
558 Toyoda H, Tada T, Yasuda S, Mizuno K, Sone Y, Kaneoka Y, Maeda A, Akita T, Tanaka J, Kumada T. The emergence of non-hypervascular hypointense nodules on Gd-EOB-DTPA-enhanced MRI in patients with chronic hepatitis C. Aliment Pharmacol Ther 2019;50:1232-8. [PMID: 31588590 DOI: 10.1111/apt.15490] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
559 Yan LT, Wang LL, Yao J, Yang YT, Mao XR, Yue W, Mao YW, Zhou W, Chen QF, Chen Y, Duan ZP, Li JF. Total bile acid-to-cholesterol ratio as a novel noninvasive marker for significant liver fibrosis and cirrhosis in patients with non-cholestatic chronic hepatitis B virus infection. Medicine (Baltimore) 2020;99:e19248. [PMID: 32080129 DOI: 10.1097/MD.0000000000019248] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
560 Patel K, Benhamou Y, Yoshida EM, Kaita KD, Zeuzem S, Torbenson M, Pulkstenis E, Subramanian GM, Mchutchison JG. An independent and prospective comparison of two commercial fibrosis marker panels (HCV FibroSURE and FIBRO Spect II) during albinterferon alfa-2b combination therapy for chronic hepatitis C. Journal of Viral Hepatitis 2009;16:178-86. [DOI: 10.1111/j.1365-2893.2008.01062.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 2.2] [Reference Citation Analysis]
561 Deng Y, Zhao H, Zhou J, Yan L, Wang G; China HepB-Related Fibrosis Assessment Research Group. Complement 5a is an indicator of significant fibrosis and earlier cirrhosis in patients chronically infected with hepatitis B virus. Infection. 2017;45:75-81. [PMID: 27605044 DOI: 10.1007/s15010-016-0942-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
562 Lee HH, Cho Y, Choi YJ, Huh BW, Lee BW, Kang ES, Park SW, Cha BS, Lee EJ, Lee YH, Huh KB. Non-alcoholic steatohepatitis and progression of carotid atherosclerosis in patients with type 2 diabetes: a Korean cohort study. Cardiovasc Diabetol 2020;19:81. [PMID: 32534588 DOI: 10.1186/s12933-020-01064-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
563 Kim YW, Kwon JH, Jang JW, Kim MJ, Oh BS, Chung KW, Park ES, Nam SW. Diagnostic usefulness of real-time elastography for liver fibrosis in chronic viral hepatitis B and C. Gastroenterol Res Pract 2014;2014:210407. [PMID: 25180031 DOI: 10.1155/2014/210407] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
564 Backus LI, Belperio PS, Shahoumian TA, Loomis TP, Mole LA. Effectiveness of sofosbuvir-based regimens in genotype 1 and 2 hepatitis C virus infection in 4026 U.S. Veterans. Aliment Pharmacol Ther. 2015;42:559-573. [PMID: 26113432 DOI: 10.1111/apt.13300] [Cited by in Crossref: 75] [Cited by in F6Publishing: 71] [Article Influence: 12.5] [Reference Citation Analysis]
565 Sun W, Cui H, Li N, Wei Y, Lai S, Yang Y, Yin X, Chen DF. Comparison of FIB-4 index, NAFLD fibrosis score and BARD score for prediction of advanced fibrosis in adult patients with non-alcoholic fatty liver disease: A meta-analysis study. Hepatol Res. 2016;46:862-870. [PMID: 26763834 DOI: 10.1111/hepr.12647] [Cited by in Crossref: 68] [Cited by in F6Publishing: 62] [Article Influence: 13.6] [Reference Citation Analysis]
566 Li DK, Ren Y, Fierer DS, Rutledge S, Shaikh OS, Lo Re V, Simon T, Abou-samra A, Chung RT, Butt AA. The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals: An ERCHIVES study. Hepatology 2018;67:2244-53. [DOI: 10.1002/hep.29707] [Cited by in Crossref: 83] [Cited by in F6Publishing: 91] [Article Influence: 27.7] [Reference Citation Analysis]
567 Kong Y, Sun Y, Zhou J, Wu X, Chen Y, Piao H, Lu L, Ding H, Nan Y, Jiang W, Xu Y, Xie W, Li H, Feng B, Shi G, Chen G, Li H, Zheng H, Cheng J, Wang T, Liu H, Lv F, Shao C, Mao Y, Sun J, Chen T, Han T, Han Y, Wang L, Ou X, Zhang H, Jia J, You H. Early steep decline of liver stiffness predicts histological reversal of fibrosis in chronic hepatitis B patients treated with entecavir. J Viral Hepat. 2019;26:576-585. [PMID: 30624000 DOI: 10.1111/jvh.13058] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
568 Sung MJ, Lim TS, Jeon MY, Lee HW, Kim BK, Kim DY, Ahn SH, Han KH, Park JY, Kim SU. Sarcopenia Is Independently Associated with the Degree of Liver Fibrosis in Patients with Type 2 Diabetes Mellitus. Gut Liver 2020;14:626-35. [PMID: 32135582 DOI: 10.5009/gnl19126] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
569 Chen S, Zhou J, Wu X, Meng T, Wang B, Liu H, Wang T, Zhao X, Kong Y, Wu S, Ou X, Jia J, Sun Y, You H. Comparison of fibrosis regression of entecavir alone or combined with pegylated interferon alpha2a in patients with chronic hepatitis B. Hepatol Int 2021;15:611-20. [PMID: 33677771 DOI: 10.1007/s12072-021-10162-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
570 Besa C, Wagner M, Lo G, Gordic S, Chatterji M, Kennedy P, Stueck A, Thung S, Babb J, Smith A, Taouli B. Detection of liver fibrosis using qualitative and quantitative MR elastography compared to liver surface nodularity measurement, gadoxetic acid uptake, and serum markers. J Magn Reson Imaging 2018;47:1552-61. [PMID: 29193508 DOI: 10.1002/jmri.25911] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 5.5] [Reference Citation Analysis]
571 Kwak MS, Kim KW, Seo H, Chung GE, Yim JY, Kim D. Non-obese fatty liver disease is associated with lacunar infarct. Liver Int. 2018;38:1292-1299. [PMID: 29220869 DOI: 10.1111/liv.13663] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
572 Anand V, Hyun C, Khan QM, Hall C, Hessefort N, Sonnenberg A, Fimmel CJ. Identification and Fibrosis Staging of Hepatitis C Patients Using the Electronic Medical Record System. J Clin Gastroenterol 2016;50:664-9. [PMID: 26974763 DOI: 10.1097/MCG.0000000000000519] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
573 Kim M, Lee Y, Yoon JS, Lee M, Kye SS, Kim SW, Cho Y. The FIB-4 Index Is a Useful Predictor for the Development of Hepatocellular Carcinoma in Patients with Coexisting Nonalcoholic Fatty Liver Disease and Chronic Hepatitis B. Cancers (Basel) 2021;13:2301. [PMID: 34064988 DOI: 10.3390/cancers13102301] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
574 Tada T, Toyoda H, Yasuda S, Miyake N, Kumada T, Kurisu A, Ohisa M, Akita T, Tanaka J. Natural history of liver-related disease in patients with chronic hepatitis C virus infection: An analysis using a Markov chain model. J Med Virol 2019;91:1837-44. [PMID: 31254403 DOI: 10.1002/jmv.25533] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
575 Wang H, Xu H, Wang X, Wu R, Gao X, Jin Q, Niu J. Red Blood Cell Distribution Width to Platelet Ratio is Related to Histologic Severity of Primary Biliary Cirrhosis. Medicine (Baltimore) 2016;95:e3114. [PMID: 26986159 DOI: 10.1097/MD.0000000000003114] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
576 Ishigami M, Hayashi K, Honda T, Kuzuya T, Ishizu Y, Ishikawa T, Nakano I, Urano F, Kumada T, Yoshioka K. Daclatasvir and asunaprevir treatment in patients infected by genotype 1b of hepatitis C virus with no or subtle resistant associated substitutions (RAS) in NS5A-Y93. J Med Virol. 2018;90:736-744. [PMID: 29111616 DOI: 10.1002/jmv.24978] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
577 Sebastiani G, Rollet-Kurhajec KC, Pexos C, Gilmore N, Klein MB. Incidence and predictors of hepatic steatosis and fibrosis by serum biomarkers in a large cohort of human immunodeficiency virus mono-infected patients. Open Forum Infect Dis 2015;2:ofv015. [PMID: 26034765 DOI: 10.1093/ofid/ofv015] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
578 Stibbe KJ, Verveer C, Francke J, Hansen BE, Zondervan PE, Kuipers EJ, de Knegt RJ, van Vuuren AJ. Comparison of non-invasive assessment to diagnose liver fibrosis in chronic hepatitis B and C patients. Scand J Gastroenterol. 2011;46:962-972. [PMID: 21623677 DOI: 10.3109/00365521.2011.574725] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 3.9] [Reference Citation Analysis]
579 Abdelsameea E, Alsebaey A, Abdel-Samiee M, Abdel-Razek W, Salama M, Waked I. Direct acting antivirals are associated with more liver stiffness regression than pegylated interferon therapy in chronic hepatitis C patients. Expert Rev Anti Infect Ther 2021;19:1053-9. [PMID: 33307880 DOI: 10.1080/14787210.2021.1864326] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
580 Nishikawa H, Yoh K, Enomoto H, Ishii N, Iwata Y, Takata R, Nishimura T, Aizawa N, Sakai Y, Ikeda N, Hasegawa K, Takashima T, Iijima H, Nishiguchi S. The Relationship between Controlling Nutritional (CONUT) Score and Clinical Markers among Adults with Hepatitis C Virus Related Liver Cirrhosis. Nutrients 2018;10:E1185. [PMID: 30158477 DOI: 10.3390/nu10091185] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
581 Hanafy AS, Seleem WM, El-Kalla F, AbdAlkhalik Basha M, Abd-Elsalam S. Efficacy of a non-invasive model in predicting the cardiovascular morbidity and histological severity in non-alcoholic fatty liver disease. Diabetes Metab Syndr. 2019;13:2272-2278. [PMID: 31235168 DOI: 10.1016/j.dsx.2019.05.032] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
582 Ewid M, Sherif H, Allihimy AS, Alharbi SA, Aldrewesh DA, Alkuraydis SA, Abazid R. AST/ALT ratio predicts the functional severity of chronic heart failure with reduced left ventricular ejection fraction. BMC Res Notes 2020;13:178. [PMID: 32209113 DOI: 10.1186/s13104-020-05031-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 10.0] [Reference Citation Analysis]
583 Su F, Green PK, Berry K, Ioannou GN. The association between race/ethnicity and the effectiveness of direct antiviral agents for hepatitis C virus infection. Hepatology. 2017;65:426-438. [PMID: 27775854 DOI: 10.1002/hep.28901] [Cited by in Crossref: 51] [Cited by in F6Publishing: 48] [Article Influence: 10.2] [Reference Citation Analysis]
584 Chen HW, Chiu YL, Hsieh TY, Chen PJ, Huang TY, Lin HH, Shih YL, Lin JC. Relationships Between Vitamin D Status and Cytokine: Results from Interferon-Based Therapy in Non-Cirrhotic, Treatment-Naïve Patients with Chronic Hepatitis C Infection. J Inflamm Res 2020;13:1207-18. [PMID: 33402842 DOI: 10.2147/JIR.S283768] [Reference Citation Analysis]
585 Tahata Y, Sakamori R, Yamada R, Kodama T, Hikita H, Hagiwara H, Imai Y, Hiramatsu N, Tamura S, Yamamoto K, Oshita M, Ohkawa K, Hijioka T, Fukui H, Ito T, Doi Y, Yamada Y, Yakushijin T, Yoshida Y, Tatsumi T, Takehara T; Osaka Liver Forum. Prediction model for hepatocellular carcinoma occurrence in patients with hepatitis C in the era of direct-acting anti-virals. Aliment Pharmacol Ther 2021;54:1340-9. [PMID: 34618934 DOI: 10.1111/apt.16632] [Reference Citation Analysis]
586 Wang SF, Huang YT, Huang CH, Chang SH, Lin CY. Fibrosis index predicts variceal bleeding and reduces need for nonselective beta-blocker in compensated cirrhosis with initial small esophageal varices without red-color sign. Ann Transl Med 2020;8:1223. [PMID: 33178755 DOI: 10.21037/atm-20-2444] [Reference Citation Analysis]
587 Tamaki N, Kurosaki M, Matsuda S, Muraoka M, Yasui Y, Suzuki S, Hosokawa T, Ueda K, Tsuchiya K, Nakanishi H, Itakura J, Takahashi Y, Asahina Y, Izumi N. Non-invasive prediction of hepatocellular carcinoma development using serum fibrosis marker in chronic hepatitis C patients. J Gastroenterol. 2014;49:1495-1503. [PMID: 24337828 DOI: 10.1007/s00535-013-0914-y] [Cited by in Crossref: 32] [Cited by in F6Publishing: 38] [Article Influence: 4.0] [Reference Citation Analysis]
588 Scognamiglio P, Piselli P, Fusco M, Pisanti FA, Serraino D, Ippolito G, Girardi E; Collaborating Study Group. Declining unawareness of HCV-infection parallel to declining prevalence in Southern Italy. J Med Virol. 2017;89:1691-1692. [PMID: 28464363 DOI: 10.1002/jmv.24840] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
589 Zhong W, Zhang F, Huang K, Zou Y, Liu Y. Development and Validation of a Nomogram Based on Noninvasive Liver Reserve and Fibrosis (PALBI and FIB-4) Model to Predict Posthepatectomy Liver Failure Grade B-C in Patients with Hepatocellular Carcinoma. J Oncol 2021;2021:6665267. [PMID: 34221013 DOI: 10.1155/2021/6665267] [Reference Citation Analysis]
590 Jun T, Hsu YC, Ogawa S, Huang YT, Yeh ML, Tseng CH, Huang CF, Tai CM, Dai CY, Huang JF, Chuang WL, Yu ML, Tanaka Y, Nguyen MH. Mac-2 Binding Protein Glycosylation Isomer as a Hepatocellular Carcinoma Marker in Patients With Chronic Hepatitis B or C Infection. Hepatol Commun. 2019;3:493-503. [PMID: 30976740 DOI: 10.1002/hep4.1321] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
591 Chidi AP, Rogal S, Bryce CL, Fine MJ, Good CB, Myaskovsky L, Rustgi VK, Tsung A, Smith KJ. Cost-effectiveness of new antiviral regimens for treatment-naïve U.S. veterans with hepatitis C. Hepatology 2016;63:428-36. [PMID: 26524695 DOI: 10.1002/hep.28327] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 4.2] [Reference Citation Analysis]
592 Chen YP, Hu XM, Liang XE, Huang LW, Zhu YF, Hou JL. Stepwise application of fibrosis index based on four factors, red cell distribution width-platelet ratio, and aspartate aminotransferase-platelet ratio for compensated hepatitis B fibrosis detection. J Gastroenterol Hepatol. 2018;33:256-263. [PMID: 28452125 DOI: 10.1111/jgh.13811] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
593 Martin J, Khatri G, Gopal P, Singal AG. Accuracy of ultrasound and noninvasive markers of fibrosis to identify patients with cirrhosis. Dig Dis Sci. 2015;60:1841-1847. [PMID: 25586089 DOI: 10.1007/s10620-015-3531-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
594 Zhu YF, Tan YF, Xu X, Zheng JL, Zhang BH, Tang HR, Yang JY. Gamma-glutamyl transpeptidase-to-platelet ratio and the fibrosis-4 index in predicting hepatitis B virus-related hepatocellular carcinoma development in elderly chronic hepatitis B patients in China: A single-center retrospective study. Medicine (Baltimore) 2019;98:e18319. [PMID: 31852119 DOI: 10.1097/MD.0000000000018319] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
595 Said M, Soliman Z, Daebes H, M El-Nahaas S, El-Serafy M. Real life application of FIB-4 & APRI during mass treatment of HCV genotype 4 with directly acting anti-viral agents in Egyptian patients, an observational study. Expert Rev Gastroenterol Hepatol 2019;13:1189-95. [PMID: 31702417 DOI: 10.1080/17474124.2019.1690990] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
596 Mohanty A, Tate JP, Garcia-Tsao G. Statins Are Associated With a Decreased Risk of Decompensation and Death in Veterans With Hepatitis C-Related Compensated Cirrhosis. Gastroenterology. 2016;150:430-40.e1. [PMID: 26484707 DOI: 10.1053/j.gastro.2015.10.007] [Cited by in Crossref: 100] [Cited by in F6Publishing: 86] [Article Influence: 16.7] [Reference Citation Analysis]
597 Ahmad W, Ijaz B, Javed FT, Gull S, Kausar H, Sarwar MT, Asad S, Shahid I, Sumrin A, Khaliq S. A comparison of four fibrosis indexes in chronic HCV: development of new fibrosis-cirrhosis index (FCI). BMC Gastroenterol. 2011;11:44. [PMID: 21507271 DOI: 10.1186/1471-230x-11-44] [Cited by in Crossref: 51] [Cited by in F6Publishing: 22] [Article Influence: 5.1] [Reference Citation Analysis]
598 Egresi A, Lengyel G, Hagymási K. Options of non-invasive assessment of liver fibrosis based on the clinical data. Orvosi Hetilap 2015;156:43-52. [DOI: 10.1556/oh.2015.30069] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
599 Park HJ, Park JY, Jung SM, Song JJ, Park YB, Lee SW. Fibrosis-4 index at diagnosis is associated with all-cause mortality in patients with microscopic polyangiitis and granulomatosis with polyangiitis. BMC Gastroenterol 2019;19:90. [PMID: 31196158 DOI: 10.1186/s12876-019-1007-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
600 Manchanda M, Das P, Gahlot GPS, Singh R, Roeb E, Roderfeld M, Datta Gupta S, Saraya A, Pandey RM, Chauhan SS. Cathepsin L and B as Potential Markers for Liver Fibrosis: Insights From Patients and Experimental Models. Clin Transl Gastroenterol 2017;8:e99. [PMID: 28617446 DOI: 10.1038/ctg.2017.25] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
601 Sebastiani G. Non-invasive assessment of liver fibrosis in chronic liver diseases: Implementation in clinical practice and decisional algorithms. World J Gastroenterol 2009; 15(18): 2190-2203 [PMID: 19437558 DOI: 10.3748/wjg.15.2190] [Cited by in CrossRef: 50] [Cited by in F6Publishing: 50] [Article Influence: 4.2] [Reference Citation Analysis]
602 Ioannou GN, Green P, Kerr KF, Berry K. Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification. J Hepatol 2019;71:523-33. [PMID: 31145929 DOI: 10.1016/j.jhep.2019.05.008] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 17.5] [Reference Citation Analysis]
603 Patel K, Zickmund SL, Jones H, Reid A, Calgaro L, Otero A, Coppler T, Rogal SS. Determinants of Hepatitis C Treatment Adherence and Treatment Completion Among Veterans in the Direct Acting Antiviral Era. Dig Dis Sci 2019;64:3001-12. [PMID: 30903364 DOI: 10.1007/s10620-019-05590-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
604 Assoumou SA, Wang J, Tasillo A, Eftekhari Yazdi G, Tsui JI, Strick L, Linas BP. Hepatitis C Testing and Patient Characteristics in Washington State's Prisons Between 2012 and 2016. Am J Prev Med 2019;56:8-16. [PMID: 30467088 DOI: 10.1016/j.amepre.2018.08.016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
605 Tsochatzis EA, Castera L. Assessing liver disease in HIV–HCV coinfected patients: . Current Opinion in HIV and AIDS 2015;10:316-22. [DOI: 10.1097/coh.0000000000000176] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
606 Gonzalez HC, Jafri SM, Gordon SC. Role of Liver Biopsy in the Era of Direct-Acting Antivirals. Curr Gastroenterol Rep 2013;15. [DOI: 10.1007/s11894-012-0307-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
607 Uchida Y, Naiki K, Kouyama JI, Sugawara K, Nakao M, Motoya D, Inao M, Nakayama N, Imai Y, Tomiya T, Mochida S. Serum asunaprevir concentrations showing correlation with the extent of liver fibrosis as a factor inducing liver injuries in patients with genotype-1b hepatitis C virus receiving daclatasvir plus asunaprevir therapy. PLoS One 2018;13:e0205600. [PMID: 30308053 DOI: 10.1371/journal.pone.0205600] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
608 Toyoda H, Kumada T, Tada T, Shimada N, Takaguchi K, Senoh T, Tsuji K, Tachi Y, Hiraoka A, Ishikawa T, Shima T, Okanoue T. Efficacy and tolerability of an IFN-free regimen with DCV/ASV for elderly patients infected with HCV genotype 1B. Journal of Hepatology 2017;66:521-7. [DOI: 10.1016/j.jhep.2016.11.012] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 8.0] [Reference Citation Analysis]
609 Huang C, Liu L, Wang H, Fang M, Feng H, Li Y, Wang M, Tong L, Xiao X, Wang Z, Xu X, He Y, Gao C. Serum N-glycan fingerprint nomogram predicts liver fibrosis: a multicenter study. Clin Chem Lab Med 2021;59:1087-97. [PMID: 33554541 DOI: 10.1515/cclm-2020-1588] [Reference Citation Analysis]
610 Vidovic N, Lochowsky RS, Goldmann G, Rockstroh J, Wasmuth JC, Spengler U, Sauerbruch T, Lammert F, Oldenburg J, Grünhage F. Correlation of transient elastography with APRI and FIB-4 in a cohort of patients with congenital bleeding disorders and HCV or HIV/HCV coinfection: NON-INVASIVE MARKERS IN HCV-POSITIVE HAEMOPHILIC PATIENTS. Haemophilia 2010;16:778-85. [DOI: 10.1111/j.1365-2516.2010.02204.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
611 Brozzetti S, Tancredi M, Bini S, De Lucia C, Antimi J, D'Alterio C, De Sanctis GM, Furlan C, Malpassuti VC, Lucatelli P, Di Martino M, Bezzi M, Ciardi A, Pascale RM. HCC in the Era of Direct-Acting Antiviral Agents (DAAs): Surgical and Other Curative or Palliative Strategies in the Elderly. Cancers (Basel) 2021;13:3025. [PMID: 34204186 DOI: 10.3390/cancers13123025] [Reference Citation Analysis]
612 Hilscher MB, Johnson JN, Cetta F, Driscoll DJ, Poterucha JJ, Sanchez W, Connolly HM, Kamath PS. Surveillance for liver complications after the Fontan procedure: HILSCHER et al. Congenital Heart Disease 2017;12:124-32. [DOI: 10.1111/chd.12446] [Cited by in Crossref: 41] [Cited by in F6Publishing: 28] [Article Influence: 10.3] [Reference Citation Analysis]
613 Motola DL, Caravan P, Chung RT, Fuchs BC. Noninvasive Biomarkers of Liver Fibrosis: Clinical Applications and Future Directions. Curr Pathobiol Rep 2014;2:245-56. [PMID: 25396099 DOI: 10.1007/s40139-014-0061-z] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
614 Koizumi Y, Hirooka M, Abe M, Tokumoto Y, Yoshida O, Watanabe T, Nakamura Y, Imai Y, Yukimoto A, Kumagi T, Takeshita E, Ikeda Y, Hiasa Y. Comparison between real-time tissue elastography and vibration-controlled transient elastography for the assessment of liver fibrosis and disease progression in patients with primary biliary cholangitis. Hepatol Res. 2017;47:1252-1259. [PMID: 28044427 DOI: 10.1111/hepr.12861] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
615 Wang J, Xia J, Zhang R, Yan X, Yang Y, Zhao X, Chang H, Wang G, Chen G, Liu Y, Chen Y, Jia B, Zhang Z, Ding W, Huang R, Wu C. A novel index using routine clinical parameters for predicting significant liver inflammation in chronic hepatitis B. J Viral Hepat 2018;25:1151-60. [PMID: 29741221 DOI: 10.1111/jvh.12925] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
616 Beste LA, Green PK, Berry K, Kogut MJ, Allison SK, Ioannou GN. Effectiveness of hepatitis C antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma. J Hepatol 2017;67:32-9. [PMID: 28267622 DOI: 10.1016/j.jhep.2017.02.027] [Cited by in Crossref: 91] [Cited by in F6Publishing: 81] [Article Influence: 22.8] [Reference Citation Analysis]
617 Fuster D, Sanvisens A, Bolao F, Rivas I, Tor J, Muga R. Alcohol use disorder and its impact on chronic hepatitis C virus and human immunodeficiency virus infections. World J Hepatol 2016; 8(31): 1295-1308 [PMID: 27872681 DOI: 10.4254/wjh.v8.i31.1295] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 5.4] [Reference Citation Analysis]
618 Arai T, Atsukawa M, Tsubota A, Mikami S, Ono H, Kawano T, Yoshida Y, Tanabe T, Okubo T, Hayama K, Nakagawa-Iwashita A, Itokawa N, Kondo C, Kaneko K, Emoto N, Nagao M, Inagaki K, Fukuda I, Sugihara H, Iwakiri K. Effect of sodium-glucose cotransporter 2 inhibitor in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus: a propensity score-matched analysis of real-world data. Ther Adv Endocrinol Metab 2021;12:20420188211000243. [PMID: 33815743 DOI: 10.1177/20420188211000243] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
619 Tsui JI, Williams EC, Green PK, Berry K, Su F, Ioannou GN. Alcohol use and hepatitis C virus treatment outcomes among patients receiving direct antiviral agents. Drug Alcohol Depend 2016;169:101-9. [PMID: 27810652 DOI: 10.1016/j.drugalcdep.2016.10.021] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 6.8] [Reference Citation Analysis]
620 French AL, Grennan D, Daubert E, Seaberg EC, Peters M, Augenbraun M, Fischl M, Kassaye S, Franco R, Kuniholm M, Adimora AA, Workowski K, Weber KM. Decreases in markers of monocyte/macrophage activation after hepatitis C eradication in HIV/hepatitis C virus coinfected women. AIDS 2021;35:1433-8. [PMID: 33710024 DOI: 10.1097/QAD.0000000000002869] [Reference Citation Analysis]
621 Xie K, Chen CH, Tsai SP, Lu PJ, Wu H, Zeng Y, Ye Y, Tu H, Wen C, Huang M, Zhang Y, Lee JH, Tsai MK, Wen CP, Wu X. Loss of Life Expectancy by 10 Years or More From Elevated Aspartate Aminotransferase: Finding Aspartate Aminotransferase a Better Mortality Predictor for All-Cause and Liver-Related than Alanine Aminotransferase. Am J Gastroenterol. 2019;114:1478-1487. [PMID: 31425154 DOI: 10.14309/ajg.0000000000000332] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
622 Grammatikos G, Ferreiros N, Bon D, Schwalm S, Dietz J, Berkowski C, Fitting D, Herrmann E, Zeuzem S, Sarrazin C, Pfeilschifter J. Variations in serum sphingolipid levels associate with liver fibrosis progression and poor treatment outcome in hepatitis C virus but not hepatitis B virus infection. Hepatology 2015;61:812-22. [PMID: 25348752 DOI: 10.1002/hep.27587] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 4.7] [Reference Citation Analysis]
623 Himoto T, Miyatake K, Maeba T, Masaki T. Verification of the Nutritional and Dietary Factors Associated with Skeletal Muscle Index in Japanese Patients with Nonalcoholic Fatty Liver Disease. Can J Gastroenterol Hepatol 2020;2020:3576974. [PMID: 32695733 DOI: 10.1155/2020/3576974] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
624 Muga R, Sanvisens A, Fuster D, Tor J, Martínez E, Pérez-Hoyos S, Muñoz A. Unhealthy alcohol use, HIV infection and risk of liver fibrosis in drug users with hepatitis C. PLoS One 2012;7:e46810. [PMID: 23056462 DOI: 10.1371/journal.pone.0046810] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
625 Backus LI, Belperio PS, Shahoumian TA, Loomis TP, Mole LA. Real-world effectiveness of ledipasvir/sofosbuvir in 4,365 treatment-naive, genotype 1 hepatitis C-infected patients. Hepatology 2016;64:405-14. [PMID: 27115523 DOI: 10.1002/hep.28625] [Cited by in Crossref: 148] [Cited by in F6Publishing: 140] [Article Influence: 29.6] [Reference Citation Analysis]
626 Gallo S, Calle RA, Terra SG, Pong A, Tarasenko L, Raji A. Effects of Ertugliflozin on Liver Enzymes in Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis of Phase 3 Trials. Diabetes Ther 2020;11:1849-60. [PMID: 32648108 DOI: 10.1007/s13300-020-00867-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
627 Suárez-Zarracina T, Valle-Garay E, Collazos J, Montes AH, Cárcaba V, Carton JA, Asensi V. Didanosine (ddI) associates with increased liver fibrosis in adult HIV-HCV coinfected patients. J Viral Hepat 2012;19:685-93. [PMID: 22967099 DOI: 10.1111/j.1365-2893.2012.01596.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
628 Atsukawa M, Tsubota A, Kondo C, Uchida-Kobayashi S, Takaguchi K, Tsutsui A, Nozaki A, Chuma M, Hidaka I, Ishikawa T, Iwasa M, Tamai Y, Tobari M, Matsuura K, Nagura Y, Abe H, Kato K, Suzuki K, Okubo T, Arai T, Itokawa N, Toyoda H, Enomoto M, Tamori A, Tanaka Y, Kawada N, Takei Y, Iwakiri K. A novel noninvasive formula for predicting cirrhosis in patients with chronic hepatitis C. PLoS One 2021;16:e0257166. [PMID: 34506563 DOI: 10.1371/journal.pone.0257166] [Reference Citation Analysis]
629 Ruan D, Shi Y, Jin L, Yang Q, Yu W, Ren H, Zheng W, Chen Y, Zheng N, Zheng M. An ultrasound image-based deep multi-scale texture network for liver fibrosis grading in patients with chronic HBV infection. Liver Int 2021. [PMID: 34219353 DOI: 10.1111/liv.14999] [Reference Citation Analysis]
630 Ozel BD, Poyrazoğlu OK, Karaman A, Karaman H, Altinkaya E, Sevinç E, Zararsiz G. The PAPAS index: a novel index for the prediction of hepatitis C-related fibrosis. Eur J Gastroenterol Hepatol 2015;27:895-900. [PMID: 25951491 DOI: 10.1097/MEG.0000000000000379] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
631 Akahane T, Kurosaki M, Itakura J, Tsuji K, Joko K, Kimura H, Nasu A, Ogawa C, Kojima Y, Hasebe C, Wada S, Uchida Y, Sohda T, Suzuki H, Yoshida H, Kusakabe A, Tamada T, Kobashi H, Mitsuda A, Kondo M, Shigeno M, Ide Y, Morita A, Kitamura T, Abe T, Izumi N. Real-world efficacy and safety of sofosbuvir + ribavirin for hepatitis C genotype 2: A nationwide multicenter study by the Japanese Red Cross Liver Study Group. Hepatol Res. 2019;49:264-270. [PMID: 30171740 DOI: 10.1111/hepr.13246] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
632 Takahashi A, Moriya K, Ohira H, Arinaga-Hino T, Zeniya M, Torimura T, Abe M, Takaki A, Kang JH, Inui A, Fujisawa T, Yoshizawa K, Suzuki Y, Nakamoto N, Koike K, Yoshiji H, Goto A, Tanaka A, Younossi ZM, Takikawa H; Japan AIH Study Group. Health-related quality of life in patients with autoimmune hepatitis: A questionnaire survey. PLoS One 2018;13:e0204772. [PMID: 30286131 DOI: 10.1371/journal.pone.0204772] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
633 Sun YM, Chen SY, You H. Regression of liver fibrosis: evidence and challenges. Chin Med J (Engl) 2020;133:1696-702. [PMID: 32568866 DOI: 10.1097/CM9.0000000000000835] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
634 Wu WC, Chiou YY, Hung HH, Kao WY, Chou YH, Su CW, Wu JC, Huo TI, Huang YH, Lee KC. Prognostic significance of computed tomography scan-derived splenic volume in hepatocellular carcinoma treated with radiofrequency ablation. J Clin Gastroenterol. 2012;46:789-795. [PMID: 22941428 DOI: 10.1097/mcg.0b013e31825ceeb5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
635 Perumalswami PV, Patel N, Bichoupan K, Ku L, Yalamanchili R, Harty A, Motamed D, Khaitova V, Chang C, Grewal P, Liu L, Schiano TD, Woodward M, Dieterich DT, Branch AD. High baseline bilirubin and low albumin predict liver decompensation and serious adverse events in HCV-infected patients treated with sofosbuvir-containing regimens. J Viral Hepat 2016;23:667-76. [PMID: 26989855 DOI: 10.1111/jvh.12530] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
636 Dowman JK, Tomlinson JW, Newsome PN. Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2011;33:525-540. [PMID: 21198708 DOI: 10.1111/j.1365-2036.2010.04556.x] [Cited by in Crossref: 195] [Cited by in F6Publishing: 178] [Article Influence: 17.7] [Reference Citation Analysis]
637 Calès P, de Ledinghen V, Halfon P, Bacq Y, Leroy V, Boursier J, Foucher J, Bourlière M, de Muret A, Sturm N. Evaluating the accuracy and increasing the reliable diagnosis rate of blood tests for liver fibrosis in chronic hepatitis C. Liver Int. 2008;28:1352-1362. [PMID: 18492022 DOI: 10.1111/j.1478-3231.2008.01789.x] [Cited by in Crossref: 81] [Cited by in F6Publishing: 75] [Article Influence: 6.2] [Reference Citation Analysis]
638 Iroezindu MO, Agbaji OO, Daniyam CA, Isiguzo GC, Isichei C, Akanbi MO. Liver function test abnormalities in Nigerian patients with human immunodeficiency virus and hepatitis B virus co-infection. Int J STD AIDS 2013;24:461-7. [PMID: 23970749 DOI: 10.1177/0956462412473889] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
639 Ogawa E, Furusyo N, Nomura H, Dohmen K, Higashi N, Takahashi K, Kawano A, Azuma K, Satoh T, Nakamuta M, Koyanagi T, Kato M, Shimoda S, Kajiwara E, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group. NS5A resistance-associated variants undermine the effectiveness of ledipasvir and sofosbuvir for cirrhotic patients infected with HCV genotype 1b. J Gastroenterol. 2017;52:845-854. [PMID: 27913920 DOI: 10.1007/s00535-016-1290-1] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 7.4] [Reference Citation Analysis]
640 Lefton HB, Rosa A, Cohen M. Diagnosis and Epidemiology of Cirrhosis. Medical Clinics of North America 2009;93:787-99. [DOI: 10.1016/j.mcna.2009.03.002] [Cited by in Crossref: 59] [Cited by in F6Publishing: 52] [Article Influence: 4.9] [Reference Citation Analysis]
641 Güzelbulut F, Sezikli M, Cetinkaya ZA, Ozkara S, Gönen C, Ovünç AO. A lower serum gamma-glutamyltransferase level does not predict a sustained virological response in patients with chronic hepatitis C genotype 1. Gut Liver. 2013;7:74-81. [PMID: 23423958 DOI: 10.5009/gnl.2013.7.1.74] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
642 Ito T, Kumada T, Toyoda H, Tada T. FIB-4 index for assessing the prognosis of hepatocellular carcinoma in patients with Child-Pugh class A liver function. J Cancer Res Clin Oncol. 2015;141:1311-1319. [PMID: 25648362 DOI: 10.1007/s00432-015-1922-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
643 Moon AM, Green PK, Berry K, Ioannou GN. Transformation of hepatitis C antiviral treatment in a national healthcare system following the introduction of direct antiviral agents. Aliment Pharmacol Ther 2017;45:1201-12. [PMID: 28271521 DOI: 10.1111/apt.14021] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 10.0] [Reference Citation Analysis]
644 Aita JS, Harrison SA. Liver biopsy versus noninvasive testing in chronic hepatitis C: Where do we stand in 2008? Curr hepatitis rep 2008;7:51-9. [DOI: 10.1007/s11901-008-0008-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
645 Jin YJ, Shim JH, Kim GA, Yu E, Kim KM, Lim YS, Lee HC. Clinicobiochemical prediction of biopsy-proven cases of severe hepatic fibrosis in patients with chronic hepatitis C infection. BMJ Open 2014;4:e006255. [PMID: 25431223 DOI: 10.1136/bmjopen-2014-006255] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
646 Liu L, Cao J, Zhong Z, Guo Z, Jiang Y, Bai Y, Xu J. Noninvasive indicators predict advanced liver fibrosis in autoimmune hepatitis patients. J Clin Lab Anal 2019;33:e22922. [PMID: 31115929 DOI: 10.1002/jcla.22922] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
647 Wei W, Wu X, Zhou J, Sun Y, Kong Y, Yang X. Noninvasive Evaluation of Liver Fibrosis Reverse Using Artificial Neural Network Model for Chronic Hepatitis B Patients. Comput Math Methods Med 2019;2019:7239780. [PMID: 31428186 DOI: 10.1155/2019/7239780] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
648 Saito M, Yano Y, Hirano H, Momose K, Yoshida M, Azuma T. Serum NX-DCP as a New Noninvasive Model to Predict Significant Liver Fibrosis in Chronic Hepatitis C. Hepat Mon 2015;15:e22978. [PMID: 25788955 DOI: 10.5812/hepatmon.22978] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
649 Martinez SM, Fernández-Varo G, González P, Sampson E, Bruguera M, Navasa M, Jiménez W, Sánchez-Tapias JM, Forns X. Assessment of liver fibrosis before and after antiviral therapy by different serum marker panels in patients with chronic hepatitis C. Aliment Pharmacol Ther. 2011;33:138-148. [PMID: 21083589 DOI: 10.1111/j.1365-2036.2010.04500.x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 63] [Article Influence: 5.9] [Reference Citation Analysis]
650 Parikh NS, Koh I, VanWagner LB, Elkind MSV, Zakai NA, Cushman M. Liver Fibrosis is Associated with Ischemic Stroke Risk in Women but not Men: The REGARDS Study. J Stroke Cerebrovasc Dis 2021;30:105788. [PMID: 33866274 DOI: 10.1016/j.jstrokecerebrovasdis.2021.105788] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
651 Mummadi RR, Petersen JR, Xiao SY, Snyder N. Role of simple biomarkers in predicting fibrosis progression in HCV infection. World J Gastroenterol 2010; 16(45): 5710-5715 [PMID: 21128320 DOI: 10.3748/wjg.v16.i45.5710] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
652 Dong J, Zhang X, Zhu Y, Ma F, Liu C, Wang W, Liu X, Wang B, Lv Y. The Value of the Combination of Fibrosis Index Based on the Four Factors and Future Liver Remnant Volume Ratios as a Predictor on Posthepatectomy Outcomes. J Gastrointest Surg 2015;19:682-91. [DOI: 10.1007/s11605-014-2727-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
653 Ochi H, Hirooka M, Koizumi Y, Miyake T, Tokumoto Y, Soga Y, Tada F, Abe M, Hiasa Y, Onji M. Real-time tissue elastography for evaluation of hepatic fibrosis and portal hypertension in nonalcoholic fatty liver diseases. Hepatology 2012;56:1271-8. [PMID: 22488593 DOI: 10.1002/hep.25756] [Cited by in Crossref: 75] [Cited by in F6Publishing: 66] [Article Influence: 8.3] [Reference Citation Analysis]
654 Hayashi M, Abe K, Fujita M, Okai K, Takahashi A, Ohira H. Association between sarcopenia and osteoporosis in chronic liver disease. Hepatol Res 2018;48:893-904. [PMID: 29734510 DOI: 10.1111/hepr.13192] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
655 Pijls KE, Smolinska A, Jonkers DM, Dallinga JW, Masclee AA, Koek GH, van Schooten FJ. A profile of volatile organic compounds in exhaled air as a potential non-invasive biomarker for liver cirrhosis. Sci Rep. 2016;6:19903. [PMID: 26822454 DOI: 10.1038/srep19903] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 5.8] [Reference Citation Analysis]
656 Su GL, Glass L, Tapper EB, Van T, Waljee AK, Sales AE. Virtual Consultations Through the Veterans Administration SCAN-ECHO Project Improves Survival for Veterans With Liver Disease. Hepatology. 2018;68:2317-2324. [PMID: 29729194 DOI: 10.1002/hep.30074] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 12.7] [Reference Citation Analysis]
657 Holmberg SD, Lu M, Rupp LB, Lamerato LE, Moorman AC, Vijayadeva V, Boscarino JA, Henkle EM, Gordon SC. Noninvasive serum fibrosis markers for screening and staging chronic hepatitis C virus patients in a large US cohort. Clin Infect Dis. 2013;57:240-246. [PMID: 23592832 DOI: 10.1093/cid/cit245] [Cited by in Crossref: 89] [Cited by in F6Publishing: 93] [Article Influence: 11.1] [Reference Citation Analysis]
658 Na JH, Park SW, Kang Y, Koh H, Kim S. The clinical significance of serum ferritin in pediatric non-alcoholic Fatty liver disease. Pediatr Gastroenterol Hepatol Nutr 2014;17:248-56. [PMID: 25587525 DOI: 10.5223/pghn.2014.17.4.248] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
659 Xu XL, Jiang LS, Wu CS, Pan LY, Lou ZQ, Peng CT, Dong Y, Ruan B. The role of fibrosis index FIB-4 in predicting liver fibrosis stage and clinical prognosis: A diagnostic or screening tool? J Formos Med Assoc 2021:S0929-6646(21)00344-2. [PMID: 34325952 DOI: 10.1016/j.jfma.2021.07.013] [Reference Citation Analysis]
660 Nagaoki Y, Imamura M, Teraoka Y, Morio K, Fujino H, Ono A, Nakahara T, Murakami E, Yamauchi M, Kawaoka T, Miki D, Tsuge M, Hiramatsu A, Hayes CN, Chayama K, Aikata H. Impact of viral eradication by direct-acting antivirals on the risk of hepatocellular carcinoma development, prognosis, and portal hypertension in hepatitis C virus-related compensated cirrhosis patients. Hepatol Res 2020;50:1222-33. [PMID: 32767446 DOI: 10.1111/hepr.13554] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
661 Yeh CS, Hsu CW, Liang KH, Chen YC, Lin CL, Chien RN, Hu TH, Lin WR, Lai MW, Chu YD, Yeh CT. Development of a fibrosis index including hepatitis B virus basal core promoter A1762T mutation for pretherapeutic evaluation. J Gastroenterol Hepatol 2018;33:1530-7. [PMID: 29424069 DOI: 10.1111/jgh.14120] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
662 Zeng DW, Zhang JM, Liu YR, Dong J, Wu YL, Lin S, Jiang JJ, Zhu YY. A new model for predicting liver cirrhosis in chronic hepatitis B virus carriers with low serum alanine transaminase activity. Clin Res Hepatol Gastroenterol. 2014;38:727-734. [PMID: 25048838 DOI: 10.1016/j.clinre.2014.06.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
663 Atsukawa M, Tsubota A, Shimada N, Yoshizawa K, Abe H, Asano T, Ohkubo Y, Araki M, Ikegami T, Okubo T, Kondo C, Osada Y, Nakatsuka K, Chuganji Y, Matsuzaki Y, Iwakiri K, Aizawa Y. Effect of native vitamin D 3 supplementation on refractory chronic hepatitis C patients in simeprevir with pegylated interferon/ribavirin: Effect of vitamin D in simeprevir triple therapy. Hepatol Res 2016;46:450-8. [DOI: 10.1111/hepr.12575] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
664 Liu CH, Liu CJ, Hong CM, Su TH, Yang HC, Chen KM, Huang YP, Yeh YM, Tien HL, Liu YC, Kao JH, Chen DS, Chen PJ. A noninvasive diagnosis of hepatic fibrosis by BioFibr